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Background: Chronic kidney disease (CKD) is a rising global health problem. African 
Americans bear a greater proportion of CKD burden compared to Caucasians. Little is known 
about the relationship of CKD with bone loss and body composition distribution with biomarkers 
of CKD in blacks.  
Objective: The prevalence of CKD among Tobago black, African American and Caucasian men, 
aged 40 years and older were determined and compared. The risk factors of CKD, the association 
of body composition with biomarkers of CKD and the effect of CKD on longitudinal bone loss 
were examined among Tobago black males.  
Methods: Tobago men were recruited from Tobago Island in 2004-2007. Counterparts from U.S 
were obtained from the National Health and Nutrition Examination Survey (NHANES) 2003-
2006. Standardized serum creatinine, cystatin C and urinary albumin were measured using Jaffè 
reaction, Dade Behring nephelometer and fluorescent immunoassay respectively.  Longitudinal 
Bone Mineral Density changes in trochanter, femoral neck and total hip from 2004/2007-2012 
were measured using Dual X-Ray Absorptiomertry (DXA). Body composition was measured 
using DXA and Peripheral Quantitative Computed Tomography (PQCT). Covariates were 
assessed from questionnaires in 2004-2007.  
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ABSTRACT
 
iv 
Results: The prevalence of CKD was 19.7%, 23.4% and 19.7% in Tobago black, African 
American and Caucasian men respectively. Age, hypertension and diabetes were significantly 
associated with CKD in Tobago men.  Lean body mass and calf muscle area were positively 
associated with serum creatinine. All adiposity measures were positively associated with cystatin 
C, but not with calf muscle area. There was consistent greater decline in BMD across quartiles of 
ACR, serum creatinine and cystatin C in trochanter, femoral neck and total hip bones. The rate of 
bone loss in Tobago men was similar to that in Caucasian men. 
Public Health Significance: The biomarkers used for assessing CKD (serum creatinine and 
cystatin C) are influenced by body composition. Future CKD screening among blacks with high 
lean or muscle mass should include cystatin C assessment due to the influence of muscle mass on 
serum creatinine.  
CKD is associated with bone loss. Proper management of bone minerals and DXA screenings are 
necessary in order to reduce bone loss among individuals with CKD. 
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1.0  INTRODUCTION 
Chronic kidney disease (CKD) is a major health problem posing serious public health 
challenge. The U.S Center for Disease Prevention and Control (CDC) report from 1999-2004 
indicates that CKD affects over 10% of Americans 20 years or older and the incidence of CKD 
has continued to increase since 1994 [1]. The rising CKD incidence is paralleled by a rising 
elderly population, obesity, cardiovascular disease (CVD) and diabetes in U.S. As the population 
ages and the number of people with CKD risk factors increases such as diabetes and 
hypertension, the incidence of CKD is expected to continue to rise in the coming years.  
CKD is associated with progression to End Stage Renal Disease (ESRD), which in turn is 
associated with several health complications including bone loss, anemia and CVD. The 
conversion rate of CKD to ESRD requiring renal replacement therapy is also on the rise. In U.S, 
the annual incidence of ESRD is 354 persons per million. Approximately 595,000 ESRD patients 
are on dialysis at an annual cost of approximately $48 billion [2].  The mortality rate associated 
with ESRD is  about 152 per 1,000 patient years, and this  rate is expected to double in the next 
decade [2].  African Americans and other racial minorities are disproportionately affected by 
ESRD.  During the period 1994-2004, the age adjusted incidence of ESRD declined from 63.5 to 
55.0 per million among African Americans and from 25.2 to 22.8 per million among Caucasians 
[1] due to improved treatment and increased awareness of ESRD. Despite the decline, African 
Americans are four times more likely to develop ESRD compared to Caucasians [2].   
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Suggested reasons for CKD/ESRD disparity between African Americans and Caucasians 
includes heritability of susceptible genes of kidney disease and differences in modifiable risk 
factors [1]. The role of susceptible genes of CKD/ESRD will be the consideration of future 
studies. In the meantime, it is important to focus on the role of modifiable risk factors including 
hypertension, diabetes, smoking, alcohol, obesity and low socioeconomic status in the 
development of CKD/ESRD and observed racial disparities. Much of the work on ESRD/CKD 
disparities has been focused on African Americans and Caucasians. Given the ancestral 
similarities between blacks of West African descent and African Americans, it is important to 
also examine and compare the role of modifiable risk factors of ESRD/CKD among blacks of 
West African descent. Therefore, the goal of our project is to determine and compare the 
prevalence of CKD among African Americans, Caucasians and populations of West African 
descent and identify modifiable risk factors affecting CKD among populations of West African 
descent. Furthermore, this study will attempt to evaluate the association of several body 
composition measures with kidney function biomarkers and the effect of worsening kidney 
function on bone loss among populations of West African descent.   
1.1 BACKGROUND 
A recent report indicates that worldwide, over 2 million people with ESRD are kept alive 
or are being treated with renal replacement therapy and the number is expected to double in the 
next decade [3-5]. Compared to U.S, publications of prevalence and incidence rates of ESRD for 
some countries show that the prevalence of ESRD is 800 Persons per million[6] in Europe. The 
U.K, data for 2008, shows that the prevalence of ESRD, is 774 persons per million [7]. African 
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countries lack reliable statistics for ESRD. This is probably a reflection of poor data collection 
and insufficient data to characterize ESRD in Africa. However, some experts suggests an  ESRD 
prevalence of  approximately 150 persons per million in Africa [6]. There are also no reliable 
estimates of ESRD prevalence for the Caribbean as a whole. Although, a renal registry (The 
Caribbean Renal Registry) was set up in 2009, this registry is not fully functional and is 
inadequate to characterize ESRD in the Caribbean region at present.  However, Barton E.N et al, 
found ESRD prevalence rate of  316 persons per million in Jamaica [8]. A study found that 
ESRD prevalence rate was 2.53% among Chinese adult 35-75years [9]. Table 1 shows 
unadjusted prevalence rates of ESRD for select countries. Japan and Taiwan have some of the 
world’s largest prevalence rates of ESRD, while Russia has the lowest prevalence rate. This may 
be due to much better treatment enabling so many more survival on dialysis in Japan and 
Taiwan, contrary to Russia where low rates may be due to poor access to treatment and poor 
survival, even with treatments. 
 
Table 1. Prevalence of ESRD (Per Million Populations) for Select Countries/Region, 2009 
Country Prevalence Rate Country Prevalence Rate 
Brazil 481 Russia 173 
Argentina 634 Finland 780 
U.S.A 1811 Romania 502 
Canada 1119 Croatia 930 
Japan 2205 UK 793 
Taiwan 2447 France 1094 
Source: USRDS Annual Data Report 2011[2]. 
 
Taken together, CKD/ESRD presents a global challenge. Current population distribution 
points to an increasing problem that is fast becoming an epidemic. A majority of the new ESRD 
cases is expected to occur in the less developed countries, including countries in Africa and the 
Caribbean where kidney transplant and dialysis services are either rudimentary, totally lacking or 
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if present are unaffordable. In addition, ESRD and ESRD complications are a financial burden to 
less developed countries already overburdened by communicable and non communicable 
diseases. The distribution of CKD/ESRD worldwide, underscores a need for action. Concerted 
preventive strategies are needed to slow progression form CKD to ESRD in order to address 
complications and health consequences of ESRD. The nonprofit organization of Kidney Disease 
Improving Global Outcomes (KDIGO), established in 2003 and the U.S National Kidney 
Foundation’s Kidney Disease Outcome Quality Initiative (KDOQI) established in 1997 have 
been creating clinical practice guidelines to improve clinical outcome in chronic kidney disease 
worldwide using evidence based approach. 
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2.0  KIDNEY DISEASE 
Kidney disease is a multi-etiologic disorder which may lead to short-term acute kidney 
injury (AKI) or persistent long term CKD. Kidney diseases affect kidney function and 
accompanied with a wide spectrum of prognosis. The diseases of the kidney are collectively 
known as glomeruli diseases and two major categories: 1, Glomerulonephritis; and 2, 
Glomerulosclerosis. Glomerulonephritis results in inflammation of the glomerular filtration 
membrane while Glomerulosclerosis results in scarring and hardening of blood vessels of the 
kidney. Several diseases may lead to either one or both types of glomerular diseases including, 
autoimmune disease, systemic lupus erythematosus, Good-pasture syndrome, IgA nephropathy, 
hereditary nephritis-Alport syndrome, infection-related glomerular disease, glomerulosclerosis, 
diabetic nephropathy, focal segmental glomerulosclerosis, CVD(hypertension), membranous 
nephropathy and minimal change disease [10].  
AKI and CKD are directly related. Many AKI's will resolve without further damage to 
kidney, whereas in some individuals, AKI may progress to CKD. Whenever AKI or CKD 
occurs, the filtration capacity of the kidney is affected, followed by loss of kidney physiological 
function and declining glomerular filtration. 
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2.1 ACUTE KIDNEY INJURY (AKI) 
AKI is an inflammatory disease [11, 12], leading to sudden onset of impaired kidney 
function: oliguria (low urine volume) or anuria (no urine production). The occurrence of AKI 
leads to high blood concentrations of nitrogenous compound including urea and creatinine, a 
condition known as azotemia [13].The causes of AKI are multifactorial and are classified into 
three etiological sources: pre-renal azotemia, intra-renal azotemia and post-renal azotemia[13]. 
In pre-renal azotemia, the events leading to kidney injury occurs before the kidney. Among the 
causes are cardio-renal system disturbances including heart failure and congestive heart diseases, 
hepatic-renal syndrome and renal-pulmonary disturbances. In intra-renal azotemia, the events 
leading to kidney injury arises within the kidney and they include polycystic kidney disease, 
glomerular nephritis and tubular necrosis. In post-renal azotemia, the events leading to kidney 
injury are found below or after the kidney and they include urinary tract infection, infection from 
kidney stone formation, tubular obstruction and back-leaking of solute. AKI may involve one or 
a combination of these sources.  
Individuals with AKI have a significant risk of developing CKD [14] especially among 
those with history of dialysis [15]. An estimated 10-25% of those with history of AKI develop 
CKD within few months of having AKI [16]. Age, glomerular filtration rate, high levels of 
serum albumin, diabetes mellitus and severity of AKI are some factors that determines whether 
an individual with a history of AKI will eventually develop CKD [17]. Conversely, individuals 
with CKD are also susceptible to AKI. This condition is referred to as acute-on-chronic kidney 
condition. Study show that acute-on-chronic CKD is associated with severe adverse health 
outcomes and increased risk of mortality [14].  
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The mechanism underlying AKI is not fully understood.  However, the widely accepted 
mechanism involves renal tubular cell injury resulting from renal ischemia [13]. In this model, 
hypovolemia (low blood volume), activates the Renin Angiotensin System (RAS), followed by 
vasoconstriction of renal vessels (afferent and efferent capillaries vessels). In turn, reduced renal 
blood flow and renal under-perfusion ensues, leading to ischemia, oxidative stress, and release of 
reactive oxygen species, such as O2 and OH radicals, hydrogen peroxide, hypo-chloric acid and 
ozone radicals. Cell injury and tissue damage is mediated by release of inflammatory mediators 
(Tumor Necrosis Factors, Chemokine’s, Cytokines and Interleukins) and eventual AKI.  
Persistent occurrence of renal ischemia may lead to epithelial and endothelial tissue damage, 
tubular dysfunction, histological changes, severe loss of kidney function marked by reduced 
glomerular filtration rate and rise in serum creatinine. Further damage may lead to leakage of 
small amounts of protein molecules including albumin into urine, a condition known as micro 
albuminuria. As glomeruli damage occurs further, larger amounts protein molecules will leak 
into urine also known as macroalbuminuria or proteinuria. Proteinuria represents a more 
extensive damage of kidney glomerulus marking an advanced stage of kidney function loss. 
Proteinuria is associated with significant health problems including fluid and electrolyte 
imbalance, acid base disorder, uremic syndrome, impairment of red blood cell formation and 
hemostasis, impaired immune response, increased risk of infection and death [18].  
2.1.1 SYSTEM OF AKI CLASSIFICATION 
The first national multidisciplinary consensus to classify AKI was developed in 2004, by 
the Acute Dialysis Quality Initiation (ADOQI).  The RIFLE acronym was developed referring to 
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Risk, Impairment, Failure, Loss of function and End stage, for characterizing AKI severity, 
diagnosis and treatment as shown in Table 2. 
 
Table 2. AKI Stages by RIFFLE System of Classification   
RIFFLE GFR Criteria Urine Output Criteria 
Risk Increased Serum Creatinine X1.5, or GFR decrease 
>25%  
UO < 0.5ml/kg/hr×6hr 
Injury Increased Serum Creatinine X2, or GFR decrease 
>50% 
UO < 0.5ml/kg/hr×12hr 
Failure Increased Serum Creatinine X3, GFR decrease >75% 
or Serum Creatinine>4mg/dl 
UO < 0.3ml/kg/hr×24hr  or 
anuria×12hr 
Loss Persistent ARF: Complete Loss of Kidney Function >4wks 
ESRD End Stage Kidney Disease >3 Months 
Source: KDIGO Clinical Practice Guideline for Acute Kidney Injury http://www.kidney-
nternational.org: UO: Urine Output, ESRD: End Stage Renal Disease. 
 
Because RIFLE classification did not take into account, baseline serum creatinine 
changes occurring within a short time period, subsequent modification by the Acute Kidney 
Injury Network (AKIN) resulted in creation of another AKI classification to recognize small 
changes in serum creatinine occurring within 48 hours shown in Table 3. 
Table 3 AKI Stages by AKIN System of Classification 
Stage Serum Creatinine Urine Output 
1 1.5-1.9 times baseline, or ≥0.3mg/dl increase <0.5ml/kg/h for 6-12hrs 
2 2.0-2.9 times baseline <0.5 ml/kg/h for ≥12hrs 
3 3.0 times baseline or Increase in serum 
creatinine≥4.0mg/dl, or Initiation of renal therapy or 
in patients less than 18 yrs., decrease in eGFR to 
<35ml/min/1.73m2 
0.3ml/kg/h ≥24 hrs., or Anuria 
for≥12hrs 
Source: KDIGO Clinical Practice Guideline for Acute Kidney Injury http://www.kidney-
international.org 
 
The current system of AKI classification combines both RIFLE and AKIN systems to 
generate a composite system which now includes changes in urine output and serum creatinine 
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for determining AKI severity. Based on RIFLE/AKIN system,  AKI is defined as  increase in 
serum creatinine by 0.3mg/dl within 48 hours or increase in serum creatinine to 1.5 times the 
baseline within 7 days or presence of urine volume less than 0.5ml/kg/h for 6 hours[19]. The 
RIFLE/AKIN system has been validated and is found to be more accurate in staging and 
diagnosing AKI compared to either RIFFLE or AKIN system alone [20, 21].   
However, because serum creatinine is affected by several factors including age, muscle 
mass, gender and ethnicity, there is growing concern in the use of serum creatinine for staging 
and classification of AKI. Recent developments have identified Interluekin-6 (Il-6), Cystatin C 
and Neutrophil Gelatinase-Associated Lipocalin (NGAL) as alternative biomarkers of AKI. 
However, as at present, none have been standardized and validated for population use.  
2.2 CHRONIC KIDNEY DISEASE (CKD) 
In U.S, according to the National Kidney Foundation Kidney Disease Outcome Quality 
Initiative (KDOQI), CKD   is defined as presence of kidney damage and estimated glomerular 
filtration rate (eGFR) less than 60ml/min/1.73m2 occurring for at least three months irrespective 
of etiological origin[22]. CKD is progressive and irreversible and is characterized by kidney 
fibrosis [14]. Because of the pathophysiology of renal disease, CKD does not manifest in signs 
and symptoms until in the later stages when treatment may be less effective. In the majority of 
cases, early kidney function impairment is often missed leaving an individual unaware of 
impending kidney failure. CKD may eventually progress to ESRD and is associated with several 
health complications including bone mineral density loss, anemia, depression and mental health, 
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CVD and CVD deaths. The risk factors of CKD include hypertension, diabetes, obesity and 
persistent AKI lasting for at least three months. 
2.2.1 SYSTEM OF CKD CLASSIFICATION 
In 2002, the Kidney Disease Outcome Quality Initiative (KDOQI) classified CKD into 
five stages on the basis of eGFR shown in Table 4[23].  
Table 4. Stages of Kidney and Associated Risk of CVD  
CKD Stage eGFR (ml/min/1.73m2) Characteristics 
1 Greater or equal to 90 Some renal damage 
2 60-90 Mildly decreased eGFR with some Kidney damage 
3 30-59 Moderate decreased eGFR 
4 15-29 Severely decreased eGFR 
5 Less than 15 Kidney failure ( may require dialysis or transplant) 
 
  In the year 2004, Kidney Disease Initiative on Global Outcome (KDIGO) adopted the 
five-stage classification with little modification. However, in October 2009, two changes, 
allowing determination of prognosis were made. First, stage three was split into moderate and 
mild/severe stages. Second, albumin creatinine ratio (ACR) was included in the system of 
classification. By the new classification system, a composite ranking system was developed with 
color chart as shown in (Figure 1) for guiding risk of CKD outcome. Each color represents a 
combination of eGFR and ACR that is associated with risk of CKD. The direction of increasing 
risk or worsening outcome is indicated by going from green to red. Accordingly, individuals with 
normal eGFR may be at high risk of worsening outcome due to increasing ACR resulting from 
inapparent kidney damage. Also, because of the limitation of albuminuria as a non-specific 
biomarker of CKD, the combination eGFR and ACR in Figure 1, allows for appropriate staging 
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and diagnosis of CKD in populations of non-CKD induced albuminuria including diabetic and 
CVD populations.  
 
Figure 1. Composite Ranking for Relative Risk of CVD 
CKD was defined by glomerular filtration rate (GFR) and Albuminuria by the Kidney Disease: 
Improving Global Outcomes (KDIGO) 2009. Source: Levey et al.[24] 
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3.0  ESTIMATING GLOMERULAR FILTRATION RATE (EGFR) 
The filtering capacity of the glomeruli determines kidney function. Whenever that 
capacity is impaired, toxins are suspended in circulation and glomerular damage occurs, leading 
to leakage of small protein molecules including albumin into urine. The gold standard for 
assessing the filtering capacity of kidney is by measuring the rate at which Iothalamate or Inulin 
is cleared from the blood plasma. Iothalamate/Inulin clearance tests are costly, cumbersome and 
not widely recommended for population screening. Other methods for assessing kidney function 
rely on 24-hour creatinine clearance test. This method is also cumbersome, and because it 
requires 24 hour urine collection, variability in urine collection renders the results inaccurate. 
Nowadays, estimating equations, based on serum creatinine and demographic characteristics 
have found practical use in clinics and research for estimating glomerular filtration rate (eGFR), 
expressed in units of (ml/minute/1.73m2). The KDOQI clinical guidelines recommend routine 
annual assessment of eGFR for determining kidney function among at risk populations [25]. 
The equations for estimating eGFR include: Cockcroft–Gault (CG)[26], Modification of 
Diet in Renal Disease (MDRD)[27] and Chronic Kidney Disease –Epidemiology Collaboration 
(CKD-EPI) equations [28, 29]. 
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3.1 COCKROFT-GAULT (C-G) 
Prior to 1999 there were several equations for estimating glomerular filtration capacity of 
kidney. Among them is Cockcroft-Gault (C-G) equation which received the most attention, 
whereby eGFR was expressed as:  
eGFR (ml/min)= [(140 - Age) × Weight / (0.814 × Serum. Creatinine ( µmol/L)] × (0.85 
if female). 
C-G equation was validated and found to have a correlation coefficient of (0.8) with gold 
standard Iothalamate test. However, the use of C-G equation soon became unpopular due to 
requirement of weight in the formula. Nevertheless, some clinical laboratories still make use of 
C-G equation to estimate glomerular filtration rate [26]. Studies show that compared to MDRD 
and CKD-EPI equations, C-G is least accurate in estimating glomerular filtration rate. However, 
it has been shown that C-G compared to other equations, is more accurate for estimating 
glomerular filtration rates among the elderly and those with low BMI's  [30].  
3.2 MODIFICATION DIET IN RENAL DISEASE (MDRD) 
Levey et al, in 1999 developed the MDRD equation. In the early stage, MDRD made use 
of 6 variables: serum creatinine, age, gender, ethnicity, urea and albumin concentrations to 
estimate eGFR [27]. The utility of this equation was limited due to urea and albumin 
requirements in the formula, which restricted its use as a practical clinical diagnostic tool. In 
2000, Levey et al, modified the equation to include only four variables: serum creatinine, age, 
gender and race [31] whereby glomerular filtration rate was expressed as: 
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eGFR (ml/min/1.73m2) = 186 (Serum Creatinine (µmol/l) × 0.011312) -1.154 × (age)-0.203 × 
(0.762 if female) × (1.212 if African/American Black). 
New developments in analytical techniques led to calibration of serum and plasma 
creatinine to an international standard using an isotope dilution mass spectrometry (IDMS) 
reference. Therefore, if serum creatinine measurement is standardized against IDMS, then the 
constant 186 is replaced by 175 [32]. 
The ease of MDRD use and the non-requirement of body weight, unlike C-G, gave it a 
worldwide appeal and acceptance. However, MDRD suffers from several limitations. Although, 
MDRD has been validated with Iothalamate test, validation was performed among a small 
number of U.S. Caucasians and African Americans between ages 18-70 with eGFR less than 
60(ml/min/1.73m2), therefore, it may not work well in other population groups. MDRD is 
sensitive to low eGFR and performs best with eGFR between 15-30, but not as sensitive to GFR 
greater than 60(ml/min/1.73m2) [33].Therefore, MDRD may overestimate CKD stages  3-5 and 
underestimate those with higher eGFR in a population. 
3.3 CHRONIC KIDNEY DISEASE-EPIDEMIOLOGY COLLABORATION (CKD-
EPI) 
In 2009, Levey et al tackled the problem of CKD stage 3-5 overestimation of MDRD by 
modifying MDRD to the CKD-EPI equation [29]. CKD-EPI reflects the effect of gender and 
age-decline on eGFR especially among the elderly who may have low eGFR but do not show 
any evidence of impaired kidney function. MDRD was modified to reflect changes at creatinine 
values < 60 µmol/L and > 60 µmol/L for males and females of different races.  
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eGFR= 141 × min(Scr/κ, 1)α × max(Scr/κ, 1)-1.209 × 0.993Age × 1.018 [if female] _ 
1.159 [if black], where Scr is serum creatinine, κ is 0.7 for females and 0.9 for males, α is -0.329 
for females and -0.411 for males, min indicates the minimum of Scr/κor 1, and max indicates the 
maximum of Scr/κ or 1 [29] 
CKD-EPI was found to yield lower prevalence of CKD compared to the MDRD 
equation, which has a tendency to overestimate the prevalence of stages 3-5. Levey et al, 
suggested replacement of MDRD equation with CKD-EPI.  In U.S, although there are a few 
laboratories that have converted to CKD-EPI, MDRD is still universally applied for estimating 
eGFR. 
3.4 OTHER MEASURES OF KIDNEY FUNCTION 
In epidemiological and clinical studies, serum creatinine based equations are the most 
widely used biomarkers for estimating glomerular filtration rate. However, serum creatinine is 
influenced by age, gender, race, nutrition (meat consumption) and body composition. Serum 
creatinine levels increase with age. Individuals with high BMI or high lean muscle mass 
resulting from exercise or weight training have a disproportionately higher serum creatinine 
compared to those with low BMI and/or lean mass[34, 35]. Serum creatinine is slow in 
responding to kidney damage. It is estimated that about 20% of kidney function damage would 
have occurred before serum creatinine rises to a significant level [36]. Studies show that 
creatinine is produced by several tissues and organs of the body at different rates in different 
individuals. The variability of serum creatinine makes comparison of GFR among individuals 
difficult. To overcome these problems, alternative measure of kidney function makes use of 
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cystatin C biomarker.  Cystatin-C is now beginning to gain popularity in epidemiological and 
clinical studies [37]. A recent validated cystatin-C based equation estimates glomerular filtration 
rate as: 
                                            eGFRcys = 76.7 × Scys−1.18   [37]. 
3.4.1 CYSTATIN C 
Cystatin C is a low molecular weight (13 kilodalton) biochemical compound belonging to 
the human cystatin family. The cystatin family comprises of 11 homologues (A, B, C, D, E, F, S, 
SA, SN and, low and high molecular weight KININOGEN) grouped into three subfamilies; 
cystatin C belongs to the second family. Cystatin C is mainly found in extracellular fluid and its 
function is to inhibit cysteine protease. It is produced by all nucleated cells in the body and is 
freely filtered at a constant rate in the glomerulus. As cystatin C passes through glomerulus, 
about 99% is completely catabolized in the proximal tubule leaving only a tiny fraction for 
reuptake [38]. These properties make cystatin C an attractive candidate as a biomarker of kidney 
function, unlike creatinine for which serum concentration is influenced, among other factors, by 
diet(meat consumption),  muscle mass production and, tubular production and reabsorption [39].  
A meta-analyses comparing cystatin C and creatinine show overall, cystatin C has a 
higher correlation with a standard Iothamalate test, compared to serum creatinine [40]. Although, 
earlier report suggests that serum cystatin C is independent of body composition, a recent study 
now find that lean body mass is a predictor of cystatin C [41]. Also large doses of 
glucocorticoids [42] and hyperthyroidism have been shown to increase serum cystatin C [43]. 
Therefore, in applying cystatin C to estimate GFR, these factors need to be considered. The 
greatest disadvantage of cystatin C in estimating kidney function is due to lack of 
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standardization. Because several different assay methods are used with different formulas, it is 
challenging comparing cystatin C based eGFR across different assay platforms.   
3.4.2 ALBUMIN CREATININE RATIO (ACR) 
Extensive damage of the kidney glomerulus is associated with an advanced stage of 
kidney function loss and is often marked by proteinuria. Proteinuria is characterized by leaking 
of protein into urine especially of albumin. Proteinuria is not only found among patients with 
renal impairment, it has also been implicated in diabetes and cardiovascular disease conditions 
[44] . Proteinuria is measured by a 24-hour urine collection. However, such method has become 
less useful, due to the inconvenience of a 24-hour timed urine collection [45]. Proteinuria is 
measured by quantifying urine Albumin to Creatinine Ratio (ACR). A normal ACR is less than 
30mg/g. ACR greater than 30mg/g but less than 300mg/g is defined as microalbuminuria and 
ACR greater than 300mg/g is referred to as macroalbuminuria. Micro and macro albuminuria 
represent more extensive kidney damage. The essence of ACR is to accurately diagnose and 
stage CKD alongside an eGFR estimating equation as shown in Figure 2.  
ACR measure is not without controversy. It is argued  that the use of ACR in CKD 
staging is flawed and misleading because the correction factor in the denominator ( urine 
creatinine), is dependent on muscle mass and does not correct for body surface area BSA [45]. 
Also, it is well known that the quantity of protein and creatinine excretion depends on time of the 
day.  Woman and the elderly generally have lower creatinine production compared to men and 
the young respectively [46]. These variations limit comparisons across individuals. In spite of 
these controversies, the National Kidney Disease Education Program Current guidelines 
recommend ACR as a surrogate for collection of timed urine samples [47].  
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3.5 C-G, MDRD, CKD-EPI AND CYSTATIN C COMPARED 
Several studies comparing eGFR estimating equations with cystatin C show that cystatin 
C is superior to MDRD, C-G and CKD-EPI equations. In a study to compare cystatin C with the 
C-G equation, cystatin C based eGFR showed a higher correlation with the gold standard 
compared to C-G equation [48]. In the Multi-Ethnic Study of Atherosclerosis (MESA) and the 
Cardiovascular Health Study (CHS), to assess risks for complications, Paralta et al, also showed 
that cystatin C identified persons with CKD having the highest risk for complications much more 
frequently compared to CKD-EPI equation [49]. Thus, cystatin C is seen as a better biomarker 
for estimating kidney function compared to the estimating equations.  
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4.0  CKD AND CARDIOVASCULAR DISEASE 
The interrelationship of CVD and CKD has received a lot of attention in recent time. 
CVD is any disease that involves the heart and blood vessels. The common CVD’s are coronary 
heart disease, cerebrovascular disease (stroke) and hypertension. Others include arrhythmias, 
heart failure and heart valve problems [50]. Estimates compiled between 1997-2009  show that 
among adults 18 years and older,  the prevalence rate of heart diseases remained the same from 
1997 to 2009  while the prevalence  rate of hypertension increased  from 191 to 249 cases per 
1000 in the same period[51].  Among the racial groups reported, whites had the highest 
prevalence rate of heart disease followed by blacks and Native Americans. 
In addition to being the leading cause of death in the U.S general population [52], CVD is 
a leading cause of death among patients with CKD [53]. Recent studies have reported a rising 
CVD mortality with rising CKD in the U.S population [54]. The rising trend is further 
compounded by increasing number of elderly population, and the rising incidence of diabetes, 
hypertension and obesity, which are risk factors associated with both CKD and CVD.  A study 
also showed that a majority of CKD cases are more likely to die from CVD than progress to 
renal failure [55], and, among those who progress to renal failure, about half will eventually 
develop CVD or die from CVD [56].  Evidence from several studies also suggests CVD is 
increasing among patients with earlier stages of CKD [53, 55-58].  
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CKD is an independent risk factor for CVD. In a recent pooled study comprising data 
from four community-based longitudinal studies( Atherosclerosis Risk in Communities Study, 
Cardiovascular Health Study, Framingham Heart Study, and Framingham Offspring Study), after 
adjusting for confounding variables, CKD was found to be an independent predictor of CVD. In 
addition, blacks with CKD had significantly higher risk of CVD outcome compared to whites 
with CKD [59].   
Conversely, CVD is also an independent predictor of CKD. In a study to evaluate the 
relationship between the levels of kidney function on all-cause mortality Al-Ahmad et al, showed 
that worsening renal function was associated with  patients with CVD [60]. Similar result was 
reported among men hospitalized for heart disease, who subsequently developed CKD with 
decreasing kidney function [61] [62].  
In light of these findings, it is evident that the relationship between CVD and CKD is 
bidirectional. Moreover, it has been shown that acute or chronic changes in one organ(heart or 
kidney) can lead to acute or chronic changes in the other [57]. CVD and CKD not only share 
common risk factors which includes atherosclerosis, diabetes mellitus, dyslipidemia, renal 
vascular disease, anemia, and hypertension [63], interactions among these risk factors may also 
exist[64]. The consequence of the interrelatedness of CVD and CKD is to create a vicious cycle 
that further complicates morbidity and mortality outcomes. 
In 2008, the Acute Disease Outcome Quality Initiative (ADOQI) introduced a 
classification system to characterize the joint relationship between the cardiac and renal system, 
also known as the cardio-renal syndrome (CRS). CRS is classified into 5 stages, each with 
specific primary and secondary causes as shown in Table 6. 
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Table 5.Cardio-Renal Syndrome Classification and Definition 
CRS  Definition Primary Event Secondary Event 
Acute cardio-renal (type 1)  Acute worsening of heart 
function (AHF–ACS) leading 
to kidney injury and/or 
dysfunction 
Acute heart failure 
(AHF) or acute 
coronary syndrome 
(ACS) or 
cardiogenic shock 
AKI 
Chronic cardio-renal (type 2)  Chronic abnormalities in 
heart function (CHF-CHD) 
leading to kidney injury or 
dysfunction 
Chronic heart 
disease (LV 
remodeling and 
dysfunction, 
diastolic 
dysfunction, 
chronic 
abnormalities in 
cardiac function, 
cardiomyopathy) 
CKD 
Acute reno-cardiac (type 3)  Acute worsening of kidney 
function (AKI) leading to 
heart injury and/or 
dysfunction 
AKI AHF, ACS, arrhythmias, 
shock 
Chronic reno-cardiac (type 4)  Chronic kidney disease 
(CKD) leading to heart 
injury, disease and/or 
dysfunction 
CKD CHD (LV remodeling and 
dysfunction, 
diastolic dysfunction, 
abnormalities 
in cardiac function), AHF, 
ACS 
Secondary CRS (type 5) Systemic conditions leading 
to simultaneous injury and/or 
dysfunction of heart and 
kidney 
Systemic disease 
(sepsis, 
amyloidosis, etc.) 
AHF, ACS, AKI, CHD, 
CKD 
Adapted from Ronco et al.,(Open Access) [55]. 
The mechanism involved in CRS begins with a failing heart, leading to reduction of 
cardiac output. In attempt to compensate for reduction in cardiac output, the heart expands and 
enlarges. That is why cardiac hypertrophy is a common feature among patients with CRS, 
occurring at the advanced stage of CRS [58]. Reduced cardiac output in turns leads to renal 
under perfusion accompanied with release of rennin. Renin leads to the release of angiotensin II, 
arginine vasopressin (AVP), aldosterone, and activation of sympathetic nervous system 
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(collectively referred to as the RAAS system: Renin Angiotensin and Aldosterone System). 
Activation of the RAAS system, in turn results in vasoconstriction and compensatory increase in 
systemic demand of increased cardiac output and increased renal perfusion. In the heart organ, 
the resultant effect is cardiac hypertrophy and the stretching of the heart muscles [58]. In the 
kidney, trans-membrane secretion of proteins is vital components for the normal functioning 
kidney. These proteins are produced by the endoplasmic reticulum ER [57]. The presence of 
cardiac hypertrophy stimulates the production of proteins by ER. Continuous and prolonged 
stimulation of ER may result in ER stress which further exacerbates cardiac hypertrophy, leading 
to reduction in cardiac output and subsequent congestive heart failure [58] and protein secretion. 
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5.0  CKD AND DIABETES 
An estimated 360 million people worldwide have diabetes [65]. In 2004, 3.4 million 
people worldwide died from diabetes complications [65]. According to the World Health 
Organization (WHO), it is projected that deaths from diabetes will double by the year 2030 [65]. 
In U.S, diabetes is the seventh leading cause of death. About 25.8 million adults representing 
8.3% of the U.S population have diabetes [66]. Approximately 18.8 million are diagnosed and 7 
million undiagnosed.  In 2005–2008, based on fasting glucose or hemoglobin A1C levels, 35% 
of U.S. adults aged 20 years or older had pre-diabetes [66]. Diabetes is increasingly recognized 
as a public health problem associated with increased mortality and co-morbid conditions 
including excess adiposity, dyslipidemia, CVD, stroke, limb amputation, blindness and kidney 
failure [66-68]. It has been established that diabetes is the leading cause of kidney failure among 
adults in U.S [66]. In fact, in 2008, diabetes accounted for 44% of new cases of kidney failure 
among adults in the U.S population [66]. According to the USRDS, in 2008, approximately 
48.2% of patients with diabetic nephropathy were CKD stages 1 or 2, whilst 49.4% were stages 3 
to 5 [68]. Even among those with undiagnosed or pre-diabetes, an estimated 17.7% have some 
level of kidney impairment [69]. As the number of people with risk factors contributing to 
diabetes rises in the general population, such as obesity and over nutrition [70], it is expected that 
the number of diabetic cases will continue to rise, and the incidence of diabetic nephropathy will 
likely increase as a consequence. Even though the prevalence of diabetes is high in U.S, African 
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Americans are disproportionately affected [71]. In 2010, 18.7% of all non-Hispanic blacks aged 
20 years or older had either diagnosed or undiagnosed diabetes compared to 10.2% among non-
Hispanic whites [72]. This trend correlates with high prevalence of diabetic complications in 
these populations. African Americans with diabetes are more likely, compared to other ethnic 
groups, to develop diabetic nephropathy [73]. In 2006, the rate of initiation of treatment for end-
stage renal disease related to diabetes was 2.2 times among blacks compared to whites [74]. In a 
study by Young et al. African Americans with diabetes were more likely than whites to develop 
micro vascular complications, such as renal disease compared to whites [75]. Similar observation 
was made by Karter AJ et al, who reported significant differences in ESRD among ethnic 
minorities compared to whites [76].  Environment, lack of social and economic resources, access 
to healthcare and poor disease management are common among minorities and may be the 
reason among others, for the observed racial disparities. In 1986, the Office of Minority Health 
(OMH) within the National Institute of Health (NIH) was established to address poor health 
outcomes among minorities and bridge the disparity gap between minorities and their white 
counterparts [77]. 
A hallmark of diabetes is the presence of albuminuria, defined as protein creatinine ratio 
greater than 30mg/g. Presence of micro-albuminuria is an early indicator of proteinuria. While 
many with micro-albuminuria will revert back to norm-albuminuria spontaneously [78], 
approximately 30% of people with micro-albuminuria go on to develop proteinuria[79]. 
Albuminuria is regarded as a general marker of vascular dysfunction throughout the body, and a 
predictor of both micro-vascular disease such as diabetes nephropathy and retinopathy, and 
macro-vascular dysfunction such as CVD as suggested by Steno hypothesis [80].  Among several 
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causative factors, diabetes, hypertension, dyslipidemia and inflammatory mediators have been 
identified as the leading causes of albuminuria [80].  
Not all diabetes is associated with albuminuria. But if present, albuminuria is a marker of 
diabetic nephropathy and also of progression to kidney failure [81-83]. The effect of diabetes on 
diabetic nephropathy depends on the diabetes type, and whether albuminuria is present or absent. 
Among type I diabetes patient with albuminuria, about 80% will progress to diabetic 
nephropathy whilst among Type II diabetic patients with albuminuria, about 20-40% will 
progress to diabetic nephropathy [82, 84, 85]. Although progression is influenced by many risk 
factors, hypertension is by far the most important factor influencing progression to kidney 
failure. In a study by Nielson et al, among patients with type 1 diabetes who have hypertension, 
approximately half of the patients developed kidney failure within a decade [86, 87]. That is why 
current clinical guidelines recommend the lowering of blood pressure to below 130/80 among 
diabetic patients [88]. Other factors that determine progression to kidney failure among diabetic 
patients include uncontrolled glucose levels, cholesterol, activated inflammatory mediators and a 
patient’s genetic predisposition to kidney failure [89, 90]. 
It has also been established that diabetes is an independent predictor of CVD. Diabetic 
patients experience higher rate of CVD complications compared to non-diabetic [91]. According 
to National Cholesterol Evaluation Program (NCEP) report, diabetes is a risk equivalent of CHD, 
meaning that 20 out of 100 individuals with diabetes will develop CHD or have a recurrent CHD 
within 10 years [92]. In addition, several studies have shown that many patients with diabetes 
have generalized arteriosclerosis manifesting in vascular stiffness [80, 93, 94]. The combined 
effect of CKD and diabetes confers a higher risk of CVD outcomes and CVD mortality among 
patients with both diabetes and CKD, than among patients with diabetes or CKD alone. The risk 
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of CVD increases as the GFR declines among patients with diabetes. In a cross-sectional study to 
determine risk of CVD events among patients with diabetes, it was shown that the risk of CVD 
events was approximately 40% higher among those with CKD compared to those without CKD 
[69]. This finding suggests an interaction between diabetes and CKD with respect to CVD 
events. In a similar study, Mann FHE et al, reported a significant increase in CVD events 
resulting from interaction between CKD risk factors and diabetes [71]. In addition, the risk of 
CVD mortality among diabetic patients with reduced eGFR was further increased in the presence 
of uncontrolled high blood glucose, high blood pressure, high cholesterol mediated by 
inflammatory markers, which enhanced the degree of susceptibility to developing advanced 
diabetes nephropathy. Thus diabetes confers excess risk on CKD resulting in CVD events.  
The mechanisms involved in diabetic nephropathy are multiple and complex. Distinct 
stages in the mechanism involve structural, hemodynamic and metabolic changes leading to 
diabetic nephropathy.  Studies have established that diabetes and CKD are micro vascular 
diseases [95, 96]. It is generally believed that the process begins with early hemodynamic 
changes resulting in glomerular hyper-perfusion and hyper -filtration [97]. Hyper-filtration has 
been reported in as many as 66% of type 1 and 50% of type 2 patients with diabetes [98, 99]. In 
addition, most small arteries depend on myogenic response to auto regulate the diameter of blood 
vessels and blood flow. In diabetic patients, there is a loss of myogenic response resulting in 
dysfunctional auto regulation and blood flow. The loss of myogenic function is exacerbated by 
mild increases in blood pressure resulting in the frequent vascular disease often observed in 
diabetic patients and in patients with diabetic nephropathy [100, 101].Consequently, the loss of 
auto-regulation in small arteries leads to damage of the glomerular filtration barrier. Concurrent 
rise in blood pressure leads to elevation of glomerular capillary pressure causing hyper filtration 
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and permeability of protein across the membranes. With time, concomitant hyper filtration and 
high glomerular capillary pressure leads to capillary endothelium damage, fibrotic changes in 
connective tissues characteristic of diabetic nephropathy, glomerular damage, albuminuria and 
declining kidney function [102]. 
The complex relationships between CKD, diabetes, CVD and albuminuria are modeled in 
Figure 2. Three disease combinations observed in this model are: Cardio-Renal diseases (CVD & 
CKD), Diabetic Nephropathy (Diabetes & CKD) and Cardio-Diabetic diseases (CVD & 
Diabetes). The first two are well established, while the last have not been well documented. 
While CKD and CVD are bidirectionaly linked, there is no evidence suggesting a causal link 
from CKD to diabetes, although, the reverse is a well-established causal link as shown by one 
directional arrow from diabetes to CKD in Figure 2.  The role of albuminuria in the triad is 
complex and controversial. Not all cardio-renal, diabetic-nephropathy, CKD, diabetes or CVD 
patients develop albuminuria [79, 103, 104].  However, studies have shown that whenever 
albuminuria occurs it is associated with increased risk of CVD and CVD mortality, diabetic 
nephropathy, decline in renal  function, renal histological damage and increased risk of 
progression to ESRD [105, 106]. In view of these complexities, it is not clear whether 
albuminuria is a biomarker or a mediator in the causal pathways of the diseases in the triad. The 
biological plausibility of albuminuria as a mediator is rationalized through a suggestion that 
albuminuria is a pro-inflammatory molecule. Therefore, when reabsorbed by the renal tubule, 
albuminuria induces production of profibrotic- cytokines leading, to tubule-interstitial fibrosis 
and glomerulosclerosis [107]. Further studies are needed to validate this hypothesis. Meanwhile, 
much less controversial is the etiology of albuminuria, which many believes occurs as a result of 
generalized endothelial and vascular dysfunction [80]. 
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Figure 2. Model Linking Diabetes, CKD/DN, CVD and MA  
Chronic Kidney Disease; DN, Diabetic Nephropathy; CVD, Cardiovascular Disease; ALB, 
Albuminuria. 
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6.0  CKD AND OBESITY 
Excess body fat is a considerable cause of morbidity and mortality. A common measure 
used for determining and classifying excess body fat is Body Mass Index (BMI), obtained by 
dividing an individual’s weight in (kg) by height in (m) squared. A BMI of 25 and less than 30 is 
defined as overweight whereas a BMI of 30 or greater is defined as obese [51, 108, 
109].Worldwide in 2008, an estimated 1.4 billion adults and 40 million children were 
overweight[109]. Overweight and obesity are the fifth leading risks of death in human population 
[109]. Once common in developed western countries, overweight and obesity are now on the rise 
in low and middle income counties, and are associated with significant public health problems 
[109]. In U.S, obesity is an epidemic [51, 108]. One in three adults and one in six children and 
adolescents are obese [110]. The prevalence of obesity has more than doubled since 1980, in 
particular among young adolescents [108, 111] due mostly to changes in dietary habit and 
sedentary lifestyle. Prior forecast had noted that by the year 2030, the prevalence of obesity may 
reach 30% among children and adolescents and 50% among adults. But, a recent 2012 Center for 
Disease Prevention and Control (CDC) report indicates that the prevalence of obesity is leveling 
off at 17% among children and adolescent and 36% among adults [111]. 
The health consequence of obesity is enormous. Obesity has been found to reduce life 
expectancy by 6 years in men and 7 years in women [112]. It is associated with sleep apnea, 
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certain malignancies such as renal cell carcinoma, nephrolithiasis (kidney stone), hyperlipidemia, 
insulin resistance, diabetes, hypertension and cardiovascular disease (CVD) [113]. 
Early hints of the association between obesity and kidney function were introduced in the 
early seventies. In 1974, Weisinger et al, described four patients with massive obesity and 
nephrotic syndromes. Proteinuria was noted among these patients, and tended to decrease with 
dietary weight loss. Mesangial glomerulopathy (a form of kidney disease affecting the 
glomerulus) was noted among two of the patients. The study concluded that the observed 
proteinuria was as a result of renal venous hypertension [114]. Subsequent studies reported 
occurrence of glomerulosclerosis (scarring of the glomerulus, which are of two types: primary 
and secondary) with proteinuria among obese patients, which increased with increasing BMI 
[115, 116].  
In recent years, several studies have examined the rising trend in CKD with the 
increasing prevalence of obesity [117, 118]. In 2004, Iseki et al found that BMI was associated 
with an increased risk of ESRD in men in the general population in Okinawa [119] after 
controlling for age, sex, systolic blood pressure, and proteinuria. Similar findings were made by 
Ejarbald et al, who showed that overweight at age 20 was associated with a three-fold excess risk 
for chronic renal failure [120], however, hypertension and diabetes were not adjusted for. 
Obesity has not only been noted as a cause of renal disease, but also to its deterioration [116]. 
Hsu et al found that high BMI was independently associated with ESRD and the risk of ESRD 
increased with rising BMI [121].  In all, there is growing evidence suggesting that obesity is a 
significant risk factor in CKD and progression to ESRD. 
The term Obesity Related Glomerulopathy (ORG) refers to glomerular changes 
associated with obesity. ORG is characterized by proteinuria and kidney failure complications 
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[114]. The severity of ORG outcome is further amplified in the presence of hypertension or 
diabetes, which are known risk factors for CKD and CVD.  Recent epidemiological studies show 
that the prevalence of ORG is on the rise, the trend of ORG parallels the rising trend in obesity 
and is an emerging epidemic [122].  
Closely related to obesity are a group of risk factors collectively termed metabolic 
syndrome (MetS): diabetes, hypertension, high triglyceride, low HDL and abdominal obesity. 
According to the Adult Treatment Panel (ATP) of the National Cholesterol Evaluation Program 
(NCEP) guideline, a diagnosis of MetS is made when a combination of three or more of these 
risk factors are present [123] [124].  It has been well established that MetS is more likely to 
develop among obese individuals compared to non-obese. It has also been established that 
occurrence of these factors together increases the risk of CVD and diabetes.  Many studies have 
now shown that MetS is also directly associated with CKD [125]. Each component of MetS is an 
independent predictor of CKD and the higher the number of MetS components, the greater the 
risk of CKD, thus, suggesting that MetS is a mediator between obesity and kidney failure [125]. 
Because a majority of people who are obese also have hypertension and or diabetes, it is 
not clear whether obesity and MetS can initiate CKD independent of hypertension and diabetes. 
In a study by Bonnet et al it was shown that among patients with IgA nephropathy, excess body 
weight was predictive of chronic renal failure [126]. In another to study to evaluate the outcome 
among recipients of kidneys from 37 living donors with obesity, it was reported that glomerular 
filtration rate was lower among patients who had organs from obese donors compared to non-
obese donors [127].In the prevention of renal and vascular disease (PREVEND) study, among 
7676 participants without diabetes, central obesity was associated with decreased kidney 
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function in obese and normal weights [128]. These findings suggest not only the association of 
obesity with CKD but also in initiating CKD.  
Obesity itself is the result of excess calorie intake. Adipose tissues growth is a common 
feature of obesity. Not only does adipose tissues provide insulation in cold and heat and padding 
of organs, the locations and distribution have also been shown to predict health outcomes 
including CVD, diabetes and hypertension, which are known risk factors for CKD. The body fats 
located around internal organs in the trunk region called visceral fat(also referred as central 
obesity or central adiposity) has been shown to correlate well with MetS, while the fats located 
beneath the skin called subcutaneous fat (also known as peripheral fat) tend to have opposite 
effect [129]. Given the association of MetS with CKD, it is likely that central adiposity is also 
associated with CKD. Indeed, a number of studies have shown increasing risk of CKD with 
rising central obesity [120, 128, 130]. In the Framingham studies, it was shown that overweight 
and obesity is associated with increased odds of CKD, but after adjusting for CVD risk factors 
the effect disappeared [131]. This may have been due to use of BMI in excess-fat classification. 
BMI measures general-obesity but not abdominal adiposity which is assessed by waist 
circumference or waist hip ratio. It has also been shown that, because BMI is affected by muscle 
mass, central or abdominal obesity is a better predictor of health outcomes compared to BMI.  It 
may also be that, CVD is a mediator in the relationship between obesity and CKD. Further 
studies are needed in this area.    
Paradoxically, excess adipose tissue may be protective of patients with ESRD.  Studies 
aimed at determining the protective effect of obesity among CKD patients undergoing dialysis 
are beginning to emerge [132, 133]. Kalanter et al, found that higher BMI (up to 45) and higher 
serum creatinine concentration were incrementally and independently associated with greater 
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survival, even after adjustment for nutritional status and inflammation [134]. This paradoxical 
relationship between obesity and CKD survival, termed “reverse epidemiology” is not fully 
understood. One explanation attributes it to Protein Energy Malnutrition (PEM), in the sense 
that, obese individuals with CKD undergoing dialysis suffer from malnutrition due to loss of 
protein. Therefore, high BMI compensates for the metabolic demands among these patients 
[132]. It has also been speculated that greater survival may be due to protective effect of 
inflammation which tend to be unusually common among obese individuals [133].While this 
theory may be plausible, the proponents failed to proffer possible mechanisms of action. 
However, large studies are needed to better understand the relationship and mechanism linking 
obesity to longer survival among ESRD patients. 
Another common feature among overweight/obese individuals is dyslipidemia. 
Dyslipidemia is characterized by hyper-triglyceridemia, elevated level of very low density 
lipoprotein (VLDL), high plasma concentration of lipoprotein, accumulation of oxidized lipids 
and lipoproteins, low plasma HDL cholesterol concentration and impaired HDL maturation and 
function [135]. In obesity, the three common types of dyslipidemia are high triglycerides, low 
HDL and high LDL, which are the result of insulin resistance, caused in particular by central 
obesity [136]. Studies have shown that among patients with kidney failure, the level of 
triglycerides, HDL and LDL varies. The pattern of lipid profile among chronic kidney disease 
patients with or without proteinuria is shown in Table 7.  
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Table 6. Lipid/Lipoprotein Profile in CKD Patients and Proteinuria  
 
Serum Lipid 
CKD Patients 
Heavy Proteinuria Minimal Proteinuria 
Triglyceride ↑ ↑ 
Total cholesterol ↑ ↔,↓ 
LDL-Cholesterol ↑ ↔,↓ or ↑ 
Small dense LDL ↑ ↑ 
IDL Cholesterol ↑ ↑ 
HDL Cholesterol ↓ ↓ 
apoA-1, apoA-11 ↓ ↓ 
apoC-111 ↑ ↑ 
Adapted from Vaziri et al., (Open Access) [135]. CKD, Chronic kidney disease; LDL, low 
density lipoprotein; IDL, intermediate density lipoprotein;  HDL, high density lipoprotein;  apo, 
apolipoprotein. 
 
The role of dyslipidemia in arteriosclerosis formation begins when oxidized LDL 
Cholesterol is engulfed by macrophages leading to foam cell formation and subsequently 
forming atherosclerosis. The net effect is endothelial and epithelial tissue damage resulting in 
impaired glomerular filtration[135]. HDL plays a major role in mitigating this process by 
limiting LDL-Cholesterol oxidation by retrieving surplus cholesterol from vascular tissues for 
disposal in the liver through a process commonly known as reverse cholesterol transport. 
The mechanism linking obesity with CKD is complex and not clear. It is important to 
note that in addition to being a fat storage site, adipose tissue is an endocrine organ. As such, 
adipose tissue is involved in the release of pro-inflammatory cytokines including leptin, 
interluekin-6, C - reactive protein and tumor necrotic factor, and anti-inflammatory factor 
including adiponectin. These pro and anti inflammatory factors regulate the activity of adipose 
tissue and its systemic effect. The inflammatory process begins with invasion of adipose tissue 
with macrophages which result in the release of cytokines and free fatty acids [135]. While 
cytokines tend to promote glomerulus kidney damage through expansion of the mesangial cells 
and destruction of podocytes, adiponectin acts in opposite manner to attenuate the effect of 
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cytokines by regulating the actions of reactive oxygen species (ROS) [137]. In addition to this 
mechanism, animal and human models have also shown that obesity is associated with renal 
hyperperfusion, hyperfiltration and hypertrophy [138, 139]. Adrenergic and rennin-angiotensin-
aldosterone systems as well as glucocorticoids are stimulated in the process, resulting in afferent 
arteriolar dilatation and efferent arteriolar vasoconstriction due to stimulation of the rennin-
angiotensin system [140]. These in turn lead to increased renal tubular reabsorption, volume 
expansion and increased blood pressure and glomerular damage. 
In all, the constellations of inflammation, oxidative stress, hemodynamic changes, lipid 
disorders coupled with metabolic abnormalities of insulin resistance, diabetes mellitus and 
hypertension [141] together, are largely responsible for the atherosclerosis process resulting in 
endothelial dysfunction, renal cell damage leading to CKD and kidney failure in obesity [142]. 
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7.0  CKD-MINERAL BONE DISORDER (CKD-MBD) 
Bone and mineral disorder affects a substantial number of people in the U.S population, 
in particular dialysis patients[143]. The first awareness about bone disorders in dialysis patient 
was reported by Pendras and Erickson in 1966 [144]. Since then, there is increasing body of 
evidence showing that CKD is associated with bone and mineral disorders. Levin et al., showed 
that patients with CKD stage 3-5 developed bone mineral disorders compared to controls without 
CKD [145]. In a similar study, Melamed et al., reported a high prevalence of bone mineral 
abnormalities including calcium, phosphorous and parathyroid hormone PTH, among stage 5 
renal patients [146]. In  U.S, the incidence of bone disorders is on the increase, and it is 
paralleled by a rising number of CKD patients and a rising elderly population who also have a 
high risk of CKD [147]. 
Before 2005, bone disorders ensuing from renal disease were collectively termed renal 
dystrophy. In 2005, a KDIGO conference understudied the effect of renal system on bone and 
recommended a new system of classification. Currently, renal dystrophy refers to the various 
bone pathological and histological disorders, including osteitis fibrosa, osteomalacia, 
osteoporosis and adynamic (osteodystrophy characterized by reduced osteoblast and osteoclast 
activities) bone diseases that may be associated with the renal system, while Chronic Kidney 
Disease – Mineral & Bone Disorder Disease (CKD-MBD) refers to broader effect of CKD on 
bone, which includes mineral disorders, bone disorders and cardiovascular disease [148]. 
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7.1 CKD-MINERAL BONE DISORDER-MINERAL DISORDERS 
Animal and human models have shown that the effect of CKD on bone is largely 
mediated by imbalances in serum minerals and certain biochemical compounds. The majority of 
these imbalances begin from CKD stage 3 when the eGFR drops below 60ml/min/1.73/m2 and 
gradually worsens as eGFR falls below 15ml/min/1.73/m2 [149]. In children, minerals and 
biochemical imbalances have been reported as early as stage 2 of CKD [150]. The mineral and 
biochemical regulators involved in bone metabolism include mainly calcium, phosphorous, 
vitamin D and parathyroid hormone (PTH). Others include alkaline phosphatase (ALP), vitamin 
D receptors (VDR) and most recently, fibroblast growth factor -twenty three (FGF-23). These 
regulators are all interrelated and highly integrated. Whenever any event alters the level of one of 
the components, the levels of the others adjust to maintain constant balance and homeostasis. 
Also, there is increasing evidence suggesting that each factor alone, may independently predict 
the risk of mortality in CKD patients, For instance a study found that increased ALP 
independently predicted the risk of mortality among stage 5, CKD patients [151, 152].  
 
7.1.1 CALCIUM 
Calcium is predominantly stored in the bone and regulated by PTH. About 99% of 
calcium is stored in bone matrix while only 1%  circulates in the extracellular compartment as 
either ionized (the active form) or un-ionized (less active form bound to albumin) calcium [153]. 
Approximately half of serum calcium is in the active, ionized form, while the remaining half is 
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bound to albumin. To correct for albumin-bound calcium, 0.8mg/dl is added to every 1 mg/dl 
decrease in serum albumin below 4mg/dl [153]. 
Serum calcium is absorbed from intestine or released from bone. Vitamin D aids in 
intestinal absorption of calcium. CKD is associated with vitamin D deficiency [154, 155] which 
in turn is associated with low serum calcium, increased serum phosphorous and elevated PTH, 
leading to bone calcium resorption. 
7.1.2 PHOSPHOROUS 
Phosphorous is a vital component of cellular membranes and nucleic acid, and essential 
for many cellular functions. Phosphorous is also a component of bone matrix. Like calcium,  
approximately 85% of phosphorus is stored in intercellular compartments of bone [156]. Serum 
phosphorous is obtained from bone and through intestinal absorption, regulated by vitamin D. 
Low serum calcium and vitamin D results in elevation of serum phosphorous (also called 
hyperphosphatemia). Elevated serum phosphorous in turn, is associated with release of PTH. 
Because of the impaired capacity of the kidney to filter phosphorous in individuals with  CKD 
and ESRD , hyperphosphatemia is worsened, leading to further elevation of PTH [156]. High 
levels of phosphorous and PTH are associated with high risk of mortality among CKD and 
dialysis patients [157]. It has also been established that hyperphosphatemia is associated with 
precipitation of calcium along soft tissues including arterial vessels, which increases the risk of 
vascular calcification among CKD patients [158]. 
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7.1.3 VITAMIN D 
Vitamin D is a compound name of two related forms of vitamins: vitamin D2, and 
vitamin D3. The metabolism of each is initiated in the liver, then, converted by a complex 
biochemical reaction in the skin to 25-hydroxyl vitamin D (also known as calcidiol). In the 
kidney, calcidiol is converted to 1-25-hydroxyl vitamin D (calcitriol: active form of vitamin D) 
by the action of alpha-hydroxylase enzyme [36].The first effect in onset of CKD, when eGFR 
falls below 60ml/min/1.72m2, is a deficiency of vitamin D[36]. This occurs as a result of 
reduction or absence of kidney alpha-hydroxylase which catalyzes the final hydroxylation step of 
calcidiol to calcitriol (Vitamin D).  
Because vitamin D is required for intestinal calcium absorption, deficiency of Vitamin D 
results in calcium depletion which in turn increases serum PTH, thereby leading to bone calcium 
resorption. In addition to aiding intestinal absorption of phosphorous and calcium, vitamin D 
also controls the release of PTH through the mediating action of vitamin D receptors (VDR), 
located in the parathyroid gland. To achieve this, vitamin D forms a complex with VDR. The 
(calcitriol/VDR- complex) effectively blocks transcription of PTH genes, inhibiting PTH 
production, while at the same time, increasing intestinal calcium absorption [159, 160]. The role 
of VDR has been confirmed in several studies, Cozollino M. et al. showed that, administering 
VDR activators (a vitamin D analog, given to patients who have low or lacks VDR e.g. 
paricalcitol) resulted in increased serum vitamin D and reduced serum PTH among CKD patients 
[161]. A similar study also showed that VDR activator among CKD patients with secondary 
hyperparathyroidism (SHPT) resulted in lower serum PTH and better health outcomes [162].  
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7.1.4 PARATHYROID HORMONE (PTH) 
PTH is produced by parathyroid gland. Elevated serum PTH is common among CKD 
patients and has been shown to be associated with CVD mortality [163, 164] and bone disorders 
[165, 166]. Serum PTH is regulated by calcium, phosphorous and vitamin D. In fact, among 
bone minerals, serum calcium is the main, minute -by- minute regulator of PTH. In early stages 
of CKD, the parathyroid gland becomes hyperactive resulting in excess PTH production, a 
condition known as hyperparathyroidism [167]. Continual rise in serum PTH results in 
secondary and even tertiary hyperparathyroidism, characterized by parathyroid hyperplasia and, 
elevated serum phosphorous and calcium [168].Studies have shown that, secondary and tertiary 
hyperparathyroidism are associated with increased risk of vascular calcification and CVD 
mortality among CKD patients [169-171].  
7.1.5 FIBROBLAST GROWTH FACTOR-23  (FGF-23) 
FGF-23 has received considerable attention as a regulator of vitamin D and phosphorous, 
and therefore of PTH and bone mass. Several studies have shown a correlation between 
increasing stages of CKD and increasing serum FGF-23 [172-174]. The mechanism underlying 
the action of FGF-23 is not fully understood. But, animal models show that in early stages of 
impaired kidney function, high serum FGF-23 regulates phosphorous by promoting elimination 
of phosphorous in the urine and blocking resorption of phosphorous from the tubules[175, 176]. 
However, in the later stages of impaired kidney function, increased serum FGF-23 decreases the 
level of alpha hydroxylase, the enzyme responsible for converting 25-Hvdroxyl vitamin D to 
calcitriol [176].  Deficiency of vitamin D in turn results in impaired intestinal phosphorous and 
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calcium absorption and increased serum PTH production, which further reduces serum 
phosphorous [177].  
Thus, by its action, FGF-23 appeared to be protective in early stages of CKD, by 
triggering an adaptive response for maintenance of phosphate balance. The extent to which FGF-
23 maintains mineral homeostasis is limited in early CKD. A study found that, FGF-23 was no 
longer responsive to mineral imbalances in patients with hyperparathyroidism with advanced 
stage of CKD and on dialysis or have been on long time dialysis[178].The reason for FGF-23 
unresponsiveness at advanced stage of CKD is not known and warrants further investigation. 
However, some theory suggests that it may be due to declining levels of Klotho (a FGF- 23 co-
receptor aiding FGF-23 expression) or to fewer functional nephrons for filtering phosphorous 
[178]. But, none of these mechanisms have been confirmed in separate studies.  
7.1.6 ALKALINE PHOSPHATASES (ALP) 
A majority of ALP is found in liver and bone. The action of ALP is tissue specific. There 
are two types of ALP (a-ALP and b_ALP). b-ALP enzyme is specific to bone. A product of the 
action of ALP is phosphate ions released from phosphate containing compounds. High b-ALP 
results in elevated PTH and b-ALP is an indicator of bone mineral disorders. ALP along with 
PTH is applied in clinical practice to monitor the rate of bone turnovers. A recent study found 
that ALP, was associated with a significant increase in the hazard of all-cause mortality among 
hemodialysis (HD) patients with secondary hyperparathyroidism [179]. 
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7.2 CKD-MINERAL BONE DISORDER: BONE DISORDERS 
CKD-MBD bone disorder is a condition emanating from mineral and biochemical 
imbalances of calcium, phosphorous, vitamin D and PTH. Low serum calcium or vitamin D and 
high phosphorous promotes release of PTH and hyperparathyroidism.  High circulating PTH in 
turn triggers bone resorption of calcium. Persistent occurrence of bone resorption leads to bone 
loss and ultimately affects rate of bone turnover, volume and mineralization. Bone disorder is 
further worsened among CKD and ESRD patients, who are unable to produce vitamin D and 
filter high serum phosphorous due to impaired kidney function [36, 145].  
Bone disorder is associated with several complications including fracture, infection, 
bone-pain, retarded growth in children, abnormal height and brittle bones (also known as renal 
rickets). The most common complication of bone is fracture, and is associated with increased 
mortality. The factors determining bone fracture includes previous fracture, age, gender and 
stage of CKD [180-184]. Danese et al, showed that the risk of a new fracture was seven times 
higher among patients with CKD stage 5 who had previous fracture compared to those without 
fracture [185].  In a similar study, Mittalhenkle et al., showed that mortality from fracture was 
2.15 times higher among CKD patients compared to controls and it is independent of age and 
gender [186]. 
Bone is composed of cortical and trabecular bone. Trabecular bone is porous and spongy 
compared to hard cortical bone. The forearm is made up of cortical bones while the spine and 
femur are made up of 42% and 25% trabecular bone respectively [187]. These findings are 
important, because studies have shown that CKD patients with  elevated PTH tend to have bone 
composition made up of greater quantity of   trabecular bone than of cortical bone[188], which 
may be influencing bone metabolism  among individuals with CKD.  
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7.3 CKD-MINERAL BONE DISORDER: CARDIOVASCULAR DISORDERS 
In general, calcification, which means deposition of calcium, is a highly regulated 
process involving the bone and teeth. However, calcification outside of these structures 
(extraosseous calcification) often occurs. Among many sites, vascular tissues are the most 
common sites, especially the arteries. Arterial calcifications are involved in formation of 
atherosclerotic plaques, in turn associated with increased risk of CVD and CVD deaths [189]. In 
dialysis patients, arterial calcification is a common feature [190, 191]. There is increasing 
evidence suggesting arterial calcification occurs in earlier stages of CKD as well. In fact, a 
pooled study of about twenty five reports containing over 4,000 participants, showed that about 
47-83% of patients in stage 3-5 CKD have cardiovascular calcification [192].  
The pathophysiologic effect of vascular calcification leads to stiffening of vascular walls. 
In CKD patients, the media and intima layers of arteries are affected, resulting in restricted flow, 
increased pulse wave velocity and elevated pulse pressures.   
The mechanism involved in calcification of arterial wall among CKD patients was 
originally thought to be a passive processes involving calcium ion precipitation from serum 
calcium super-saturation as well as increased calcium phosphate product (Ca × P). Recent studies 
have shown that vascular calcification is also an active process dependent on some biochemical 
promoters and inhibitors, the most common promoter being phosphorous. Others include 
osteopontin, osteocalcin, bone morphorgenic protein (BMP), sialoprotein, type 1 collagen and 
ALP. The main inhibitors are Fetuin A, and Osteoprogetrin (OPG) [193-198]. In CKD patients, 
inhibitors are down regulated while the promoters are up regulated [194]. In  an ex vivo 
experimental study, it was discovered that up-regulation of  biochemical inducers of osteogenic 
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cells caused differentiation of vascular smooth muscles into  Osteoblast-like cells, which in turn 
promoted calcification of arterial walls[194].  
The role of bone in vascular calcification has received considerable attention. Vascular 
calcification is associated with bone demineralization and loss among dialysis patients [199]. 
Recent studies among dialysis patient also show that vascular calcification was related to bone 
loss and osteoporotic fracture [200]. These findings suggest that bone loss is associated with 
vascular calcification. Further studies are needed to determine if indeed there is a causal link 
between bone loss and vascular calcification among CKD patients independent of other risk 
factors including age. 
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8.0  CKD AND HEREDITY 
CKD/ESRD results from diverse biological processes in interplay with environmental 
and behavioral factors. However, certain aspects of CKD/ESRD are hereditary. One of the 
commonest and earliest known genetic disorders of kidney is polycystic kidney diseases (PKD). 
The heritability of PKD was first documented in 1957 by Dalgaard OZ[201], since then, several 
family studies have increasingly reported the role of hereditary in kidney disease and declining 
kidney function. Ferguson et al. demonstrated that individuals with family history of CKD had a 
significant risk of being on dialysis [202]. Similar findings were made by Seaquist et al, who also 
showed that diabetic nephropathy occurred in family clusters [203]. Modern genetic techniques 
and approaches, including Linkage Studies, Mapping by Admixture Locus Disequilibrium 
(MALD), Association Studies, and Genome –Wide Association Studies (GWAS) are 
increasingly applied to further understand the genetic bases of kidney diseases and impaired 
kidney function in the general population. 
Inherited kidney diseases arise from mutated genes occurring at one or several sites in the 
genome and subsequently transmitted to offspring. While some genes, such as PKD genes, are 
expressed by simple Mendelian transmission from parents to offspring, others involve complex 
interaction with other genes, environment and lifestyles. Mendelian and complex inherited 
kidney diseases are rare and have low penetrance in human population. Nonetheless, several 
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candidate genes, and single nucleotide polymorphism (SNP’s) have been implicated in the 
spectrum of kidney diseases affecting humans [204].  
Much of kidney diseases disproportionately affect blacks compared to whites. The 
prevalence of kidney disease is approximately four times higher among African Americans 
compared to European Americans [205]. Despite controlling for social and environmental 
factors, African Americans presents with far greater risk of CKD and ESRD compared to 
European Americans. The reason for the apparent disparity is not fully clear, but there is a high 
possibility that it may be due to genetic differences in expression of kidney diseases among 
blacks and whites. Indeed, studies have shown that candidate genes and SNP’s of kidney disease 
are clustered in the African American population. Freedman et al, showed that familial history of 
CKD and ESRD was associated with nine fold increased risk of CKD/ESRD among those with 
family history compared to matched controls without family history of CKD/ESRD[206]. Lei 
HH et al., also reported a familial aggregation of CKD independent of race [207], however, 
Spray BJ et al, found that familial aggregation was not as strong among whites as in blacks 
[208]. In all, there is strong evidence supporting familial aggregation of CKD which tend to be 
stronger in blacks than in whites.  
It has been suggested that African Americans and Caucasians may not share similar 
pathophysiology or etiology for CKD/ESRD.  Evidence of this assertion was hinted by Appel LJ 
et  al., showing that despite beneficial effect of ACE therapy in slowing hypertensive CKD 
progression in the general population, a majority of African Americans continued to progress to 
CKD/ESRD [209]. Bleyer AJ et al., also reported that, arteriosclerosis formation was more 
strongly associated with ESRD among whites compared to blacks [210]. These findings suggest 
that two different mechanisms that are race-dependent may be involved  in CKD/ESRD, 
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explained by genetic differences among blacks and whites. However, additional studies are 
needed to confirm this hypothesis.  
8.1 PKD GENES 
According to the National Kidney Foundation, PKD is the most common life-threatening 
genetic disease[211]. Two genes are associated with PKD: PKD1 and PKD2. PKD1 is located on 
chromosome 16 [204], while PKD2 is located on chromosome 4. PKD affects approximately 
12.5 million people of all race and gender worldwide including approximately 600,000 people in 
U.S [211]. PKD is characterized by cyst formation in kidney and other organs, progressive 
decline in kidney function and kidney failure. It is estimated that approximately 5-8% of all 
ESRD cases requiring dialysis are due to PKD [201]. 
There are two types of PKD: Autosomal Recessive PKD (ARPKD) and Autosomal 
Dominant PKD (ADPKD). ADPKD is more common and occurs among adults. Approximately 
85% of PKD is due to ADPKD, while 15% of PKD is due to ARPKD[211].  ADPKD and 
ARPKD are passed from parents to offspring in a simple Mendelian fashion. If one parent is 
affected with ADPKD, the offspring have a 50% chance of developing PKD whereas in ARPKD, 
if both parents are carriers of ARPKD genes, their offspring will have a 25% chance of 
developing PKD [211].  
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8.2 SINGLE NUCLEOTIDE POLYMORPHISMS (SNP) 
In 2008, Kao WH et al., and Kopp JB et al, showed that MYH9 candidate gene is 
associated with kidney disease [212, 213]. To date, several other candidate genes and Single 
Nucleotide Polymorphisms (SNP) have been linked or associated with genes linked to kidney 
disease and declining function. These SNP's includes Uromodulin (UMOD), Shroom Family 
Member 3 (SHROOM3), Spermatogenesis Associated 5-Like 1 - Glycine Amidinotransferase 
(SPATA5L-GATM), Jagged 1 (JAG1), Stanniocalcin 1 (STC1), Cystitis-C (CST) , Engulfment 
and Cell Motility Protein 1 (ELMO1), PVT1, CNDP1, CNDP2,ENOS, ACTN4 , Chromogranin-
A Gene Polymorphisms (CHGA), EPO, SOD1, CARS, NPHSI, NPHS2, PLCEI, TRPC6, 
TCF7L2, MMP1, UCP2 [214] and most recently, APOL1 gene [215]. A majority of these SNP's 
have not been replicated in large population studies. Therefore, their degree and strength of 
association with CKD and ESRD have not been validated.  
SPATA5L-GATM and CST are involved in creatinine and cystatin-C synthesis 
respectively. They do not play a role in kidney function decline. CHGA is associated with ESRD 
among African Americans. Table 8 shows select genes and SNP’s associated with diabetic 
nephropathy, non-diabetic nephropathy and renal function.  
Table 7. Genes Associated With Diabetic, Non-diabetic Nephropathy and Renal Function 
Diabetic 
Nephropathy 
Non- Diabetic Nephropathies Kidney Function Regulation 
EPO MYH9 UMOD 
SOD1 NPHS1 SHROOM3,STC1 
CARS CHGA TCF7L2 
PVT1 NPHS2 MMP1 and UCP2 
ELMO PLCE1  
CNDP1,CNDP2 ACTN4  
eNOS TRPC6  
Source: Divers J. et al. [204]. 
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8.2.1 MYH9 GENE 
MYH9 gene, located on chromosome 22, is the first candidate gene linked to kidney 
function.  MYH9 polymorphism is found mostly among non-diabetic nephropathy patients. In 
fact, MYH9 polymorphism is responsible for approximately 70% of the non-diabetic ERSD 
among blacks.  The major risk haplotype of MYH9 is E1,  present in approximately 60% of 
African Americans, 36% of whom carry two copies of the homozygous haplotype (E1)[212, 
213]. In contrast, only about of 4% of whites carry MYH9 gene [216].  Future studies should aim 
at comparing the distribution of MYH9 gene among Tobago and U.S black males, in particular 
non-diabetic nephropathy patients.      
Evidence shows that haplotype E1 may be involved in gene-environment interaction. For 
example, while about 4-5% of the patients with homozygous condition will develop 
nephropathy, about 20% will develop nephropathy in the presence of HIV and two E1 
haplotypes, suggesting a possible gene-environment interaction of HIV and MYH9. About 14 
MYH9 SNP’s have been identified and all are associated with non-diabetic ESRD. The spectrum 
of kidney diseases resulting from MYH9 includes Focal Segmented Glomerulo-Sclerosis, HIV –
associated-FSGS and hypertensive nephropathy. When MYH9 genes are expressed, it results in 
production of non-muscle myosin heavy chain 9 proteins, which are found in almost all 
extracellular compartments. The function of this protein is to maintain cell function and 
structure. The effects of the non-muscle myosin heavy chain 9 proteins in the kidney are not 
fully understood, but it has been suggested that it disrupts and depletes podocyte formation in the 
glomerulus [214] leading to declining kidney function.   
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8.2.2 UMOD GENE 
UMOD gene encodes the most abundant protein in urine.  Its mechanism of action is not 
fully understood, but it has been shown that UMOD gene is significantly associated with 
declining kidney function among all types of patient including diabetic and non-diabetic CKD 
patients [214].  
8.2.3 APOL1 GENE 
APOL1 gene is relatively newly studied, common, highly penetrant, and found in humans 
and a few primates [217]. APOL1 gene is located on chromosome 22 near the MYH9 gene. 
MYH9 has been shown to exert strong effect in FSGS, hypertensive-ESRD and HIV- 
nephropathy [218, 219]. Therefore, the proximity of APOL1 genes to MYH9 gene, suggests that 
FSGS, hypertensive-ESRD and HIV- nephropathy may share similar etiology, mediated by 
APOL1 and MYH9 gene. APOL1 gene is made up of two variant alleles: G1 and G2. G1 is 
formed by two base substitutions, and G2 is formed by deletion of two amino acid residues 
which ultimately alters sequence of APOL1 amino acids. Both alleles are recessively inherited, 
and have been found to be more common in the African American population compared to other 
racial groups. Studies are beginning to emerge suggesting that APOL1 gene may be partly 
responsible for the high rate of kidney disease among African Americans. Indeed, approximately 
50% of African Americans have been shown to have either G1 or G2 alleles alone, while 10-
12% is reported to have both G1 and G2 alleles.  
The origin of APOL1 has been examined. It is widely believed APOL1gene arose from 
adaptive mechanism against Trypanosome Brucei (bacteria that causes sleeping sickness, 
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common in Africa). Protection from T. Brucei in nature is achieved by the lysing action of 
APOL1 on T. Brucei. However, in the course of evolution, a new resistant strain, T. Bruce 
Rhodesianse, emerged (TBR).  TBR is resistant to the lysing action of APOL1 and over time, G1 
and G2 variants of APOL1 gene emerged to confer selective advantage and protection against 
TBR [220, 221]. The likelihood of the presence of APLO1 gene variant depends on ancestry. 
while it has been established that APOL1 gene variants are present in large populations of West 
Africans, those in east Africa, such as Ethiopia, show no evidence of APOL 1 gene variants 
[222]. 
The mechanism involving APOL1 in kidney function decline is not understood. APOL 1 
has been linked to cell apoptosis, autophagy, ion-channel function and lipid biology. Therefore, 
it is probable APOL1 action may be mediated by one or combinations of these pathways. Further 
studies are needed to verify this hypothesis.  
Discoveries of candidate genes, SNP’s of kidney diseases and their plausible biological 
pathways are still on-going. The task is challenging and may require many years. However, with 
the advent of new methodological approaches and improvement in existing ones, susceptible 
genes of kidney disease and function will be discovered. As such, new preventive measures 
focusing on susceptible genes may be applicable in reducing kidney diseases worldwide, in 
particular among blacks. 
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9.0  CKD AND OTHER HEALTH OUTCOMES 
CKD is a continuum and in many cases, it is accompanied with co morbid conditions 
with considerable burden on patients. CKD co morbidity includes anemia, depression, infection, 
anxiety, dementia and physical disability. Some occur before the stage of kidney failure and 
others occur after kidney failure and initiation of dialysis.  Of considerable importance are 
behavioral risk factors including diet, cigarette smoking and alcohol abuse in kidney disease 
initiation and complications.  
9.1 CKD AND ANEMIA 
Anemia is characterized by imbalance in hemoglobin level. Anemia occurs when the rate 
of hemoglobin or red blood cell depletion outpace its production in the bone marrow leading to 
hemoglobin deficiency. According to WHO, anemia is blood hemoglobin less than 12g/dl in 
non-pregnant women and 13g/dl in men [223]. The National Kidney Foundation (NKF) defines 
anemia as hemoglobin less than 12 g/dl and 13.5g/dl in females and males respectively[224]. 
Anemia is associated with several health outcomes including increased mortality, weakness, 
fatigue, physical and mental impairment, dyspnea and impaired cognition [225-228].  
The prevalence of anemia tends to increase with increasing age especially among men. 
By WHO criteria, an estimated 11% of men and 10.2% of women 65 years or older, have anemia 
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in the U.S. population [229]. Other factors affecting hemoglobin deficiency includes altitude, 
smoking, pregnancy and race [223].  Blacks have higher prevalence of anemia compared to 
whites. Guralnik et al., found that among blacks, the prevalence of anemia is 27.5 % in men and 
28% in women, whereas among whites the prevalence of anemia is 9.2 % in men and 8.7% in 
women [229]. Other studies have also demonstrated anemia prevalence rate of about 3 to 4 times 
higher among blacks compared to whites[230, 231].   
Anemia is a complication of CKD [229]. There are no clear cut eGFR values that are 
associated with increased risk of anemia among CKD patients. However, according to KDIGO, 
anemia in CKD is diagnosed in adults greater than 15 years old when hemoglobin levels falls 
below 13.0g/dl in males and 12.0g/dl in females[232]. Anemia further complicates the strongly 
coupled relationship between CKD and CVD and CKD and diabetes. In fact, a study found that 
individuals with CKD and CVD have increased mortality and CKD progression in the presence 
of anemia compared to those without anemia [233, 234]. Another study also showed that anemia 
increases the risk of mortality and worsening of CKD among diabetic-CKD patients [235, 236]. 
An estimated one in five diabetic-CKD patients have anemia and the risk of mortality increases 
with increasing stage of CKD [237-239].  
The causes of anemia are multifactorial and they include nutrient deficiency, chronic 
disease and inflammation. In CKD, the contributing factors are iron and erythropoietin 
deficiency. Both factors are known to have anti-apoptosis and anti-inflammatory properties 
[240]. Iron-deficiency is common among individuals with CKD. A study reported iron 
deficiencies among 50% of CKD patient in stages 2-5 of CKD [241]. The mechanism linking 
CKD to anemia is not fully understood, but involves inflammation, micro-vascular damage of 
the bone marrow and release of cytokines, leading to erythropoietin unresponsiveness and iron 
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deficiency [242, 243] among individuals with kidney failure. Further loss of proteins, iron and 
erythropoietin  due to kidney damage  leads to  further iron and erythropoietin deficiency and 
anemia [244].  
Replenishment of iron is accomplished by administering erythropoietin stimulating agent 
(ESA).  However, studies on the effect of ESA have generated mixed result. While some found 
benefits others reported toxic effects [245, 246]. In light of these findings, NKD recommend 
hemoglobin target range not exceeding 13.0g/dl for optimal performance of ESA [25]. 
9.2 CKD DEPRESSION AND MENTAL HEALTH 
The psychological state of individuals with CKD has been studied extensively. Merrill 
FE and associates found that low eGFR was associated with cognitive function impairment and 
that higher creatinine was associated with lower cognitive function even after adjusting for 
demography, CVD and Stroke [247]. A similar study also found a graded inverse relationship 
between CKD stages and cognitive function outcome measures [248]. Several other studies have 
shown similar inverse relationship between CKD and cognitive functions [249-251]. The effect 
of CKD on mental health is so profound, that the term “psycho-nephropathy” was introduced by 
Levy et al to underscore impact of CKD on mental health [252].  
Mental health is a complex condition with different phenotypes. The most common 
mental health condition among individuals with CKD or ESRD is depression and anxiety [253, 
254]. In U.S, the precise estimate of individuals with CKD and mental depression is unknown. 
Several studies have found a range between 30-46% [255-257]. Kutner et al, Taskapan et al and 
Cukor et al, each found prevalence rates of 45, 30 and 45.7 % of depression respectively among 
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ESRD patients. In a systematic review of 59 studies, Murtahgh FE et al, showed the prevalence 
of anxiety ranged between 12-52% [258]. Experts believe the rate of depression and anxiety may 
be much higher in U.S. due to under diagnosis resulting from barriers preventing access to 
healthcare and treatment [259]. 
There are no data showing prevalence of anxiety and depression in the milder stages of 
CKD. However, Hailpern SM et al, showed that moderate CKD was associated with functional 
cognitive abilities relating to learning, concentration and visual attention [249]. In a similar 
study, Seliger  SL et al, also showed that moderate renal impairment was associated with 
dementia even among men in good health with moderate CKD [260]. 
In addition to the existing mental health burden on individuals with CKD, studies show 
that many are also faced with several social behavioral problems, including suicide, substance 
abuse, low quality of life and adherence to therapy [261-264]. While the mechanisms for these 
behavioral issues are not fully understood, it is plausible that the degree of hope among 
individuals with CKD may be related to depressive and anxiety moods impacting mental health. 
Other theories suggest neuropathological changes in the brain caused by oxidative stress, 
inflammation and micro vascular disease [251, 265], similar to the mechanism involved in 
atherosclerosis. But further research is needed to validate these hypotheses.  
9.3 CKD, PHYSICAL DISABILITY AND MUSCLE WASTING 
Muscle wasting is a significant cause of disability in diseases including chronic kidney 
disease. Occurrence of muscle wasting leads to many complications including sedentary 
lifestyle, decreased quality of living which further promotes and complicates CKD and CVD 
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mortality. Under normal circumstance, the skeletal muscle is in a state of homeostasis and 
therefore maintains a balance of muscle mass according to the Schoenheimer theory [266]. 
However, when catabolic conditions exist, far greater amount of muscle proteins are broken 
down to amino acids resulting in lower muscle mass[267]. In CKD patients, the systems that 
have been identified to play a significant role in protein breakdown in muscles include the 
Cathespin and the calcium-dependent Calpain, and Ubiquitin-Proteasome Systems (UPS). The 
UPS is by far the most active system involved in muscle wasting among CKD patients [268]. 
9.4 CKD AND INFECTIONS 
CKD often coexists with other conditions including diabetes, proteinuria, physical and 
functional impairments, amputation and cognitive function.  In the clinical settings, many who 
are receiving dialysis have vascular access [269], which are sites of possible pathogen entry. 
During dialysis, blood comes in contact with equipment’s that are reused among several dialysis 
patients who also have a high rate of contact with hospitals and clinics [53]. This increases the 
chances of nosocomial infection. In addition, studies have shown that CKD patients have a lower 
rate of response to vaccines and declining levels of antibody compared to non-CKD patients 
[270]. Very little is known about bacteria, viral and fungal infections in the early stages of CKD.  
However, among patients with ESRD, studies have shown that, urinary tract infection, 
pneumonia, sepsis (from abscess formation) are the leading causes of hospitalization and 
mortality [271].  Pneumonia and septicemia are associated with 10 and 100 fold increases in 
mortality respectively [272, 273] and are responsible for longer length of hospital stay compared 
to the general population [274]. The risk factors predisposing CKD patients to infections include 
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age, immunosuppressive therapy, anemia, uremia and malnutrition [269, 275, 276]. These factors 
singly or in combination, results in alterations of the white blood cells, monocyte and 
lymphocytes, leading to impaired response to infection [277, 278].  
The role of Hepatitis C virus in CKD has received considerable attention in recent time. 
A study found that HCV positive patients have a 40% higher likelihood of developing renal 
insufficiency compared to sero-negative patients [279]. The chances of CKD progression to 
ESRD are higher in HCV patients due to other co-morbid illnesses [280]. Little is known about 
the prevalence of Hepatitis C in early stages of CKD, but, Hepatitis C is common in ESRD 
patients on dialysis.  In U.S, an estimated 14% of ESRD patients are reported to have Hepatitis C 
[281], in particular stage 5 CKD patients on dialysis. In general, approximately 60-85% [282] of 
those with Hepatitis C will develop the chronic form of Hepatitis C and about 5-25% [283] will 
develop cirrhosis, associated with increased risk of liver cancer. The degree of susceptibility to 
infections depends on several risk factors including age, immunosuppression, obesity, alcohol 
consumption, coexisting illnesses, malnutrition and nephritic syndrome [269, 275, 276, 284-
286].   
Although it is a common knowledge that a majority of Hepatitis C infections in ESRD 
patients are acquired from contaminated equipment and blood transfusion in hospitals and 
clinics[287, 288], there is increasing evidence suggesting Hepatitis C may be an initiator of CKD 
[289]. The most common Hepatitis C related infection among CKD patients is 
Membranoproliferative Glomerular Nephritis (MPGN)[290].  MPGN is mediated by 
cryoglobulin, a protein that precipitates other serum proteins, and it is invoked as an immune 
response to Hepatitis C infection in the body [289, 291].  Because of persistent Hepatitis C 
infection, cryoglobulin are deposited in mensangial cells and capillary vessels of the kidney. Not 
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all patients with cryoglobulin will develop MPGN [292]. Only about one third of patients with 
cryoglobulin will develop MPGN. The selective action of cryoglobulin is not fully understood. 
Cryoglobulin also affects other tissues including the skin and nervous system [292]. The 
selective action of cryoglobulin in MPGN formation may be due to selective preference for the 
skin or nervous system tissues. Further studies are needed to confirm this theory.  
Other forms of CKD that have been associated with Hepatitis C include IgA 
nephropathies, post infectious glomerulonephritis, membranous nephropathy, thrombotic 
nephropathy, focal and segmented glomerulosclerosis, fibrilary and immunotactoid 
glomerulopathy[[293].  
9.5 CKD, SMOKING AND ALCOHOL 
9.5.1 TOBBACO SMOKING 
According to the report of the Surgeon General, smoking harms nearly every organ of the 
body including the kidneys[294]. Smoking is the leading preventable cause of disease and 
mortality in U.S, resulting in about 440,000 deaths annually [294]. Tobacco smoke is known to 
contain over 4000 chemicals and 400 toxins, in particular cadmium and lead which are easily 
accumulated in the kidney and are toxic to kidney at low dosages[295]. 
The first evidence of impact of smoking on CKD risk was observed in 1978 by Dales and 
associates [296].  Dales et al, observed proteinuria, appeared in heavy smokers compared to light 
smokers. Since then, several studies have confirmed this finding. In the Prevention of Renal and 
Vascular End Stage Disease (PREVEND) study, Pinto-Sietsma  et al showed that rate of urine 
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albumin excretion was associated with number of cigarette smoked, even after adjusting for 
potential confounders[297]. Similar result was shown by Halimi et al, who also observed 
irreversible kidney damage as a result of tobacco smoke [298]. In another study, Beyer et al 
showed a correlation between the number of cigarette consumed and progression of CKD [299].  
Diabetes and hypertension are established risk factors of CKD.  In view of the health 
effects of smoking which includes hypertension, diabetes [300], it is plausible diabetes, 
hypertension and cigarette smoking may be interacting to further elevate risk of CKD and CKD 
progression. Indeed, studies show cigarette smoking hastens the risk of CKD and CKD 
progression among diabetic and hypertensive patients faster, compared to non-smokers [301, 
302]. In addition, not only is smoking associated with acceleration of micro-albumin to 
proteinuria [303], the rate of CKD progression to ESRD  is associated with the number of 
cigarette smoked [304].  
The degree of susceptibility to CKD from cigarette smoking may also be dependent on 
the genetic make-up and response to the effect of cigarette smoking. The traditional risk factors 
which include smoking were found to contribute to arteriolar nephrosclerosis among European 
Americans more than any other racial group, suggesting genetics may predispose some groups to 
a greater adverse effect of cigarette smoking compared to others [210], but further studies are 
needed to confirm this hypothesis among individuals with CKD. 
The mechanism of cigarette smoking in CKD initiation or progression is multiple, 
complex and involves many systems working together to cause hemodynamic and non-
hemodynamic changes in the kidneys. One such mechanism involves nicotinic acetylcholine 
receptors which are expressed on the mensangial cells.  Activation of these receptors by 
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concentrations of cigarette smoking leads to release of Tumor Growth Factor –Beta (TGF-β1 ) 
and cell proliferation. TGF in turn leads to scaring of nephrons and tissue fibrosis [305].   
9.5.2 ALCOHOL 
The role of alcohol in CKD is not fully known. But, some studies have shown light-to-
moderate alcohol consumption is beneficial in reducing CVD and CVD mortality by providing 
cardiovascular protection, preventing arthrosclerosis and plaque formation and improving levels 
of HDL [306-310]. It is not clear whether similar benefit is conferred to individuals with 
CKD/ESRD. While some studies found none or positive benefits of alcohol, others reported a 
negative effects of alcohol with respect to CKD initiation and progression. Perneger et al and 
Schaeffner et al, reported small to moderate alcohol consumption resulted in a protective effect 
against CKD, compared to those who had fewer alcohol [311, 312]. In the Honolulu study, 
alcohol intake was reported to have protective effect on renal arteries by significantly reducing 
hyalinization [313].  Conversely,  Muthukumar et al reported  that the risk of renal dysfunction 
was significantly increased among heavy drinkers compared to light drinkers [314]. Shankar et al 
went further to show not only was heavy drinking associated with CKD,  individuals who are 
both smokers and heavy drinkers had substantially higher risk of CKD [315].   
Taken together, there is growing evidence in support of protective effect of light to 
moderate alcohol consumption on CKD [316]. In addition, KDOQI guideline recommend 
moderate alcohol intake not more than two drinks per day for men and not more than one drink 
per day for women[25]. It is believed this protection is mediated by HDL cholesterol which 
confers vascular protection by preventing formation of atherosclerosis[317].  
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10.0  SPECIFIC AIMS 
The incidence of CKD has been on the rise since the past decade[1]. African Americans 
have a higher prevalence of CKD compared to whites. A recent report indicates that the risk of 
CKD is four times higher among African Americans compared to whites[2].  Data also suggests 
an increasing trend in CKD prevalence among other populations of African descent [318]. Much 
of the risk for CKD is attributable to conventional risk factors such as hypertension and diabetes. 
However, these and several other modifiable risk factors of CKD/ESRD have not been well 
studied in populations of West African descent.  
Few studies have examined the relationship between body compositions with biomarkers 
of CKD. A majority of the studies that have examined this relationship based body composition 
on anthropometrics including BMI and waist circumference (WC). These measures do not take 
into consideration body build and lean mass. Studies using Dual X-ray Absorptiometry (DXA) 
and Peripheral Quantitative Computed Tomography (PQCT) to determine body compositions are 
not common. This may be due to concerns for radiation exposure, time and cost considerations.  
Previous study using data from the Osteoporotic Fracture in Men Study (MroS) among 
older Caucasian men with mild to moderate CKD show  a significant association between 
worsening kidney function and increasing bone loss [319]. However, this finding may not be 
generalizable to older black men with CKD. Moreover, it is not certain if rate of bone loss 
among older Caucasians and blacks with CKD is similar.   
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With these considerations in mind we propose to determine and compare the prevalence 
of CKD in populations of older Tobago black, African American and Caucasian men and to 
assess the risk factors associated with CKD among older Tobago black men. In addition, we will 
address the association of body composition with biomarkers of kidney function and the 
relationship of worsening kidney function with bone loss among Tobago black men. This project 
is an ancillary study, built upon an existing longitudinal cohort studies of bone loss  and the 
Tobago Health studies.  
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10.1 SPECIFIC AIM 1 
Determine the prevalence of CKD among Tobago black males. 
Compare prevalence with U.S black and white males, of NHANES of 2003-2006. 
Identify modifiable risk factors of CKD among Tobago black males.  
Hypothesis: We hypothesize that the prevalence of CKD will be higher among Tobago black 
men compared to U.S black and white men. We also suspect that other modifiable risk factors 
including hypertension, diabetes, markers of obesity and body composition, level of education, 
alcohol consumption and cigarette smoking will be strongly associated with CKD among Tobago 
black males independent of age. 
10.2 SPECIFIC AIM 2 
Determine the association of body composition with markers of kidney function among Tobago 
black males. 
Hypothesis: We posit that body composition measures including regional and general adiposities 
determined by DXA/PQCT are associated with serum creatinine and cystatin C among Tobago 
black males, independent of age, hypertension, diabetes and standing height. 
10.3 SPECIFIC AIM 3 
Determine whether low kidney function predicts bone loss among Afro-Caribbean black males. 
Hypothesis:  We hypothesize that increasing quartiles of serum creatinine, cystatin C and 
albuminuria are each associated with greater bone loss among Tobago black males. The rate of 
bone is loss is similar between Tobago black men and their Caucasian counterparts. 
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11.0  THE PREVALENCE AND RISK FACTORS ASSOCIATED WITH CKD AMONG 
TOBAGO BLACK MALES 40 YEARS AND OLDER, 2004-2007 
1H Egwuogu, 1,3AL Patrick, 1CH Bunker,  1I Miljkovic,  2A Youk, 1JM Zmuda  
 
1Department of Epidemiology, Graduate School of Public Health, University of Pittsburgh, 
Pittsburgh, PA 15261, USA; 2Department of Biostatistics, Graduate School of Public Health, 
University of Pittsburgh, Pittsburgh, PA 15261, USA; 3The Tobago Health Studies Office, 
Scarborough, Tobago, Trinidad & Tobago. 
 
Email: kelechiegwuogu@hotmail.com 
 
This project was funded in part by grant received from the Department of Epidemiology 
Small Grant Program, Graduate School of Public Health University of Pittsburgh and supported 
by the Tobago Health Study funded through grants R01 CA84950 from the National Cancer 
Institute, K01-DK083029 from the National Institute of Diabetes and Digestive and Kidney 
Diseases and R03-AR050107 and R01-AR049747 from the National Institute of Arthritis and 
Musculoskeletal and Skin Diseases. 
 
 
64 
 11.1 ABSTRACT 
Introduction: Chronic kidney disease (CKD) is a leading cause of morbidity and mortality. 
CKD is associated with progression to End Stage Renal Disease (ESRD) and several health 
complications. Early diagnosis, intervention and identification of risk factors are important steps 
in minimizing complications associated with CKD. African Americans and other racial 
minorities bear a greater proportion of CKD burden compared to whites. Objectives: Prior 
studies on CKD have been largely focused on African Americans and Caucasians. We extended 
study to include Afro-Caribbean men. We compared the prevalence of CKD, by criteria based on 
Modification Diet in Renal Disease (MDRD) estimated Glomerular Filtration Rate (eGFR) and 
albuminuria, between Afro-Caribbean men on the Island of Tobago and their U.S African 
American and Caucasian counterparts. The risk factors for CKD in Tobago men were 
determined. Methods: 975 Tobago black males aged 40 years and older were included in 
analyses. Data for U.S men was obtained from the National Health and Nutrition Examination 
Survey (NHANES) of the 2003-2006 cycles. It included 538 African American and 1592 
Caucasian men 40years and older. Standardized serum creatinine measurements were performed 
among Tobago and NHANES study participants, using Jaffè reaction to calculate MDRD-eGFR. 
Urinary albumin was measured among Tobago and NHANES study participants using 
fluorescent immunoassay. The prevalence of CKD defined as MDRD-eGFR <60ml/min/1.73m2 
or ACR ≥30mg/g was determined and age-standardized using U.S census 2000. Age-adjusted 
associations of potential risk factors for CKD were determined for Tobago men, using logistic 
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regression. Results: The prevalence of CKD in Tobago men was 19.7%, compared to 23.4% and 
19.7% in African American and Caucasian men respectively. Hypertension, diabetes and 
measures of obesity including BMI and waist circumference were significantly associated with 
CKD independent of age in Tobago men. Conclusion: The prevalence of CKD in Tobago men 
was lower compared to African American men, but, comparable to Caucasian men.  
Hypertension, diabetes and obesity were significant predictors of CKD risk independent of age in 
Tobago men. 
11.2 INTRODUCTION 
Chronic kidney disease (CKD) is a growing health problem in the U.S, and a leading 
cause of morbidity and mortality [1]. In the decade following 1994, CKD increased from 15.5% 
to 16.8% among Americans 20 years or older[1]. A Center for Disease Prevention and Control 
(CDC) report shows that CKD incidence is growing rapidly, in particular among people 65 years 
and older,  and people with  cardiovascular disease (CVD), hypertension, diabetes and 
obesity[320].  It is likely that this trend will continue as the aging population and the number of 
people with risk factors for CKD increases in the U.S population [131].   
CKD is associated with progression to renal failure, which in turn is associated with 
several health complications including CVD, bone loss and anemia. Approximately 530,000 
renal failure patients are on dialysis at an annual cost of approximately $40 billion [2].  Early 
diagnosis and intervention as well as identification of CKD risk factors are important steps in 
reducing these burdens. However, many people may not even be aware of the presence of early 
kidney function disorder until in later stage, when treatment is difficult. African Americans and 
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other racial minority groups are more affected by CKD than whites. In 1994-2004, the age 
adjusted incidence of renal failure was 55.0 per million among African Americans compared to 
22.8 per million among Caucasians [1] [2]. Much of the racial disparity in CKD is attributable to 
genetic susceptibility [320] and modifiable risk factors of CKD including  diabetes, obesity, 
hypertension, lifestyle and socioeconomic factors. A relatively inexpensive method of 
determining CKD is by measuring serum creatinine and using Modification Diet in Renal 
Disease (MDRD) equation to estimate glomerular filtration rate.  However, the performance of 
serum creatinine is controversial. Serum creatinine is influenced by age, race, gender and muscle 
mass [321]. Although, the effects of race, age and gender differences are corrected in MDRD 
equation, the accuracy of MDRD-eGFR alone to detect early kidney damage is uncertain. The 
nonprofit organization of the Kidney Disease Improving  Global Outcomes (KDIGO) 
recommendations include addition of albuminuria test to eGFR  for  CKD screening [322]. 
Several prior studies on CKD have been largely focused on African Americans and 
Caucasians. To explore racial/ethnic differences in CKD, it is important to extend research to 
include other racial/ethnic groups such as Afro-Caribbean. Given the ancestral similarities 
between Afro-Caribbean blacks and African Americans,  we sought to compare the prevalence of 
CKD, based on MDRD-eGFR and albuminuria [322] in Afro-Caribbean men on the Island of 
Tobago to their U.S African American and Caucasian counterparts. Furthermore, the risk factors 
for CKD among Afro-Caribbean men on the Island of Tobago will be determined.  
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11.3 DESIGN AND METHODS 
11.3.1 Study Population 
Our study participants are black males 40 years or older from the Caribbean Island of 
Tobago. Tobago Island is one of the Islands that make up Trinidad and Tobago, located in the 
southern Caribbean.  In 2000, the estimated population of Tobago was 54,084[323]. The island 
measures 42 km by 10 km and occupies a land area of 300 square kilometers. In 1997-2003, 
approximately 3094 men were enrolled into the Tobago Prostate Cancer Screening Study. 
Enrollment into the study was accomplished largely through word of mouth.  To be eligible, 
participants had to be non-institutionalized, 40 years or older, not terminally ill and must be able 
to give informed consents. After initial participation, all men were invited for a follow -up visit 
in 2004-2007.  During this visit, approximately 2,025 participants returned.  The data for this 
report include anthropometric measures, demographic variables and medical history which were 
collected by staff-administered questionnaires in the 2004/2007 visit. Informed consent was 
obtained and the study was approved by the Institutional Review Boards of the University of 
Pittsburgh and the Tobago Division of Health and Social Services. 
The comparison groups were U.S African American and Caucasian males, 40 years or 
older. Data for U.S men were obtained from National Health and Nutrition Examinations ( 
NHANES), a probability sample of the U.S population [51]. NHANES 2003-2006 cycles were 
used to determine the prevalence of CKD among approximately 538 African American and 1592 
Caucasian men 40 years and older.  
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11.3.2 Laboratory Measurements 
The present study includes approximately 1000 samples from the 2004/2007 visit. Blood 
samples were drawn from participants by venipuncture after a 12-hour fast. Drawn blood was 
allowed to sit for at least 20 min to clot before centrifugation. Samples were locally stored at -
20oC before being shipped with dry ice to the Heinz Nutrition Laboratory, where they were 
stored at -80oC. Serum creatinine was quantitatively measured by a kinetic determination based 
on the Jaffè reaction [324]. For Jaffe reaction, the Sigma Diagnostics (St. Louis, Montana) 
creatinine kit was used. Briefly, frozen samples collected in 2004-2007 were thawed. Serum was 
diluted 1:26 with picric acid/sodium hydroxide solution, incubated at 30oC for four minutes and 
read at 500 nm. Serum controls and duplicate samples were run with each assay standardized to 
IDMS-traceable creatinine value[325].The coefficient of variation between runs was 6.0%[326]. 
Similar standardized serum creatinine measurement was performed in NHANES 2003-2006 
cycles[51]. Glomerular  filtration rate  was estimated by using MDRD equation to calculate 
MDRD-eGFR[27, 61], based on the following equation: MDRD-eGFR (ml/min/1.73m2) = 175 * 
(Standard Serum Creatinine (mg/dl) ) -1.154 * (Age)-0.203 * (0.742 if Female) * (1.212 if African 
American/ Black) [37, 327]. The MDRD estimating equation was chosen because of its general 
application in many clinical and epidemiological studies for determining kidney function 
Albumin was measured using a turbidimetric procedure on the Olympus AU400 with 
reagents provided by Olympus America, Inc. (Center Valley, PA).  Briefly, 10 µl of urine was 
incubated with goat anti-human albumin antibody for 5 minutes at room temperature.  The 
resulting turbidity was measured at 340/800 nm.  The procedure was linear from 0.5 – 30 mg/dL.  
Blanks, calibrators and control pools were run simultaneously with all samples. The intra-and 
interassay coefficients of variation were below 2.5% and 5.1%, respectively[326]. Urinary 
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albumin was divided by urinary creatinine to calculate the albumin-creatinine ratio (ACR).   
Similar computation was performed in NHANES 2003[51].  
Body composition measures including percent whole body lean and fat were determined 
with Dual X-ray Absorptiometry (DXA). The Hologic QDR-4500W (Hologic Inc., Bedford, 
MA) was used to measure whole body lean and total body mass by following standard scan 
procedures for patient positioning. Each scan was read and analyzed using QDR software 
Version 8.26a. The coefficient of variations between scans was ≤ 1.16%. 
 This study was based on 975 Tobago black, 538 African American and 1592 Caucasian 
males with both serum creatinine and ACR measures. MDRD-eGFR less than 60ml/min/1.73m2 
or ACR greater than 30mg/g was defined as CKD [24]. The prevalence of CKD in Tobago black, 
African American and Caucasian  men were determined by using this definition[322].  
11.3.3 Covariates 
Hypertension was measured by taking blood pressure after five minutes of seated rest 
using an automated blood pressure machine (Omron model HEM-705CP, Illinois). The average 
of the second and third measurements was taken to calculate systolic and diastolic pressures. 
Hypertensions was defined as systolic pressure equal or greater than 140mmHg or diastolic 
pressure equal or greater than 90mmHg, or self-report of diagnosis by a doctor or other health 
professional and taking antihypertensive medications.  Cardiovascular disease included diagnosis 
of congestive heart failure, arrhythmias, angina pectoris, valvular problems or taking 
cardiovascular prescription medications for cholesterol and lipid treatments. Diabetes was 
assessed by measuring fasting blood glucose. Diabetes was defined as fasting blood glucose 
>126mg/dl, or self-report of diagnosis by a doctor or other health professional and taking anti-
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diabetic medications. BMI was measured by determining a participant’s weight in kilograms and 
height in meters and then dividing the weight by square of the height. Underweight was BMI < 
18.5 kg/m2 , normal weight was BMI (18.5 – 24.9) kg/m2 , overweight was BMI( 25.0 – 29.9) 
kg/m2 and obese was BMI > 30.0 kg/m2. Cigarette smoking was defined as current smoker. 
Alcohol consumption was defined as taking more than three drinks per week. Physical activity 
was defined as taking a walk outside home or yard for any reason including fun walk, exercise, 
walking to work, store or church for at least 5 days in a week. Education was categorized into 
three levels as none or completion of primary school, completion of high school/advanced-level 
and college/graduate or associate. All covariates were assessed in 2004-2007.  
11.3.4 Statistical Analyses 
In this study, only male subjects aged 40 years or older, who identified as Tobagonian 
blacks from the Tobago Health Studies, and African Americans or Caucasians from the 
NHANES 2003-2006 cycles were included. Observations with missing measurements for 
MDRD-eGFR and ACR were excluded. The characteristics of the remaining 975 Tobago black, 
538 African American and 1592 Caucasian men were examined. The means and standard 
deviations of continuous and percentages of categorical independent variables were examined. 
The prevalence rates of CKD by age group were determined in Tobago black, African American 
and Caucasian males. The prevalence rates across all racial/ethnic groups were direct-age-
standardized using the U.S. census 2000 population data. 
The relationships between potential risk factors and CKD were examined among Tobago 
men using logistic regression adjusting for age. A prediction model for the probability of CKD 
among Tobago men was developed using forward step-wise multiple logistic regression. 
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Interactions between main effect risk factors were examined for significance. Models were 
checked for adequacy, assumptions violations, multi co-linearity and parsimony.  A receiver 
operating characteristic curve was performed to determine the sensitivity of the final prediction 
model.  Statistical significance was determined at alpha level of 0.05. All analyses were 
performed using SAS Version 9.3 TSIMI software, SAS Inc. 
11.4 RESULTS 
The characteristics of Tobago black males are displayed in (Table 9). The average age 
was 59.1 years (SD: ±10.5). The mean serum creatinine was 1.2mg/dl (SD: ±0.5) with a mean 
MDRD-eGFR of 77.7ml/min/1.73m2 (SD: ±17.5). The median ACR was 3.3mg/g.  The mean 
waist circumference was 92.7cm (SD: ±11.6) and about 70% were either obese or overweight by 
BMI categorization. In spite of this high categorization of overweight and obesity, 80.1% (SD: 
±5.7) of the body mass was lean mass. The mean scaled body lean mass and fat were 2.1(SD: 
±0.2) and 0.5(SD: ±0.2) respectively. About 65% reported being physically active, 51.3% had 
hypertension, 22.0% had diabetes and 5.9% had cardiovascular disease. The lipids profile show 
that the mean total cholesterol was 204.9mg/dl (SD: ±44.2), the mean triglycerides was 
111.9mg/dl (SD: ±58.2), while the mean HDL and LDL were 50.1mg/dl (SD: ±13.4) and 
132.4mg/dl (SD: ±40.5) respectively. Approximately 11 % reported as current smokers and 
11.7% self identified as alcohol drinkers of more than three drinks per week. Nearly 75% had 
either no education or completed primary education, while 17.4% had secondary school (O/A 
level) and 7.9% had college/associate degree.    
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Table 8. Population Characteristics of Tobago Black Males 40 Years and Older, 2004-2007 
Characteristics  N=975 % Mean(±SD) 
Median(variance) 
 Age, (yr)  975  59.1 ±10.5 
40-49 205 21.1  
50-59 345 35.4  
60-69 237 24.3  
>70 187 19.2  
    
BMI, (kg/m2)  973  27.3±4.5 
Underweight (<18.5) 15 1.5  
Normal (18.5-24.9) 286 29.4  
Overweight  (25-29.9) 440 45.2  
Obese  (>30) 232 23.8  
    
Waist Circumference, (Cm)   972  92.7±11.6 
Scaled  Body Lean Mass* 821  2.1±0.2 
Scaled  Body Fat* 821  0.5 ±0.2 
    
    
    
Serum Creatinine (mg/dl) 975  1.2 ±0.5 
MDRD eGFR (ml/min/1.73m2)  975  77.7 ±18.8 
MDRD eGFR<60(ml/min/1.73m2) 137 14.1  
ACR, (Median) 975  3.3(18535) 
Albuminuria (ACR≥30mg/g), % 101 10.4  
    
Hypertension, (%) 500  51.3  
Diabetes, (%)  214 22.0  
CVD, (%)  57 5.9  
    
Total Cholesterol, (mg/dl) 853  204.9±44.2 
Triglycerides, (mg/dl) 853  111.9±58.2 
HDL, (mg/dl) 853  50.1±13.4 
LDL, (mg/dl) 853  132.4±40.5 
    
Current Smokers, (%) 111 11.4  
Alcohol Drinkers (> 3 Drinks Per Week); % 114 11.7  
Physical Activity, (%) 628 64.7  
    
Education, (%)    
Completed Primary School/No Education 721 74.7  
Completed Secondary School (O/A Level) 168 17.4  
College(University /Associate) 76 7.9  
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Abbreviations: Albuminuria, ACR≥30mg/g; BMI, body mass index; CVD, cardiovascular disease; Diabetes, self-
reported and taking diabetes medication or fasting glucose > 126mg/dl; eGFR, estimated glomerular filtration rate;  
Hypertension, systolic pressure≥140, or diastolic pressure ≥90, or taking medication and self-reported; SD, 
standard deviation; MDRD, modification diet in renal disease; Physical activity, taking a walk outside home or 
yard for any reason including fun walk, exercise, walking to work, store or church for at least 5 days in a week; *, 
whole body lean mass and fat were scaled by dividing each measure with square of  the standing height. 
 
The age adjusted prevalence of albuminuria defined as ACR≥ 30mg/g and low kidney 
function  defined as eGFR less than 60ml/min/1.73m2 among Tobago black, African American 
and Caucasian males is shown in (Table 10). African American had the highest prevalence of 
albuminuria across all age groups followed by Caucasians. Albuminuria was almost 2 to 3 times 
as common in African Americans compared to Tobago blacks or Caucasians except in the >70 
years group. This group showed smaller difference, but still higher prevalence rates among 
African Americans compared to Tobago blacks and Caucasians (>70years old: TB=20.3, 
AA=27.4, CC=25.6)%.  
The prevalence of low kidney function was comparable in African Americans and 
Tobago blacks, but was higher when compared to Caucasians in all age groups except in the  >70 
years  group. In this group, low kidney function was twice as common in Tobago blacks 
compared to African Americans but was comparable in Caucasians (>70years old: TB=40.1, 
AA=19.8, CC=39.3)%.   
The overall age standardized prevalence of impaired kidney function defined as MDRD 
eGFR<60ml/min/1.73m2 was higher among Tobago men(13.5%) compared to African American 
men(9.0%), while the overall age adjusted prevalence of albuminuria defined as ACR≥30mg/g 
was higher among African American men(18.7%)  compared to Tobago men (9.6%). 
Albuminuria was almost twice as common among African American men compared to Tobago 
men, while impaired kidney function was one and half times as common in Tobago men 
compared to African American men. 
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 Figure 3. Age Standardized Distribution of Low eGFR and Albuminuria 
Low eGFR was based on eGFR < 60ml/min/1.73m2 and Albuminuria defined as ACR ≥ 30 mg/g 
in Tobago black, African American and Caucasian males. 
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Table 9. Age Adjusted Prevalence of Albuminuria and MDRD-eGFR <60ml/min/1.73m2 Among Tobago Blacks, 
U.S African American and Caucasian Males 40 Years and Older, 2004/2007 
 
GFR <60ml/min/1.73m2 
 
Albuminuria: ACR>30mg/g 
 
 
TB AA CC 
 
TB 
 
AA 
 
CC 
 
 
Age STD PGFR AAR Rate AAR Rate AAR 
 
PAL 
 
AAR 
 
Rate 
 
AAR 
 
Rate 
 
AAR 
 
 
40-49 42285 1.95 82456 2.41 101907 1.68 71039 2.93 123895 10.24 432998 3.64 153917 
 
 
50-59 30531 5.22 159372 4.07 124261. 4.57 139527 9.86 301036 15.45 471704 8.23 251270 
 
 
60-69 20064 16.88 338680 16.78 336674 11.44 229532 9.7 194621 30.77 617369 14.71 295141 
 
 
>70 25300 40.11 1014783 19.81 501193 39.27 993531 20.32 514096 27.36 692208 25.62 648186 
 
118180 
 
1595291 
 
1064035 
 
1433629  1133648  2214280  1348515 
 
OAAR 
 
13.49 
 
9 
 
12.1  9.59  18.74  11.41 
 
Abbreviations:  ACR, albumin creatinine ratio; AA, African Americans; TB, Tobago black males; CC, Caucasians; CKD, chronic kidney disease; eGFR, 
estimated glomerular filtration rate; MDRD, modification diet in renal disease; AAR, age specific number of people with CKD; OAAR, overall age 
adjusted rate; STD, U.S census 2000 population data in thousand; PGFR, age specific prevalence of GFR<60ml/min/1.73m2; PAL, age specific prevalence 
of albuminuria. 
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 The overall age adjusted prevalence rate of CKD in Tobago blacks and Caucasians were surprisingly similar at 19.7%, 
compared to African Americans at 23.4 % (Table 11).  
 
Table 10. Age Standardized* Prevalence Rate of CKD Using Combined Criteria (Albuminuria and eGFR) Among 
Tobago Black, African American and Caucasian Males, Aged 40 Years and Older, 2004/2007 
 Tobago N=974 
  
African Americans N=538 U.S. Caucasians N=1592    
Age(yr) A B C: 
(A/B)
% 
D: 
C×M 
100 
E 
 
F G: 
(E/F)
% 
H: 
G×M 
100 
I J K: 
(I/J) 
% 
 
L: 
K×M 
100 
 
M 
40-49 9 205 4.4 1860.5 19 166 11.5 4862.8 19 357 5.3 2241.1 42285 
50-59 45 345 13.0 3969.0 22 123  17.9 5465.0 39 328 11.9 3633.2 30531 
60-69 55 237 23.2 4654.8 52 143 36.4 7303.3 70 306 22.9 4594.7 20064 
>70 95 187 50.8 12852.4 42 106 39.6 10018.8 305 601 50.8 12852.4 25300 
Total 204 974  23336.7 135 538  27674.9 433 1592  23321.4 118180 
 
    23336.7 
    118180 
 
    19.7 
   27649.9 
118180 
 
23.4 
  23321.4 
118180 
 
19.7 
 
Abbreviations: A, number of CKD in Tobago blacks sampled; B, age-specific number of Tobago blacks sampled; C, age-specific rate of CKD among Tobago 
blacks; D, age-specific number  of Tobago blacks with CKD;  E, number of CKD in U.S blacks sampled;  F, age-specific number of  U.S blacks sampled; G, 
age-specific rate of  CKD in U.S blacks;  H, age-specific number  of African Americans  with CKD;  I, number of CKD in U.S Caucasians sampled; J, age-
specific number of U.S Caucasians sampled; K, age-specific rate of CKD in U.S Caucasians; L, age-specific number  of Caucasians with CKD; M, U.S census 
2000 population data in thousand; ACR, albumin creatinine ratio; eGFR, estimated glomerular filtration rate; CKD, chronic kidney disease, defined as MDRD-
eGFR<60ml/min/1.73m2 or ACR≥30mg/g; *, direct age standardized using U.S census 2000 population data.
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The association of potential risk factors for CKD after adjusting for age is shown in 
(Table 12). Hypertension (OR= 2.4, P <0.0001) and diabetes (OR= 1.8, P=0.0002) were each 
associated with increased risk of CKD. CVD (OR=1.70, P=0.0754) was associated with 
increased risk of CKD but this association was not significant. Each SD of scaled body fat 
(OR=1.3, 0.0085) increased risk of CKD, and scaled body lean mass (OR=1.3, P=0.0038) 
increased the risk of CKD. One SD of waist circumference (OR=1.2, P=0.051) was marginally 
associated with increased risk of CKD. Obesity (OR=1.6, P=0.0437) was accompanied with 
increased risk of CKD. Among the lipid markers examined, only HDL (OR=0.80, P=0.0308) 
was found to be associated with a decreased risk of CKD. Smoking and alcohol were not 
significantly associated with risk of CKD.   
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Table 11. Age Adjusted Associations of Risk Factors with CKD Defined as MDRD-eGFR< 
60ml/min/1.73m2 or ACR≥30mg/g Among Tobago Black Males 40 Years and Older, 2004/2007 
Exposure (N=975) 
 Exposure variable Mean 1 STD OR 95% CI P-Value 
Age(years)S * 59.1  10.5 2.7 2.29-3.26 <0.0001 
      
WC, (cm)S 92.7 11.6 1.2 1.00-1.42 0.0511 
      
Scaled T Lean MassS  2.1 0.2 1.3 1.09-1.56 0.0038 
      
Scaled T Body FatS 0.5 0.2 1.3 1.06-1.52 0.0085 
      
Lipids ProfileS      
Total Cholesterol 204.9 44.2 1.0 0.84-1.20 0.9768 
Triglycerides 111.9 58.2 1.1 0.92-1.31 0.2946 
HDL 50.1 13.4 0.8 0.67-0.98 0.0308 
LDL 132.4 40.5 1.0 0.87-1.25 0.6296 
      
Hypertension(Yes)   2.4 1.69-3.50  <0.0001 
No   Reference   
      
Diabetes(Yes)   1.8 1.23-2.57 0.0022 
No   Reference   
      
Smoking(Yes)   0.7 0.34-1.25 0.1970 
No   Reference   
      
Alcohol(Yes)   0.6 0.34-1.18 0.1485 
No   Reference   
      
Education      
Pry/No Education   1.1 0.53-2.10 0.8840 
High Sch. O/A Level   1.4 0.64-3.04 0.4053 
College Education   Reference   
      
BMI      
Obese   1.6 1.01-2.61 0.0437 
Overweight   1.3 0.90-2.01 0.1423 
Normal   Reference   
      
CVD (Yes)   1.7 0.94-3.24 0.0754 
No   Reference   
      
Physical Activities (Yes)   1.2 0.84-1.72 0.3049 
No   Reference   
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Abbreviations: Alcohol, current alcohol drinker of greater than three drinks per week ; BMI, body mass index; 
CVD, cardiovascular disease; Diabetes, self-reported and taking diabetes medication or fasting Glucose > 
126mg/dl;  eGFR, estimated glomerular filtration rate; HDL, high density lipoproteins; Hypertension, systolic 
pressure≥140, or diastolic pressure ≥90 or taking medication and self –reported; LDL, low density lipoproteins; OR, 
odds ratio ; Physical activities,  taking a walk outside home or yard for any reason including fun walk, exercise, 
walking to work, store or church for at least 5 days in a week; Smoking, current smoker; S, continuous variables 
was standardized to mean=0 and standard deviation=1; STD, standard deviation.  * , Unadjusted for age. 
 
The relationships of hypertension and diabetes with albuminuria defined as ACR≥30mg/g 
and impaired kidney function defined as MDRD eGFR<60ml/min/1.73m2 in Tobago black males 
is shown in (Table13). The presence of hypertension was associated with 170% and 120% 
increased risk of albuminuria and impaired kidney function respectively, independent of age and 
diabetes status. In contrast, the presence of diabetes was associated with 120% increased risk of 
albuminuria independent of age and hypertension and only 20% increased risk of impaired 
kidney function but was not significant. This suggests that hypertension considerably influences 
both kidney damage (albuminuria) and impaired glomerular filtration (kidney function), while 
the influence of diabetes was mainly on kidney damage (albuminuria) and less so on impaired 
glomerular filtration (kidney function). 
Table 12. The Risk Associated with Albuminuria and Kidney Function by Hypertension and 
Diabetes Among Tobago Blacks 40 Years and Older, 2004/2007 
 Albuminuria 
(ACR≥30mg/g) 
Kidney Function 
(eGFR<60ml/min/1.73m2) 
Exposure OR 95% CI P-Value OR 95%CI P-Value 
Hypertension(yes)* 2.9 1.79-4.83 <0.0001 2.2 1.42-3.46 0.0005 
Hypertension(yes)ǂ 2.7 1.67-4.52 <0.0001 2.2 1.39-3.41 0.0006 
No Reference   Reference   
       
Diabetes(yes)* 2.4 1.53-3.68 0.0001 1.3 0.84-2.00 0.2364NS 
Diabetes(yes)ɑ 2.2 1.39-3.37 0.0007 1.2 0.78-1.86 0.4001NS 
No Reference   Reference   
       
Abbreviations: ACR, albumin creatinine ratio; CI, confidence interval; Diabetes, was defined as self- reported and 
taking diabetes medication or fasting glucose > 126mg/dl Hypertension, was defined as systolic pressure 
≥140mmHg, or diastolic pressure ≥ 90mmHg or taking medication and self-reported; OR, odds ratio; NS, Non-
statistical significance P >0.05;   
 *, adjusted for age; 
 ǂ, adjusted for diabetes and age;  
ɑ, adjusted for hypertension and age. 
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The prediction model for the probability of CKD occurrence among Tobago black males 
is shown in (Table 12). The probability of CKD was predicted by age, hypertension and diabetes 
according to the equation P(CKD)= -7.10 +Age(0.08)+ Hypertension(0.81)+ Diabetes(0.42).  
The Hosmer Lemeshow goodness of fit test was 0.5429 and the sensitivity analyses (Figure 4) 
show that approximately 79% of CKD in Tobago black males was predicted by this equation. No 
significant interactions were found among the main effect risk factors. 
 
Table 13. Prediction Model for Risk of CKD Defined Using Combined 
Criteria (MDRD-eGFR< 60ml/min/1.73m2 & Albuminuria ACR≥30mg/g) 
Among Tobago Black Males 40 years and Older, 2004/2007 
 Model  
HL=0.5429 
 
  
Exposure OR P-Value  Beta 
Coefficient 
 
Intercept - <0.0001  -7.10  
Age 1.09 <0.0001  0.08  
Hypertension 2.25 <0.0001  0.81  
Diabetes 1.52 0.0417  0.42  
      
Wald P-Val  <.0001    
Abbreviations:  CKD, chronic kidney disease; HL, Hosmer & Lemeshow; Goodness-of-Fit; OR, odds ratio. 
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Figure 4. ROC for The Probability of CKD Among Tobago Males 40Years 
and Older  
Area under the curve  is 78.74%,  indicating that 78.74% of  chronic kidney 
disease defined as albuminuria(ACR≥30mg/g) or MDRD-estimated glomerular 
filtration rate (≤60ml/min/1.73m2  is predicted by  model;  
Prediction model P (CKD) = -7.10 +Age (0.08) + Hypertension (0.81) + Diabetes 
(0.42); Abbreviations: ROC, receiver operation curve; ACR, albumin creatinine 
ratio. 
11.5 DISCUSSION 
In this study, the prevalence of CKD (Pre-dialysis) defined as eGFR less than 
60ml/min/1.73m2 or having albuminuria defined as ACR≥30mg/g was 19.7% among Tobago 
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black males aged 40 and older. Few studies have attempted to determine the prevalence of CKD 
in Caribbean countries [8, 328]. Barton et al reported unadjusted prevalence rate of 327 per 
million population in Jamaica[8]. Soyibo et al, reported from the Caribbean Renal Registry, a 
total of 564 cases of CKD/ESRD in Trinidad and Tobago [328].  Because these investigators did 
not provide a definition of CKD, it was not certain if these numbers represented those with 
earlier stages of CKD or ESRD receiving dialysis or both. It is important to emphasize that the 
Caribbean Renal Registry was set-up in 2004, to track ESRD in Caribbean countries and data 
collection still presents  a challenge [318, 328].   
 The age-standardized prevalence of CKD was lower among Tobago black males (19.7%) 
compared to African American males (23.4%), but was the same for Caucasian males (19.7%). 
Given the ancestral similarities between Tobago blacks and African Americans, the lower 
prevalence rate of CKD in Tobago black compared to African American males was unexpected. 
The higher prevalence rate of CKD among African American men may be due to higher 
incidence rate in African Americans, compared to Tobago men. Further analyses showed that 
albuminuria was twice as common among African American men compared to Tobago men. In 
addition it was also observed that albuminuria was twice as common as low eGFR among 
African Americans. These findings suggest that, not only was albuminuria behind much of the 
racial ethnic differences between Tobago black and African American men, it was also 
responsible for the observed high prevalence of CKD among African Americans. This later 
observation confirms report by Muntner et al, showing that the high incidence of CKD among 
African Americans was attributed to albuminuria [329]. In contrast, the higher prevalence of low 
eGFR compared to albuminuria among Tobago men may also imply that low eGFR may be the 
major culprit of CKD among Tobago men.  Therefore, given the results of these findings we 
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report that the driving mechanism for much of the CKD among African American males was 
albuminuria whereas among Tobago black males it was low eGFR. But additional studies are 
needed to confirm these theories.  
The conventional risk factors associated with CKD include hypertension and diabetes 
[328]. In this study, among Tobago men, hypertension and diabetes were significantly associated 
with increased risk of CKD independent of age. But further analyses also revealed that the 
relative contribution of hypertension and diabetes each to the risk of albuminuria and low eGFR 
varied. After adjusting for important confounders, the risk of albuminuria was 42% higher with 
hypertension than with diabetes and the risk of low eGFR was 500% higher with hypertension 
than with diabetes. These findings confirm that hypertension is by far the major risk factor 
driving a majority of the CKD cases among Tobago black males, in particular through reduction 
of eGFR. Our findings support reports showing hypertension was more prevalent than diabetes 
and is the cause of most CKD cases in a majority of Caribbean countries [318, 328, 330]. The 
important role of hypertension and diabetes in CKD was further highlighted in the prediction 
equation (Table 14), which along with age predicted approximately 79% of the probability of 
CKD among Tobago black males 40 years and older (Figure 4). This prediction model also 
shows that the effect of hypertension on probability of CKD was twice compared to diabetes.  
 In contrast, a recent United State Renal Data System (USRDS) report showing that, 44% 
and 28% of new cases of CKD/ESRD had primary causes of diabetes and hypertension 
respectively[331], suggests that  diabetes  is the leading risk factor for CKD/ESRD among U.S 
men, in particular among  African Americans. Given that albuminuria is an important clinical 
marker for patients with diabetes[332],  this also confirms our finding showing that albuminuria 
is the driving mechanism  behind much of CKD among African Americans.   
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Our result showed that CVD was associated with 70% increased risk of developing CKD 
independent of age,  but this association was borderline significant. This non-significant 
association may have been due to the low prevalence of CVD which was less than 6% among 
Tobago males. This, in turn, may be due to "healthy subject effect", as the participants who 
responded in this study were ambulatory and generally in good health. However, the role of 
CVD in CKD has been well documented in other populations as a major risk factor for CKD [55, 
60-62]. Not only do CVD and CKD  share common risk factors such as age, diabetes, 
dyslipidemia and hypertension, these risk factors also interact with one another to elevate the risk 
of CKD morbidity and mortality [52, 53, 55, 56, 63, 64]. Although, we did not find any 
significant interactions between CKD risk factors and CVD , nonetheless, the occurrence of 
CKD in almost half of the participants who reported having CVD (not shown), suggest an 
important connection between  CVD in CKD in Tobago black males. 
Obesity was found to be significantly associated with increased risk of CKD independent 
of age.  The relationship of BMI with CKD has been documented in other populations. Our result 
is consistent with several prior studies showing that BMI is negatively associated with kidney 
function.  Iseki et al., showed that higher BMI was associated with increased risk of CKD in men 
in the general population in Okinawa after controlling for important confounders [119]. In a 
similar study, Ejarbald et al., reported that being overweight was associated with a three-fold 
excess risk for CKD [120]. Hsu et al., also found that high BMI was independently associated 
with CKD and the risk of ESRD increased with rising BMI [121]. There is overwhelming 
evidence suggesting that obesity is a significant risk factor in CKD progression and deterioration 
[116]. The mechanism linking obesity with CKD is not clear. However, some believe it involves 
the release of pro-inflammatory cytokines and free fatty acids by adipose tissues as a result of  
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invasion by macrophages [135]. Cytokines, in turn, regulate the activities of adipose tissue and 
its systemic effect, thereby, causing kidney damage through expansion of the mesangial cells and 
destruction of podocytes [137].  
Our study has several strengths. This is a population based study with a large sample size.  
Participants were a representative sample of Tobago black males 40 years and older. The 
comparison of CKD prevalence in Tobago blacks with African American and Caucasian males 
was performed to underscore the relative difference in CKD distribution among different 
racial/ethnic groups. Our study also has some limitations. This was an observational cross-
sectional study and direct measurement of glomerular filtration rate was not possible. Therefore, 
we relied on estimates of glomerular filtration by using MDRD equation. In addition, only one 
measurement of serum creatinine and ACR were taken in 2004-2007. The use of one 
measurement to determine kidney function and albuminuria hence CKD, may be misleading and 
the MDRD equation is known to underestimate high eGFR and overestimates low eGFR. This 
may have led to misclassification in the actual CKD prevalence. Self reported responses 
including smoking, alcohol and education were not verifiable. Future direction should focus on 
environmental factors impacting CKD and their mechanisms of action among Tobago black 
males. 
11.5.1 Conclusion 
In this study, based on MDRD eGFR in combination with ACR, the prevalence of CKD 
was lower among Tobago black males at 19.7% compared to African American males at 23.4% 
but was the same as U.S white males at 19.7%. The observed prevalence rate difference between 
African American and Tobago black men was mainly due to higher prevalence of albuminuria 
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among African Americans. Hypertension, diabetes and obesity were associated with increased 
risk of CKD independent of age among Tobago black males. However, hypertension was the 
major risk factor and low eGFR was the mechanism driving CKD among Tobago black males 40 
years and older. In conclusion, Tobago black males could significantly reduce the risk of CKD, 
by eliminating or modifying risk factors leading to diabetes, obesity and in particular 
hypertension. These can be achieved through regular screening and control of hypertension, 
proper dieting, lower salt and fat consumption, increased physical activity, weight control and 
early CKD screening.  
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 12.1 ABSTRACT 
Introduction: Chronic kidney disease (CKD) is a leading cause of morbidity and 
mortality in the U.S. Serum creatinine and cystatin C are biomarkers of CKD but are influenced 
by body composition . The association of body composition with serum creatinine and cystatin C 
has not been elucidated among blacks. Objective: We sought to examine the relation of body 
composition with serum creatinine and cystatin C among older Afro-Caribbean males. Methods: 
approximately 1000 non-institutionalized and non-terminally ill males aged 40 years and older 
were recruited from Caribbean Island of Tobago. Anthropometric measures, peripheral 
quantitative computed tomography (pQCT) of a cross-section of the lower leg at the mid-calf, 
and dual X-Ray absorptiometry (DXA) scan of general and regional body compositions were 
performed. Serum creatinine and cystatin C were measured by Jaffè reaction and Dade Behring 
nephelometer respectively. Albumin creatinine ratio (ACR) was measured by fluorescent 
immunoassay. The Modified Diet in Renal Disease (MDRD) equation was used to estimate 
glomerular filtration rate and combined with ACR to determine CKD status. The relationships of 
body composition measures with serum creatinine and cystatin C were examined using robust 
regression and controlled for important confounders. Results: BMI was significantly associated 
with increase in serum creatinine. BMI and waist circumference were related to cystatin C.  
DXA lean body mass and calf muscle area were positively associated with serum creatinine. 
Cystatin C was positively associated with general and regional adiposities, but not with calf 
muscle area. Discussion/Conclusion: Body composition is related to serum creatinine and 
89 
cystatin C, therefore, should be considered when interpreting serum creatinine and cystatin C. 
Serum creatinine and cystatin C may have prognostic value in diseases related to body 
composition such as obesity related Cardiovascular Disease (CVD) and muscle related diseases 
among older Tobago black males. 
12.2 INTRODUCTION 
Chronic Kidney Disease (CKD) is a leading cause of morbidity and mortality in U.S [54]. 
The prevalence of CKD has been on the increase since the past decade due to rising incidence of 
diabetes, hypertension and obesity [54]. CKD is determined by measuring glomerular filtration 
rate, using gold standard procedures such as iothalamate or inulin clearance tests. The 
complexities and cost associated with these tests limits their practical use and clinical 
application. Alternative procedures use plasma clearance of serum creatinine and cystatin C to 
estimate glomerular filtration rate. Because of influence by extra renal sources, the utility of 
serum creatinine and cystatin C for determining glomerular filtration rate is controversial [333]. 
Serum creatinine is a byproduct of muscle metabolism. The influence  on  serum creatinine by 
age, gender, muscle mass,  protein consumption and body composition  make serum creatinine 
less sensitive as a biomarker of renal function[34, 35]. An alternative biomarker to serum 
creatinine that has gained some acceptance in recent time is Cystatin C. Cystatin C is a low 
molecular weight compound produced by all nucleated cells at a constant rate and filtered in the 
glomerulus. Cystatin C is completely catabolized in the proximal tubules and unlike creatinine, is 
not reabsorbed back into circulation. Studies show that cystatin C is a better and more sensitive 
marker of kidney function with higher precision for detecting CKD  compared to serum 
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creatinine [48, 334-337]. However, studies have also shown that   serum cystatin C is influenced 
by adiposity, inflammatory biomarkers, large doses of glucocorticoids use, hyperthyroid state 
and lean mass [41-43]. The resulting influence from several sources makes serum creatinine and 
cystatin C less sensitive biomarkers of kidney function.  Although the estimating equation of the 
Modification of Diet in Renal Disease (MDRD) Study was developed to adjust serum creatinine-
estimated eGFR for demographic variables [31],  the utility of MDRD equation has not been 
validated in many populations  and the influence of muscle mass and extra renal sources have not 
been fully addressed in this equation. Therefore, the competence of MDRD in assessing kidney 
function is controversial[33] .  
The influence of body composition on serum creatinine and cystatin C suggests, not only 
should body composition be considered when evaluating serum creatinine and cystatin C, but 
that serum creatinine and cystatin C may also have prognostic values in diseases related to body 
composition.  The majority of  prior studies assessing the relationship between body composition 
and serum creatinine and cystatin C were based on  anthropometric measures such as waist 
circumference (WC) and body mass index (BMI) [121, 338, 339].  Muntner et al., showed that 
BMI was associated with increasing serum cystatin C [340]. Steven et al, also reported that body 
anthropometrics including, height, weight, BMI and waist circumference were associated with 
increasing cystatin C [333]. Anthropometric measures are widely accepted correlates of body 
composition and their ease of measurement and low cost makes them attractive for use. 
However, they fail to take into account muscle mass and do not discriminate between general 
and regional adiposities. Moreover, despite the important role of body composition on serum 
creatinine and cystatin C, no study has been conducted in the black population to evaluate this 
relationship. Therefore, the purpose of this study is to examine the relationship of body 
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composition with serum creatinine and cystatin C among Afro-Caribbean males of West African 
ancestry. Anthropometrics, Dual X-ray Absorptiometry (DXA) and Peripheral Quantitative 
Computed Tomography (PQCT) measures of general and regional adiposities will be examined 
in relation to concentrations of serum creatinine and cystatin C, while controlling for important 
confounders.  
12.3 DESIGN AND METHODS 
12.3.1 Study Population 
Approximately 3094 unscreened men from the island of Tobago located in southern 
Caribbean were enrolled into the Tobago Prostate Cancer Survey between 1998 and 2003. 
Recruitment was done by public announcement and word of mouth. To be eligible, participants 
had to be non-institutionalized, 40 years or older, non-terminally ill and must be able to give 
informed consent. The racial composition of recruits were  97% Africans; 2% East Indian; less 
than 1% Caucasians, and less than 1% of  other race[341].  The current study is based on the 
follow-up visit, in 2004-2007, at which anthropometric measures, demographic variables, 
medical history, PQCT of the lower leg in the mid-calf region, and DXA scan of whole and 
regions of the body were performed to assess general and regional adiposities on approximately 
2,025 participants. The current study includes a subsample of approximately 1000 participants 
aged 40 years or older. Informed consent was obtained and study was approved by the 
Institutional Review Boards of University of Pittsburgh and the Tobago Division of Health and 
Social Services. 
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12.3.2 Baseline Questionnaire 
Questionnaires were administered to participants by experienced interviewers in 2004-
2007. Information about age, socioeconomic status, lifestyle, habits including cigarette smoking, 
alcohol consumption, level of education, past medical history, prescription and non-prescription 
medication use, history of diabetes and hypertension were ascertained.  
12.3.3 Laboratory Measurements 
Blood samples were collected in 2004-2007 from participants in the morning after a 12-
hour overnight fast, by venipuncture. Samples were allowed to sit at room temperature for at 
least 20 minutes to clot before centrifugation. Serum and urine samples collected were frozen at -
20◦C locally, before been shipped with dry ice to Heinz laboratory, Graduate School of Public 
Health, University of Pittsburgh, Pittsburgh, Pennsylvania, where they were stored at -80oC.   
Jaffè reaction was used to measure serum creatinine in the laboratory [324]. The Jaffe 
reaction, Sigma Diagnostics (St. Louis, Montana) creatinine kit was used. Briefly, frozen 
samples were thawed. The resulting serum was diluted one part in twenty six parts with picric 
acid/sodium hydroxide solution, incubated at 30oC for four minutes and read at 500 nm. Serum 
controls and duplicate samples were run with each assay. Each assay was standardized  to IDMS-
traceable creatinine values [325]. The coefficient of variation between runs was 6.0%[326].   
Serum cystatin C was measured at the University of Vermont. Thawed samples were 
tested using a BNII nephelometer (Dade Behring, Inc, Deerfield, Ill) with a particle-enhanced 
immunonephelometric assay (N Latex cystatin C, Dade Behring, Inc). The assay range was from 
14.6 - 549.0 nmol/L (0.195 - 7.330 mg/L). The reference range for young, healthy persons was 
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reported to be 40 - 71nmol/L (0.53 - 0.95 mg/L). The intra-assay coefficient of variation ranged 
from 2.0% - 2.8%, and the inter-assay coefficient of variation ranged from 2.3% - 3.1% [342] .  
Urinary albumin was measured using a turbidimetric procedure on the Olympus AU400 
with reagents provided by Olympus America, Inc. (Center Valley, PA).  Ten microliter of urine 
was incubated with goat anti-human albumin antibody for 5 minutes at room temperature.  The 
resulting turbidity was measured at 340/800 nm.  The procedure was linear from (0.5 to 30) 
mg/dL.  Blanks, calibrators and control pools were run simultaneously with all samples. The 
intra-and interassay coefficients of variation were below 2.5% and 5.1%, respectively[326]. In 
this study, kidney function was determined by using serum creatinine in the MDRD equation to 
estimate glomerular filtration rate (MDRD eGFR)[32]. CKD was defined as having ACR greater 
than 30mg/g or MDRD eGFR less than 60ml/min/1.73m2. 
12.3.4 Adiposity Measurements 
DXA and PQCT technologies were used to determine body composition measures 
including general and regional adiposity distributions.  
Regional and body adiposity were measured using a Hologic QDR-4500W DXA 
densitometer (Hologic Inc., Bedford, MA). During DXA measurements, standardized procedures 
for participant positioning and scan analyses were followed according to the manufacturer’s 
recommended protocol. The precision of DXA measurements was assessed in 12 subjects. The 
coefficient of variations was ≤ 1.16% and all test-retest correlations were above 0.99. To 
maintain longitudinal quality assurance of the scanner during the course of the scanning, a 
phantom was scanned daily. All scans were analyzed with QDR software version 8.26a [343].  
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An XCT-2000 scanner (Stratec Medizintechnik, Pforzheim, Germany) was used to 
measure subcutaneous, intermuscular and total adiposities, and muscle area of the lower leg in 
the mid-calf. Assessment of the scanned region was performed using the scanner "soft tissue 
algorithm" to differentiate between tissue densities. Fats, muscles and bones were measured with 
mineral equivalent densities of 0, 80, and 1200 mg/cm3, respectively. By calibrating the scanner 
to these densities, the scanner was able to detect shift in densities from one tissue type to another 
and separate the fat, muscle and bone tissues accordingly. Image processing was performed by 
Stratec analyses software (Version 5.5) [343].   
12.3.5 Covariates 
Covariates were selected based on literature findings of the risk factors associated with 
body composition measures and univariate analyses of the correlates of serum creatinine and 
cystatin C. Hypertension was measured by taking blood pressure after five minutes of seated rest 
using an automated blood pressure machine (Omron model HEM-705CP, Illinois).The average 
of the second and third measurements was taken to calculate systolic and diastolic pressures. 
Hypertensions was defined as systolic pressure equal or greater than 140 mmHg or diastolic 
pressure equal or greater than 90mmHg or self-report of diagnosis by a doctor or other health 
professional and taking antihypertensive medications. Diabetes was defined as fasting glucose 
>126mg/dl, or self-report of diagnosis by a doctor or other health professional and taking anti-
diabetic medications. Cardiovascular disease was assessed by questionnaire in 2004-2007.  It 
included diagnosis of congestive heart failure, arrhythmias, angina pectoris, valvular disease or 
taking cardiovascular prescription medications for cholesterol and lipid treatment. Body Mass 
Index (BMI) was measured by determining a participant’s weight in kilograms and height in 
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meters and then dividing the weight by square of the height. Cigarette smoking was defined as 
current smoker. Alcohol consumption was defined as taking at least three drinks per week. 
Physical activity was defined as taking a walk outside home or yard for any reason including fun 
walk, exercise, walking to work, store or church for at least 5 days in a week.  
12.3.6 Statistical Analyses 
In this study, participants with missing data for serum creatinine and cystatin C were 
excluded from analyses. The characteristics of the remaining 1000 study participants were 
examined. The means and standard deviations of continuous, and percentages of categorical 
variables were determined. Univariate analyses were performed to examine the correlates of 
serum creatinine and cystatin C. The relationships between serum creatinine or cystatin C with 
anthropometric measures of waist circumference and BMI were examined using robust 
regression and controlling for important confounders. Robust regression was used to deal with 
normality assumption violations and outliers. The results were presented as changes in serum 
creatinine or cystatin C for each standard deviation of waist circumference or BMI or other body 
composition measure. Also, the relationships between serum creatinine or cystatin C with DXA-
measured general and regional adiposities and with PQCT-measured adiposities were examined 
using robust regression and controlling for important confounders. Statistical significance was 
based on alpha of 0.05. Statistical analyses were performed using SAS Version 9.3 TSIMI 
software, SAS Inc. 
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12.4 RESULTS 
The characteristics of study participants are displayed in (Table 15).  The mean age of 
participants was 61.8 years (SD: ±11.1). The mean waist circumference was 92.8cm (SD: ±11.8). 
Approximately 70% were either overweight or obese.  The mean whole body adiposity was 
relatively low at 16.8kg, representing 19.8% of total body mass, while the mean whole body lean 
mass was 63.6kg representing 80.4% of total body mass. The mean adiposity for the trunk was 
8.2kg.  The mean muscle area of the lower leg at the calf region was 7523.9mm2. The total areal 
adiposity at this region (the lower leg at the calf) was 1864.9 mm2 (SD: ±844.5), comprising of 
1359.6mm2 and 340.0 mm2 of subcutaneous and intermuscular adiposities respectively. The 
mean serum creatinine was 1.3mg/dl (SD: ±0.4), and serum cystatin C mean was 0.8mg/L (SD: 
±0.3). Approximately 55% of participants had hypertension, 25% had diabetes, while 5.4% had 
cardiovascular disease. About 12% reported as current smokers, 9% reported consuming more 
than three alcohols per week and 61.4% were physically active. 
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Table 14. Characteristics of Tobago Black Males, 40 Years and Older, 2004-2007 
Exposure N=1000 % Mean(SD) 
    
Age (Years) 994  61.8(11.1) 
40-49 174 17.5  
50-59 261 26.3  
60-70 289 29.1  
>70 270 27.2  
BMI(kg/m2) 998  27.3(4.7) 
Underweight (<18.5) 17 1.7  
Normal (18.5-24.9) 292 29.6  
Overweight  (25-29.9) 442 44.9  
Obese  (>30) 234 23.8  
    
Waist Circumference(Cm) 996  92.8 (11.8) 
    
DXA Body Composition    
Whole Body Mass,(Kg) 743  80.4(13.6) 
    
Whole Body Lean Mass,(kg) 743  63.6(8.6) 
Whole Body Adiposity (kg) 743  16.8(6.8) 
Trunk Adiposity,(kg) 743  8.2(3.7) 
    
Peripheral PQCT of Lower Skeletal 
Muscle Composition  
   
Subcutaneous Adiposity(mm2) 945  1359.6(692.3) 
Intermuscular Adiposity(mm2) 945  340.0(432.5) 
Total Calf Adiposity(mm2) 947  1864.9(844.5) 
Muscle Area(mm2) 947  7523.9(1388.9) 
Serum Creatinine, mg/dl 1000  1.3(0.4) 
Serum Cystatin C, mg/L 1000  0.8(0.3) 
    
Hypertension, (%) 548 54.8  
Diabetes, (%) 247 24.7  
CVD, (%) 54 5.4  
    
Current Smoker, (%) 87 11.7  
Physical Activity, (%) 611 61.4  
Alcohol Drinker, (%) 170 9.0  
    
Abbreviations:  Alcohol Drinker, current alcohol drinker of more than three drinks in a week; BMI,  body 
mass index; CVD,  cardiovascular disease; Diabetes, self reported and taking diabetes medication or fasting glucose 
> 126mg/dl; DXA, dual X-ray absorptiometry; HDL, high density lipoprotein; Hypertension; systolic pressure 
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≥140mmHg, or diastolic pressure ≥90mmHg or self reported and taking medication; LDL, low density lipoprotein;  
PQCT, peripheral quantitative computed tomography; Physical activity,  taking a walk outside home or yard for 
any reason including fun walk, exercise, walking to work, store or church for at least 5 days in a week ;Smoking, 
current smoker;  SD, standard deviation.   
 
The age adjusted correlates of serum creatinine and cystatin C are displayed in (Table 
16). BMI, waist circumference, DXA whole body and trunk adiposities, and whole body total 
and lean mass, PQCT calf subcutaneous adiposity and muscle area,  hypertension and smoking 
were significant correlates of serum creatinine (p<0.05). BMI, waist, DXA whole body and trunk 
adiposities, and whole body total mass, PQCT calf intermuscular, subcutaneous and total calf 
adiposities, hypertension and alcohol were significant correlates of serum cystatin C (p<0.05).  
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Table 15. Univariate Analyses of Correlates of Serum Creatinine and Cystatin C, Among Tobago Black 
Males 40 Years and Older, 2004-2007 
 
 
Exposure  
Serum Creatinine(mg/dl) Serum Cystatin C(mg/L) 
Effect 
Change 
per STD 
Unadjuste
d P-Value 
Age-
Adjusted p-
value 
Effect 
Change per 
STD 
Unadjusted 
P-Value 
Age-Adjusted 
p-value 
Age(years) 0.0697 <0.0001 N/A 0.0744 <0.0001 N/A 
BMI, (kg/m2) 0.0165 0.0160 0.0004 0.0145 0.0019 <0.0001 
WC, (cm) 0.0262 0.0001 0.0008 0.0288 <0.0001 <0.0001 
Standing Height, (cm) -0.0164 0.0161 0.3335 -0.0248 <0.0001 0.7975 
       
DXA Body Composition       
Whole Body 
Adiposity,(Kg) 
0.0170 0.0443 0.0261 0.0235 <0.0001 <0.0001 
Trunk Adiposity, (Kg) 0.0207 0.0145 0.0063 0.0220 0.0001 <0.0001 
Whole Body Lean 
Mass,(kg) 
-0.0070 0.4072 0.0170 -0.0190 0.0010 0.0552 
Whole Body Total 
Mass,(kg) 
0.0038 0.6575 0.0110 0 0.9936 0.0004 
       
Peripheral PQCT of 
Lower Skeletal Muscle 
Composition 
      
Intermuscular Adiposity, 0.0228 0.0012 0.4720 0.0308 <0.0001 0.0002 
Subcutaneous Adiposity, 0.0026 0.7105 0.0387 0.0057 0.2485 <0.0001 
Total Calf Adiposity,  0.0093 0.1845 0.0514 0.0192 <0.0001 <0.001 
Muscle Area,(mm2) -0.0121 0.0847 <0.0001 -0.0353 <0.0001 0.6099 
       
HypertensionNS 0.0831 <0.0001 0.0004 0.0682 <0.0001 0.0050 
DiabetesNS 0.0261 0.0993 0.3900 0.0398 0.0003 0.8072 
CVDNS 0.0108 0.7221 0.4332 0.0855 <0.0001 0.1172 
Current SmokersNS -0.0986 <0.0001 0.0015 -0.0192 0.2409 0.7166 
Alcohol DrinkersNS -0.0175 0.4639 0.9216 -0.0613 0.0002 0.0041 
       
       
Abbreviations:  BMI,  body mass index; CVD,  cardiovascular disease; HDL, high density lipoprotein; LDL, low 
density lipoprotein; NS, categorical variables were not standardized, but, continuous variables were standardized to 
mean=0 and standard deviation=1; SD, standard deviation; WC, waist circumference. Bolded Figures are important 
correlates of serum creatinine and cystatin C.   
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Association of Adiposity Measures with Biomarkers of Kidney Function is shown in 
(Table 17). 
After adjusting for age, diabetes and hypertension, similar highly significant positive 
associations were observed between waist circumference (0.0190mg/dl, p=0.0044) and BMI 
(0.0201mg/dl, P=0.0027) with serum creatinine. Waist Circumference (0.0228mg/L, p<0.0001) 
and BMI (0.0189mg/L, p<0.0001) were also highly associated with cystatin C. 
For DXA/PQCT measures of adiposities, after adjusting for age, hypertension, diabetes 
and standing height, only trunk (0.0175mg/dl, P=0.0395) and subcutaneous (0.0135mg/dl, 
p=0.0485) adiposities were significantly associated with serum creatinine. All DXA/PQCT 
adiposity measures, had high significant and positive associations with serum cystatin C 
(p<0.05) 
Association of Muscle Measures with Biomarkers of Kidney Function is shown in 
(Table 17).  
Muscle area (0.0284mg/dl, P= 0.0003) was significantly associated with serum 
creatinine.  Lean mass was only associated with serum creatinine after adjusting for age 
hypertension and diabetes (0. 0205, mg/dl, 0.0170). On further adjusting for standing height the 
association was no longer significant. As expected, muscle area (0.0014mg/L, p=0.7797) was not 
associated with serum cystatin C. We also found unexpectedly, a positive association between 
lean mass (0.0140mg/L, p=0 .0266) and serum cystatin.    
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Table 16. The Association of Body Anthropometrics, General and Regional Adiposity with Serum 
Creatinine and Cystatin C as Continuous Variable 
   Serum Creatinine(mg/dl) Serum Cystatin C(mg/L) 
 
 
Exposure  
 
 
Mean  
 
 
1 STD 
Change per STD 
of Exposure 
 
p-value 
Change per STD 
of Exposure 
 
p-value 
Adiposity Measures       
Anthro-Waist 
Circumference, (Cm) 
92.8 11.8 0.0219a 0.0008 0.0235a <.0001 
   0.0190b 0.0044 0.0228b <.0001 
       
Anthro-BMI, (Kg/m2) 27.3 4.7 0.0233a 0.0004 0.0199a <.0001 
   0.0201b 0.0027 0.0189b <.0001 
       
DXA-Whole Body 
Adiposity, (kg) 
16.8 6.8 0.0179a 0.0261 0.0219a <.0001 
   0.0134ba 0.1120 0.0321ba 0.0011 
       
DXA-Trunk Adiposity, 
(kg) 
8.2 3.7 0.0220a 0.0063 0.0213a <0.0001 
   0.0175ba 0.0395 0.0211ba <0.0001 
       
PQCT-Subcutaneous  
Adiposity, (mm2) 
1359.6 692.3 0.0141a 0.0387 0.0174a <.0001 
   0.0135ba 0.0485 0.0169ba <.0001 
       
PQCT-Intermuscular 
Adiposity, (mm2) 
340.0 432.5 0.0049a 0.4720 0.0156a 0.0002 
   0.0043ba 0.5298 0.0156ba 0.0002 
       
PQCT-Total Calf 
Adiposity, (mm2) 
1864.9 844.5 0.0130a 0.0514 0.0209a <.0001 
   0.0120ba 0.0720 0.0204ba <.0001 
       
Muscle Measures       
DXA-Whole Body 
Lean Mass, (kg) 
63.6 8.6 0.0205a 0.0170 0.0099a 0.0552 
   0.0169ba 0.1110 0.0140ba 0.0266 
       
PQCT-Muscle Area, 
(mm2) 
7523.9 1388.9 0.0307a <0.0001 0.0025a 0.6099 
   0.0284ba 0.0003 0.0014ba 0.7797 
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Abbreviations: BMI, body mass index; DXA, dual X-Ray absorptiometry;; PQCT, 
peripheral quantitative computer tomography;  STD, standard deviation, exposure variables were 
standardized to mean=0 and standard deviation=1; Anthro-, anthropometric measure; a, adjusted 
for age; b, adjusted for age, hypertension and diabetes; ba, adjusted for age, hypertension, 
diabetes and standing height; Bolded Figures, were statistically significant associations P<0.05. 
 
 
 
 
Figure 5. Changes in Serum Concentration of Kidney Function Biomarkers per One SD of 
Body Composition Measure Among All Participants 
Adjusted for age, diabetes, hypertension and standing height. Abbreviations: Ant, 
Anthropometric measures; WC, waist circumference; BMI, body mass index; TA, total lower leg 
adiposity in the mid-calf; SUBC, subcutaneous adiposity; IMT; intermuscular adiposity; WBL; 
whole body lean mass; MUS, muscle area; DXA, DXA measures; PQCT, PQCT measures 
 
 
We further tested the relationships between body composition measures with serum 
creatinine and cystatin C in the absence of CKD and age related impaired kidney function. This 
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was achieved by excluding participants having eGFR less than 60ml/min/1.73m2 or ACR greater 
than 30mg/g and also participants who were greater than 70 years old.  
 
The Association of Adiposity Measures with Biomarkers of Kidney Function Among 
Participants <70years, eGFR < 60ml/min/1.73m2 or ACR >30mg/g is Shown in (Table 18).  
For anthropometric measures of adiposity, on adjusting for age, hypertension and 
diabetes, only BMI (0.0195kg/m2, p=0.0027) was positively associated with serum creatinine. 
Waist circumference and BMI were positively associated with cystatin C (p<0.05).  
For DXA/PQCT measures of adiposities,  after adjusting for age, diabetes, hypertension 
and standing height, only subcutaneous adiposity (0.0227mg/dl, p=0.0005) was positively 
associated with  serum creatinine. All DXA/PQCT adiposity measures were significantly 
associated with serum cystatin C (p<0.0001).  
The Association of Muscle Measures with Biomarkers of Kidney Function Among 
Participants <70years. eGFR <60ml/min/1.73m2 or ACR >30mg/g is Shown in(Table 18). 
Whole body lean mass (0.0188mg/dl, p=0.0591) was marginally associated with serum 
creatinine. Muscle area (0.0272mg/dl, p<0.0001) was related to serum creatinine.  
Whole body lean mass (0.0214mg/L, p=0.0009) was also unexpectedly associated with 
serum cystatin C. As expected muscle area (0.0074, mg/L, p=0.1116) was not related to serum 
cystatin C. 
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Table 17. The Association of Body Anthropometrics, General and Regional Adiposity with Serum 
Creatinine and Cystatin C as Continuous Variable Among Participants <70years old with eGFR > 
60ml/min/1.73m2 or  ACR < 30mg/g 
   Serum Creatinine 
N=671 
Serum Cystatin C 
N=671 
Exposures  
Mean 
1 STD SCr 
Change(mg/L) 
Per 1 STD 
p-val SCy 
Change(mg/dl) 
Per 1 STD 
p-val 
Adiposity Measures       
Anthro-WC(cm) 92.4 11.8 0.0102a 0.1078 0.0208a <0.0001 
   0.0093b 0.1555 0.0218b <0.0001 
       
Anthro-BMI(kg/m2) 27.5 5.0 0.0197a 0.0018 0.0213a <0.0001 
   0.0195b 0.0027 0.0222b <0.0001 
       
DXA-Whole Body 
Adiposity(kg) 
16.8 7.0 0.0072a 0.3667 0.0188a 0.0003 
   0.0066ba 0.4323 0.0197ba 0.0003 
       
DXA-Trunk Adiposity(kg) 8.2 3.7 0.0076a 0.3427 0.0179a 0.0006 
   0.0074ba 0.3815 0.0195ba 0.0004 
       
PQCT-Subcutaneous(mm2) 1432.8 705.9 0.0231a 0.0004 0.0195a <0.0001 
   0.0227ba 0.0005 0.0194ba <0.0001 
       
PQCT-Intermuscular(mm2) 275.3 328.1 -0.0031a 0.6355 0.0177a <0.0001 
   -0.0024ba 0.7149 0.0189ba <0.0001 
       
PQCT-Total Calf 
Adiposity(mm2) 
1874.6 824.0 0.0190a 0.0033 0.0237a <0.0001 
   0.0188ba 0.0036 0.0237ba <0.0001 
       
Muscle Measures       
DXA-Whole Body Lean 
Mass(kg) 
65.6 8.5 0.0185a 0.0222 0.0159a 0.0025 
   0.0188ba 0.0591 0.0214ba 0.0009 
       
PQCT-Muscle Area(mm2) 7872.4 1286.5 0.0275a <0.0001 0.0076a 0.0963 
   0.0272ba <0.0001 0.0074ba 0.1116 
       
Abbreviations: BMI, body mass index; DXA, dual X-Ray absorptiometry;  PQCT, peripheral 
quantitative computer tomography;  STD, standard deviation, exposure variables were 
standardized to mean=0 and standard deviation=1; Anthro-, anthropometric measure; a,  
adjusted for age;  b, adjusted for age, hypertension, diabetes;  ba , adjusted for age, hypertension, 
diabetes and standing height; Bolded Figures, were statistically significant associations P<0.05. 
 
105 
  
Figure 6. Changes in Serum Concentration of Kidney Function Biomarkers Per One SD of 
Body Composition Measure Among Participants Without CKD 
Adjusted for age, diabetes, hypertension and standing height. Abbreviations: Ant, 
Anthropometric measures; WC, waist circumference; BMI, body mass index; TA, total lower leg 
adiposity in the mid-calf; SUBC, subcutaneous adiposity; IMT; intermuscular adiposity; WBL; 
whole body lean mass; MUS, muscle area; DXA, DXA measures; PQCT, PQCT measures. 
12.5 DISCUSSION 
The objective of this study was to examine the association of several body composition 
measures with serum creatinine and cystatin C, among older Afro-Caribbean males. We found 
that after adjusting for age, diabetes and hypertension, BMI was significantly associated with 
serum creatinine. BMI and WC were also highly associated with cystatin C. Our result extends 
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prior studies showing that rising serum creatinine or cystatin C levels are influenced by 
anthropometric measures such as BMI and WC [340, 344]. The positive association between 
BMI and serum creatinine may have been due to high muscle mass component. It can also be 
argued that the association of BMI and WC may have also been due to adiposity components.  
The failure of anthropometric measures to distinguish between body adiposity and 
muscle mass, and its inability to discriminate between general and regional adiposity 
distributions, makes BMI and WC less ideal as surrogates for body composition. For these 
reasons, DXA and PQCT scan, which discriminate between general and regional adiposities and 
also quantify lean mass and adiposity separately, were used to assess several body composition 
measures.  
In general, we observed a positive association between measures of adiposity and cystatin 
C and positive association between measures of muscle mass and creatinine, which was 
independent of age, hypertension, diabetes and standing height. Similar results were observed 
regardless of the CKD status. This consistent association suggests that rising serum 
concentrations of creatinine or cystatin C are not only the result of renal impairment, but are in 
fact also due to body compositions.   Our results extends reports from previous studies showing 
that serum concentrations of creatinine and cystatin C are influenced by muscle mass and 
regional adiposities [41, 333, 344, 345].  
It is emphasized here that even though the magnitude of association between various 
body compositions with biomarkers of kidney function was highly significant, the effect change 
was very small in the order of (10-2). Therefore, the clinical relevance of this small change in 
serum creatinine and cystatin C by body composition is not certain. Nonetheless, our findings 
highlight the important role of body composition on biomarkers of kidney function.  
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In view of this, the contribution of body composition measures should be considered 
when interpreting serum concentrations of creatinine and cystatin C. The MDRD equation is 
widely used for estimating kidney function for determining CKD. But the utility of MDRD in 
determining CKD among  blacks is highly questionable [33].  Although, MDRD is standardized 
using demographic characteristics including age, gender and race, it still does not account for the 
effect of lean or muscle mass for accurate estimation of glomerular filtration rate. To this end, 
the use of MDRD GFR for an estimating equation in a population with high mean percent lean 
body mass as in Tobago men (80% -Percent lean body mass ) without correction factor for lean 
and muscle mass may not be accurate. The use of cystatin C as an alternate biomarker of kidney 
function may also be inadequate as it is influenced by body adiposity. However, given the high 
muscle mass (80% of body mass) and relatively low adiposity (20% of body mass) body 
composition of Tobago black males, it is our opinion that cystatin C  should be the biomarker of 
choice for assessing kidney function in this population. 
The mechanism linking body composition such as muscle and lean mass with rising 
serum creatinine is fairly well known.  Serum creatinine is a breakdown product of creatinine 
phosphate in muscle tissues. The highest concentration of creatinine is found in the skeletal 
muscle, and as such, the rate of serum creatinine production is dependent on muscle or lean 
mass. Synthesis of creatinine begins in the liver where guandinoacetate, which is produced from 
glycine and arginine, is methylated by adenosyl methionine and transported to muscle and other 
energy demanding tissues. In the muscle, methylated guandinoacetate undergoes 
phosphorylation to become phosphocreatinine. Depending on the energy need of the muscle, 
phosphocreatinine is subsequently broken down to creatinine by the action of creatinine kinase 
[346]. The body's balance of creatinine is maintained by generation from muscle cells and 
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clearance by kidney. However, in the presence of kidney disease, serum creatinine concentration 
tends to rise and the rate of clearance may represent renal impairment.  
The mechanism relating adiposity and cystatin C is complex and poorly understood. 
However, the elevation of Cystatin C in obesity suggests possible secretion by large adipose 
tissues and macrophages [347]. Additional study is needed to further understand the mechanism 
linking adiposity to higher levels of serum cystatin C. 
In this study, the association of body compositions with serum creatinine and cystatin C 
suggests that cystatin C and serum creatinine may have prognostic values. In obesity related 
CVD [348, 349], hypertension, dyslipidemia (LDL and HDL cholesterol) and diabetes are 
indirect covariates that have been used previously to link obesity with CVD. Given, the finding 
of the relationship between obesity measures with  serum creatinine and cystatin C, the 
expression of serum creatinine may have important prognostic values in  people with obesity 
related CVD. Also, given the relationship between muscle and lean mass with serum creatinine, 
serum creatinine may also be important in predicting muscle related diseases among Tobago 
men. Taken together, our findings show that body compositions are small but important extra-
renal source of circulating serum creatinine and cystatin C.  
The strength of our population-based study includes a large sample size of 1000 men to 
detect the effects of body compositions on serum creatinine and cystatin C. Adjustments were 
made for important confounding variables and risk factors via modeling.  PQCT and DXA 
scanning were used to determine body’s general and regional adiposity distributions. PQCT 
procedures use modern technologies to assess three instead of two dimensional measurements of 
regional adiposities. The advantage is that, instead of area measurements as in DXA, volume 
measurements are performed which improves accuracy and precision. 
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Our study has some limitations. This was an observational cross-sectional study.  
Temporality could not be ascertained. Therefore, true cause and effect could not be established. 
In addition, only one cross sectional measurement of serum creatinine and cystatin C were taken. 
All participants in this study are blacks. Therefore, our findings may not be generalizable to 
other racial/ethnic groups.   
12.5.1 Conclusion 
In this study, after controlling for important confounders, our findings suggest that serum 
concentrations of circulating creatinine or cystatin C are influenced by body compositions. 
Therefore, the effect of body composition on these biomarkers of kidney function should be 
considered when interpreting serum creatinine and cystatin C.  
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 13.1 ABSTRACT 
Introduction: Chronic Kidney Disease (CKD) affects over 20 million Americans 20 
years or older. One of the complications associated with CKD is bone mineral disorder. The rate 
of bone loss is mediated by highly integrated and interrelated biochemical regulators, involving 
mainly calcium, phosphorous, vitamin D and parathyroid hormone (PTH). Blacks have higher 
bone mass compared to whites. However, it is not certain whether blacks and whites with CKD, 
lose bone at similar rate. Objective: We sought to determine the relationship between markers of 
CKD, serum creatinine and cystatin C, with bone loss among Afro-Caribbean males, 40years and 
older, of similar ancestry as African Americans. We compared our findings to a MrOS 
longitudinal bone study among U.S Caucasian men with CKD. Methods: Approximately 1,425 
Afro- Caribbean males from the Caribbean Island of Tobago were included in our analyses.  In 
2004/2007, questionnaires were administered to ascertain demographic information, medical 
history and risk factors. Dual X-ray Absorptiometry (DXA) of total hip and its sub-region 
(trochanter and femoral bone) were measured in 2004-2007 and at follow-up visits in 2012. 
Serum creatinine was measured by Jaffè reaction. Serum cystatin C was measured using Dade 
Behring nephelometry.  After a mean follow-up of 6 years, the relationship of annual percent 
BMD change with makers of CKD was analyzed using quartiles of serum creatinine and cystatin 
C after controlling for important confounders. Annual percent bone loss was compared with 
published bone loss data in Caucasian men in the MrOS Study.  Result:  There was a consistent 
decline in annual percent BMD across quartiles of Albumin Creatinine Ratio (ACR) and serum 
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creatinine and cystatin C in trochanter, femoral neck and total hip bones. The rate of bone loss 
was similar to that in Caucasian men. Conclusion:   Higher levels of each of the three 
biomarkers of CKD predicted higher bone loss in Tobago men over six years follow-up. 
  
13.2 INTRODUCTION 
Chronic Kidney Disease (CKD) is a growing health problem in U.S,  affecting over 20 
million Americans  aged 20 years or older [350]. A Center for Disease Prevention and 
Control(CDC) report  indicates that the prevalence  of CKD  rose from 12.3% to 14% in the past 
decade [331]. One of the complications associated with CKD is bone mineral disorder. 
According to the Surgeon General’s report on bone health and osteoporosis, an estimated  44 
million Americans over 50 years have osteoporosis or osteopenia[351]. The first awareness 
about the relationship between bone disorders and CKD was reported among dialysis patients by 
Pendras and Erickson in 1966 [144]. Since then, there is increasing evidence suggesting that 
early CKD stages, preceding dialysis, may also be associated with bone and mineral disorders 
[145] [146]. Bone disorders from renal disease were previously termed renal dystrophy.  
However, a 1995 Kidney Disease Improving Global Outcomes (KDIGO) consensus modified the 
system of CKD classification to recognize the systemic component of bone disorders. The term 
renal dystrophy now refers to bone pathological and histological disorders, including osteitis 
fibrosa, osteomalacia, osteoporosis and adynamic bone disease, whereas Chronic Kidney Disease 
– Mineral & Bone Disorder Disease (CKD-MBD) refers to bone disorders arising from CKD and 
the broader effect of CKD on bone, such as mineral disorders [148]. In order to understand the 
113 
mechanism of CKD -MBD, it is important to first understand the bone architecture. There are 
two types of  bone: the trabecular bone which is soft, less dense and found principally in the ends 
of long bones and in vertebrae; the cortical bone which is hard, dense and  found mostly in the 
shaft of long bones, and in the  outer shell covering around the trabecular bones at the end of 
joints or vertebrae [352]. The rate of bone loss is mediated by highly integrated and interrelated 
biochemical regulators, involving mainly calcium, phosphorous, vitamin D and parathyroid 
hormone (PTH). Low serum calcium or vitamin D and high phosphorous promotes the release of 
PTH and hyperparathyroidism.  High circulating PTH in turn triggers bone resorption which 
ultimately affects the rate of bone turnover, volume and mineralization. This condition is further 
worsened in CKD and ESRD patients unable to synthesize vitamin D and excrete phosphorous 
[36, 145]. Biochemical imbalances may begin from CKD stage 3 when the eGFR drops below 
60ml/min/1.73/m2 and gradually worsens as eGFR falls below 15ml/min/1.73/m2 [149]. In 
children, minerals and biochemical imbalances have been reported as early as CKD stage 2 
[150].  
Although, cortical bones are metabolically less active compared to the trabecular bone, 
studies show that bone loss occurs more in cortical than trabecular bone due to elevated PTH 
which tends to have a protective effect on trabecular bone and deleterious effect on cortical bone 
[353-355]. The strength of cortical or trabecular bone is largely determined by bone mass, which 
is usually in a state of balance by the bone forming osteoblast and bone resorption osteoclast 
cells. Imbalances may be caused by many disease conditions including CKD, resulting in bone 
resorption taking more precedence over formation. Age, race and certain medications are known 
risk factors affecting the rate of bone resorption [356, 357]. 
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The social and economic cost, including lifestyle changes, loss of functionality, increased 
mortality and risk of  fracture associated with bone loss, makes CKD-BMD a  major public 
health burden [180-184]. The risk of fracture is seven times higher among patients with CKD 
stage 5 and among CKD patients with previous fracture compared to those without fracture [185, 
186]. Bone loss is also associated with CVD and CVD mortality through arterial calcification, a 
highly regulated process involving the bone and teeth. In CKD patients, extra-osseous 
calcification occurs in vascular tissue especially in the arteries, resulting in stiffening of arterial 
walls including the media and  intima layers, and formation of atherosclerotic plaques [189-191]. 
A study found that 47-83% of patients with CKD stage 3-5 have cardiovascular calcification and 
many die from CVD causes [192]. 
Previous studies have shown that blacks have higher bone mass compared to whites [358, 
359]. Nonetheless, it is not certain whether blacks and whites with CKD, lose bone at the same 
rate. Much of the study on bone loss has been focused on Caucasians and women, and few on 
ethnic minorities. Given the limited information on ethnic minorities and high prevalence of 
CKD among African Americans at (19.9%) compared to Caucasians at (16.1 %), we sought to 
determine the relationship between CKD, or low kidney function, with bone loss among Afro-
Caribbean males, forty years or older of similar ancestry as African Americans. This is also in 
keeping with the Surgeon General report recommending expansion of research on bone loss to 
include racial/ethnic minorities [351].  In addition, we will compare the results of our findings to 
a longitudinal study among U.S Caucasian men with CKD to ascertain racial/ethnic differences 
in the rate of bone loss among blacks and whites. 
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13.3 DESIGN AND METHODS 
13.3.1 Study Population 
 In 2000, the estimated population of Tobago was 54,084 [323].  In 1997- 2003, men 
from the Caribbean Island of Tobago were enrolled into the Tobago Prostate Cancer Survey 
[360]. Recruitment was mostly accomplished through word of mouth throughout the island. Men 
who were institutionalized, terminally ill or unable to give informed consent were excluded and 
men who are 40 years or older were included. The racial composition of recruited participants 
was 97% African, 2% East Indian and less than 0.5% Caucasian. Questionnaires were 
administered to participants by experienced interviewers. 
 Among the initial 3094 men in 1997-2003, information about demography, medical 
history, risk factors, socioeconomic status, lifestyle, habits including cigarette smoking, alcohol 
consumption, level of education, past medical history, prescription and non prescription 
medication use, history of diabetes and hypertension were recorded. After initial participation, all 
men were invited for a follow -up visit in 2004-2007. At this visit, anthropometric measures, 
medical history, risk factor profile and Dual X-ray Absorptiometry (DXA) scan of the hip were 
taken. Urine and blood samples were collected from participants and stored at -800C in the Heinz 
laboratory, located at the Graduate School of Public Health, University of Pittsburgh, 
Pennsylvania U.S. Approximately 1700 participants from 2004-2007 are currently being 
followed and measurements of anthropometrics and DXA scan of the hip, and whole body are, 
presently ongoing in 2012.  The current study includes a subsample of approximately 1492 
Tobago black males followed for an average of 6 years who have complete bone measures from 
2004-2007 to 2012. Informed consents were obtained from participants and study was approved 
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by the Institutional Review Boards of the University of Pittsburgh and the Tobago Division of 
Health and Social Services.   
13.3.2 Bone Mineral Density Measurements 
Hologic QDR-4500W densitometer (Hologic Inc., Bedford, MA) DXA machine was 
used to measure areal BMD g/cm2 of total hip and its sub regions: femoral neck and trochanter. 
Standard procedures for participant positioning and scan analyses were followed according to the 
manufacturer’s recommended protocol. Scans were analyzed with QDR software version 8.26a.  
The short-term in vivo precision of the DXA measurements was assessed in 12 subjects. The 
coefficient of variations was less or equal to 1.16% and all test-retest correlations were above 
0.99. A phantom was scanned daily and reviewed to maintain longitudinal quality assurance of 
the scanner during the course of the study [361]. In this study, annual percent BMD change was 
calculated by dividing the percent BMD change from 2004/2007 to 2012, by the number of years 
of follow-up. 
13.3.3 Laboratory Measurements 
Serum creatinine was quantitatively measured in samples collected at the 2004-2007 visit 
using Jaffè reaction[324] and Sigma Diagnostics (St. Louis, MO) creatinine kit. Serum was 
diluted 1:26 with picric acid/sodium hydroxide solution, incubated at 30oC for four minutes and 
read at 500 nm.  Serum controls and duplicate samples were run with each assay.  Serum 
creatinine assays were standardized to the national IDMS-traceable  to obtain creatinine 
value[325]. The coefficient of variation between runs was 6.0%[362].  Quartiles of serum 
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creatinine were created by using the following cut points: first, <0.7mg/dl; second, (0.7 to <1.10) 
mg/dl; third, (1.10 to 1.5) mg/dl; fourth >1.5mg/dl. 
Serum cystatin C was measured at the University of Vermont from frozen samples 
collected in 2004-2007 using BNII nephelometer (Dade Behring, Inc, Deerfield, Ill) with a 
particle-enhanced immunonephelometric assay (N Latex Cystatin C, Dade Behring, Inc). The 
assay range was from 14.6 to 549.0 nmol/L (0.195 to 7.330 mg/L). The reference range for 
young, healthy persons was reported to be 40 to 71nmol/L (0.53 to 0.95 mg/L). The intra-assay 
coefficient of variation ranged from 2.0% to 2.8%, and the inter-assay coefficient of variation 
ranged from 2.3% to 3.1% [342].Quartiles of serum cystatin C was created according to the 
following cut points: first quartile, cystatin C <0.60mg/L; second quartile, cystatin C (0.60 to 
<0.85)mg/L; third quartile, cystatin C (0.85 to 1.11)mg/L; fourth quartile, cystatin C >1.11mg/L. 
Urinary albumin was measured using a turbidimetric procedure on the Olympus AU400 
with reagents provided by Olympus America, Inc. (Center Valley, PA).  Briefly, 10 µl of urine 
was incubated with goat anti-human albumin antibody for 5 minutes at room temperature.  The 
resulting turbidity was measured at 340/800 nm.  Blanks, calibrators and control pools were run 
simultaneously with all samples.  The intra-and interassay coefficients of variation were below 
2.5% and 5.1%, respectively[326]. Urinary creatinine was measure using the Jaffe reaction as 
described above. Categories of the albumin/creatinine ratio (ACR) were created as follows: first, 
<30mg/g; second, (30 to <135) mg/g; third, (>135 to 300) mg/g; fourth, >300mg/g. 
13.3.4 Covariates 
All covariates were assessed or measured from the 2004/2007 visit. Hypertension was 
measured by taking three blood pressure measurements after five minutes of seated rest using an 
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automate blood pressure machine (Omron model HEM-705CP, Illinois).The average of the 
second and third measurements was taken to calculate systolic and diastolic pressures. 
Hypertension was defined as systolic pressure equal or greater than 140mmHg or diastolic 
pressure equal or greater than 90mmHg or self reported diagnosis by a doctor or other health 
professional and anti-hypertension medication use. Cardiovascular disease was assessed from 
questionnaire, and included diagnosis of congestive heart failure, arrhythmias, angina pectoris, 
valvular disease or taking cardiovascular prescription medications for cholesterol and lipid 
treatments. Diabetes was defined as fasting glucose >126mg/dl or self-reported diagnosis by a 
doctor or other health professional and taking anti-diabetic medications. BMI was measured by 
determining a participant’s weight in kilograms and height in meters and then dividing the 
weight by height squared. Cigarette smoking was self reported as current smoker. Alcohol 
consumption was defined as self reported current drinker of at least 3 drinks per week. Physical 
activity was defined as taking a walk outside home or yard for any reason including, walking to 
store, work, church, fun walk and exercise for at least five days in a week. Education, vitamin D 
and calcium supplements use were self reported. 
13.3.5 Statistical Analyses 
Only participants who identified as black with measurements for BMD change from 
2004-2007 to 2012 were included. The characteristics of study participants were described using 
means, standard deviations and percentages as appropriate. The primary outcome of interest is 
annual percent BMD change in each bone site examined (trochanter, femoral and total hip bone) 
and the predictor is each quartile of ACR, serum creatinine and cystatin C. Unadjusted and age-
adjusted univariate analyses were performed to examine the correlates of annual percent BMD 
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change each of trochanter, femoral neck and total hip bone. The association between annual 
percent BMD change, each,  in trochanter, femoral neck and total hip bone from 2004-2007 to 
2012 follow-up visits, with quartile of ACR, serum creatinine and cystatin C, was examined 
using robust regression. Robust regression was used to deal with possible normality violations 
and extreme data point outliers.  In each analyses, least square means (LSMEANS) was used to 
calculate mean annual percent BMD change across quartiles of ACR, serum creatinine and 
cystatin C. Four models were developed for each bone site:  First model, was unadjusted; second 
model, was adjusted for age; third model, was adjusted for age, baseline BMD of the respective 
bone site and percent weight change from 2004/2007 to 2012; fourth model, was the full model, 
which included model three in addition to other important covariates of the respective bone site 
being examined. A p-value ≤0.1 was used as cut point for including covariates from univariate 
analyses. Correlated covariates were examined and only one was chosen based on the degree of 
relevance to the primary outcome of interest.  A sub analyses involving a subsample of 219 
Tobago men aged 65 years and older was performed. The association of increasing cystatin C 
quartiles with annual percent total hip BMD change was examined and compared with 
Osteoporotic Fractures in Men study (MrOS)[319],  involving Caucasian males 65years and 
older. Categories for serum cystatin C was defined similarly as in MrOS as follows: Q1,(<0.97); 
Q2,(0.98-1.10); Q3,(1.11-1.25); Q4(≥1.26).  Test for linear trend was performed.  Statistical 
significance was based on alpha value of 0.05. Statistical analyses were performed using (SAS, 
Version 9.3, SAS Institute, Cary, NC). 
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13.4 RESULTS 
The average follow-up for all participants was 6 years. The characteristics of study 
participants are shown in (Table 19). The mean age was 57.0 years (SD: ± 9.2).The mean BMI 
was 27.6kg/m2 (SD: ± 4.5) with average waist circumference of 93.2cm (SD: ± 11.2) and mean 
whole body lean mass of 65.2kg (SD: ± 8.8). Mean percent change in body weight was 0.0037 
%( SD: ±7.2). Mean weekly calcium supplement intake was 3372.1mg (SD: ± 1621.3). 
Approximately 14% reported vitamin D supplement use. The median ACR measure was 2.9 
mg/g. The mean serum creatinine and cystatin C were 1.2mg/dl (SD: ±0.4) and 0.8mg/L 
(SD:±0.2) respectively. Approximately 48% had hypertension, 18.7% had diabetes and 3.5% 
reported CVD. About 13% reported as current smokers, 10.7% reported alcohol consumption of 
more than three drinks per week and  64.5%  reported being physically active.  The mean percent 
annual BMD change from 2004/2007 to 2012 for femoral, trochanter and total hip bone were -
0.4 (SD: ± 0.8), -0.2 (SD; ± 0.9) and -0.1 (SD: ± 0.6) % respectively. The mean BMD at baseline 
for femoral, trochanter and total hip were 1.0 (SD: ± 0.2), 0.9 (SD: ± 0.1) and 1.2 (SD: ± 0.2) 
mg/cm2 respectively. 
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Table 18. Population Characteristics of Tobago Males 40 Years and Older, 2004/2007 
Characteristics N=1425 % Mean(SD) 
Median(Variance) 
Age(yr) 1404  57.0(9.2) 
40-49 344 24.5  
50-59 548 39.1  
60-69 346 24.7  
>70 165 11.8  
    
BMI(kg/m2) 1422  27.6(4.5) 
WC (Cm) 1417  93.2(11.2) 
    
Baseline(2004-7) BMD ,(g/cm2)    
Femoral Neck Bone 1425  1.0(0.2) 
Trochanter Bone 1425  0.9(0.1) 
Total Hip Bone 1425  1.2(0.2) 
    
Annual BMD Change (2004-7 to 2012), %    
Femoral Neck Bone 1425  -0.4(0.8) 
Trochanter Bone 1425  -0.2(0.9) 
Total Hip Bone 1425  -0.1(0.6) 
    
Weekly Calcium Supplement Intake(mg) 1407  3372.1(1621.3) 
Body Weight (V3) (Kg) 1422  85.0(15.0) 
% Change in Body Weight from V3-v5 1402  0.0037(7.2)) 
ACR, (mg/g), Median(Variance) 643  2.9(23922) 
Serum creatinine(mg/dl) 1338  1.2(0.4) 
MDRD eGFR <60ml/min/1.73m2) 1334  80.6(37.0) 
Serum Cystatin C(mg/L) 592  0.8(0.2) 
    
Physical Activity  904 64.5  
Vitamin D supplement Use  ( At least one time 
per week) 
193 14.2  
Hypertension 683 48.0  
Diabetes 266 18.7  
CVD 49 3.5  
Current Smokers 144 13.0  
Alcohol Drinkers (> three drinks per week) 
 
150 10.7  
Education    
Primary/No Education 1004 72.1  
High School O/A Level 285 20.5  
College/Associate 103 7.4  
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Abbreviations: Alcohol, current alcohol drinker of more than three drinks per week; 
BMD, bone mineral density; CVD, cardiovascular disease; Diabetes, self-reported and taking 
diabetes medication or fasting glucose > 126mg/dl;  Hypertension; systolic pressure 
≥140mmHg, or diastolic pressure ≥90mmHg or taking medication and self-reported; Physical 
Activity, taking a walk outside home or yard for any reason including fun walk, exercise, 
walking to work, store or church for at least 5 days in a week  SD, standard deviation;  Smoking, 
current smokers; WC, waist circumference .   
 
Correlates of trochanter, femoral and total hip annual percent BMD change after 
adjusting for age are shown in (Table 20).  
Trochanter Bone 
For trochanter bone, BMI, waist circumference, percent change in body weight, physical 
activity, vitamin D supplement intake, diabetes and CVD were each associated with annual 
percent BMD change in trochanter bone (p≤0.1). 
Femoral Bone 
 For femoral bone, waist circumference, percent change in body weight, physical activity, 
vitamin D supplement intake, hypertension, diabetes and CVD were each associated with annual 
percent BMD change in femoral bone (p≤0.1).  
Total Hip Bone 
BMI, waist circumference, percent change in body weight, vitamin D supplement intake, 
diabetes, CVD and smoking, were each related to annual percent BMD change in total hip bone 
(p≤0.1). 
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Table 19. The Univariate Analyses of Correlates of Percent Annual BMD Change In Trochanter, Femoral Neck 
and Total Hip Among Tobago Black Males 40 Years and Older, 2004/2007 
 Trochanter Femoral Neck Total Hip 
Exposure  AC P-Val 
 
P-Val* 
  
AC P-Val 
 
P-Val* 
  
AC P-Val 
 
P-Val*  
Age(yr)S  -0.2411 <0.0001 N/A -0.1292 <0.0001 N/A -0.1459 <0.0001 N/A 
BMI(kg/m2) S 0.0903 0.0001 0.0010 0.0298 0.1379 0.3287 0.0760 <0.0001 0.0001 
WC (Cm) 0.0852 0.0003 <0.0001 0.0385 0.0554 0.0309 0.0755 <0.0001 <0.0001 
          
 Baseline(V3)BMD 
(g/cm2)S 
0.0606 0.0101 0.0868 0.0182 0.3644 0.4706 0.0670 <0.0001 0.0058 
          
Weekly Calcium 
Intake(mg)S 
0.0199 0.4032 0.8219 0.0196 0.3327 0.6444 0.0183 0.2506 0.6657 
Whole Body Lean 
Mass(Kg)S 
0.0586 0.0251 0.8110 0.0228 0.3114 0.4915 0.0564 0.0013 0.3635 
          
% Change in Body 
Weight (V3-V5) 
0.1376 <0.0001 <0.0001 0.1447 <0.0001 <0.0001 0.1239 <0.0001 <0.0001 
          
Serum 
creatinine(mg/dl)S 
-0.0860 0.0004 0.0092 -0.0459 0.0251 0.1383 -0.0622 0.0001 0.0051 
ACR, (mg/g)S -0.0689 0.0784 0.1074 -0.0195 0.5277 0.6546 -0.0570 0.0165 0.0249 
Cystatin C,( mg/L)S -0.1341 0.0020 0.0088 -0.0599 0.0848 0.3277 -0.1010 0.0001 0.0053 
          
Physical Activity ( 
walk >5 times in 
past 7 days) 
0.1023 0.0401 0.0591 0.0596 0.0236 0.0323 0.0599 0.0737 0.1164 
Vitamin D 
supplement Use  
0.0977 0.1606 0.0397 0.0927 0.1155 0.0493 0.0643 0.1670 0.0361 
          
Hypertension -0.1348 0.0043 0.4004 -0.1043 0.0095 0.060 -0.1198 0.0008 0.2942 
Diabetes -0.2728 <0.0001 0.0004 -0.2359 <0.0001 0.0001 -0.1950 <0.0001 0.0002 
CVD -0.4007 0.0020 0.0217 -0.3429 0.0019 0.0139 -0.2476 0.0044 0.0559 
          
Current Smoker -0.0711 0.3209 0.1152 -0.0496 0.4465 0.2226 -0.0979 0.0604 0.0121 
Alcohol Drinker (> 
three drinks per 
week) 
 
0.1226 0.1096 0.1965 0.0870 0.1846 0.2310 0.0879 0.0893 0.1695 
Abbreviations:  ACR, albumin creatinine ratio; BMI, body mass index; BMD, bone mineral 
density; CVD, cardiovascular disease; AC, percent annual BMD change in %  per standard 
deviation of continuous exposure variable denoted by  S ; P-Val*,  age-adjusted P-Value; S, 
standardized to mean=0 and standard deviation=1;  WC, waist circumference; % Change in 
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Weight , percent change in weight from V3(2003-2007 to V5(2012). Bolded Figures, were 
considered significant and included in full model if P-Val was ≤0.100. 
 
Association of Quartiles of ACR with Mean Percent Annual BMD Change 
The relationships of trochanter, femoral neck and total hip annual percent BMD change 
each, with quartiles of ACR were further examined in (Table 21). In general, there was greater 
decline in annual percent BMD across increasing quartiles of ACR in all the bone sites (Figure 
7). 
Trochanter Bone 
A significant linear trend was observed with greater bone loss across increasing quartiles 
of ACR in the unadjusted model (annual percent BMD decline across ACR quartiles; -0.19, -
0.48,-0.58,-0.85. P-vale for trend=0.0482). The result was similar after adjusting for age (P for 
trend =0.0068). Further adjusting with baseline trochanter BMD and percent change in body 
weight still showed greater bone loss across increasing quartiles of ACR, but the linear trend was 
no longer significant(P=0.0644). Similar result was also observed in the full model adjusting for 
age, percent change in body weight, baseline trochanter BMD, physical activity, vitamin D 
supplement use, diabetes and CVD.   
Femoral Bone 
We observed greater femoral neck bone loss across increasing quartiles of ACR (annual 
percent BMD decline across ACR quartiles: -0.38,-0.56,-0.58,-0.83; P for trend=0.1036), without 
significant linear trend in the unadjusted model. Similar results were obtained in model 2, 
adjusting for age; model 3, adjusting for  age baseline femoral neck BMD and percent change in 
body weight;  and in the full; adjusting for age,  percent change in body weight, baseline femoral 
neck BMD, waist circumference, hypertension, diabetes, physical  activity and CVD . 
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Total Hip Bone 
The unadjusted analyses show a significant linear trend in increasing total hip bone loss 
across increasing quartiles of ACR (annual percent BMD decline across ACR quartiles: -0.10, -
0.23,-0.20,-0.73, P for trend=0.0034). Similar result was also found after adjusting for age (P for 
trend=0.0044).  Although there was attenuation of total hip bone loss after controlling for age, 
baseline total hip BMD and percent change in body weight, nonetheless, the linear trend still 
remained significant (P for trend=0.0043). Similar attenuation, but  with significant linear trend 
was also observed in the full model adjusting for age, percent change in body weight, baseline 
total hip BMD,  BMI, vitamin D supplement use, diabetes, CVD and smoking (P for 
trend=0.0089). 
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Table 20. Longitudinal Association of Quartiles of ACR With Percent Annual BMD Change From 2004/2007 to 
2012 in Trochanter, Femoral Neck and Total Hip Bone, Among Tobago Black Males 40 Years and Older 
 
 
Bone 
Annual Percent Bone Mineral Density Change (95% CI) 
Q1 
<30mg/g 
 
Q2 
(30 to -135)mg/g 
 
Q3 
(136 - 300)mg/g 
 
Q4 
>300mg/g 
 
P-Val. 
For 
Trend 
Trochanter Bone       
1 Unadjusted -0.19(-0.27,-0.11) -0.48(-0.81,-0.16) -0.58(-1.16,0.1) -0.85(-1.50,-0.20) 0.0482 
2 Age -0.19(-0.27,-0.11) -0.42(-0.74,-0.10) -0.49(-1.07,0.09) -0.81(-1.44,-0.17) 0.0068 
3 Age+%WBLM+TBMD -0.18(-0.26,-0.10) -0.42(-0.75,-0.10) -0.41(-0.98,0.17) -0.83(-1.00,-0.17) 0.0644 
4 Full Modelt -0.17(-0.25,-0.10) -0.43(-0.75,-0.11) -0.46(-1.04,0.11) -0.75(-1.39,-0.11) 0.0938 
      
Femoral Neck Bone      
1  Unadjusted -0.38(-0.44,-0.31) -0.56(-0.82,-0.31) -0.58(-1.05,-0.13) -0.83(-1.33,-0.32) 0.1036 
2  Age -0.38(-0.45,-0.32) -0.49(-0.75,-0.24) -0.51(-09.6,-0.06) -0.79(-1.29,-0.29) 0.1267 
3 Age+%WBLM+FBMD -0.39(-0.45,-0.33) -0.49(-0.74,-0.24) -0.41(-0.86,-0.04) -0.82(-1.31,-0.33) 0.1303 
4  Full Modelf -0.39(-0.45,-0.33) -0.48(-0.73,-0.23) -0.37(-0.82,0.08) -0.76(-1.26,-0.26) 0.2138 
      
Total Hip Bone      
1  Unadjusted -0.10(-0.14,-0.05) -0.23(-0.43,-0.04) -0.20(-056, 0.15) -0.73(-1.12,-0.34) 0.0034 
2  Age -0.10(-0.15,-0.05) -0.18(-0.37,0.01) -0.13(-0.48,0.21) -0.70(-1.08,-0.32) 0.0044 
3 Age+%WC+HBMD -0.09(-0.14,-0.05) -0.19(-0.37,0.00) -0.06(-0.40,0.28) -0.72(-1.09,-0.34) 0.0043 
4 Full Modelh -0.12(-0.17,-0.07) -0.18(-0.37,0.02) -0.03(-0.39,0.34) -0.77(-1.19,-0.35) 0.0089 
      
Abbreviations: Full modelt,  adjusted for age, percent change in body weight from 
V3(2003/2007) to V5(2012), baseline trochanter BMD, physical activity, vitamin D supplement 
use,  diabetes and CVD; Full modelf,  adjusted for age , percent change in body weight from 
V3(2003/2007 to V5(2012), baseline femoral neck BMD, waist circumference, hypertension, 
diabetes, physical  activity and CVD; Full modelh,  adjusted for age, percent change in body 
weight from V3(2003/2007) to V5(2012), baseline total hip BMD,  BMI, vitamin D supplement 
use, diabetes, CVD and smoking; TBMD, trochanter baseline BMD;  FBMD, femoral neck 
baseline BMD; HBMD, total hip bone baseline BMD; Q1-4, quartiles of Albumin Creatinine 
Ratio(ACR). 
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 Figure 7. Multivariable Adjusted Percent Annual BMD Change Across Bone Sites with ACR 
Abbreviations: TB,trochanter bone; FN, femoral-neck bone; TH, total hip bone; ACR, albumin 
creatinine ratio; BMD, bone mineral density;  Q1-4, Categories of ACR; Q1, <30mg/g; Q2, (30-
135)mg/g; Q3, (136-300)mg/g; Q4, >300mg/g;  Q2 +Q3, micro-albuminuria; Q4, macro-
albuminuria. 
 
Association of Quartiles of Serum Creatinine with Mean Annual Percent BMD Change 
The relationships of trochanter, femoral neck and total hip annual percent BMD change 
each with quartiles of serum creatinine were examined in (Table 22). There was no significant 
trend in all the bone sites examined across increasing quartiles of serum creatinine (Figure 8).  
Trochanter Bone 
There was no significant linear trend in annual percent BMD change of trochanter bone 
across increasing quartiles of serum creatinine in the unadjusted model(annual percent BMD 
decline across serum creatinine quartiles: 0.16, -0.16,-0.24, -0.64,  P for trend=0.1073). Similar 
results were found for model 2, adjusting for age; model 3, adjusting for age, baseline trochanter 
BMD and percent change in body weight; and in the full model, adjusting for age, percent 
change in body weight, baseline trochanter BMD, physical activity, vitamin D supplement 
intake, diabetes and CVD. 
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Femoral Neck Bone 
There was increasing bone loss at the femoral neck across increasing quartiles of serum 
creatinine in the unadjusted model (annual percent BMD decline across serum creatinine 
quartiles:-0.36, -0.37, -0.40, -0.66, P for trend=0.5030). Similar results were found after 
adjusting for age.  On further adjustment with, baseline femoral BMD and percent change in 
body weight and in the full model adjusting for age,  percent change in body weight, baseline 
femoral neck BMD, waist circumference, hypertension, diabetes, physical  activity and CVD , 
similar results were found. 
Total Hip Bone 
In the unadjusted model, we observed slight increase in mean annual percent total hip 
bone in the first quartile of serum creatinine. However, the higher quartiles of serum creatinine 
were associated with increasing bone loss (annual percent BMD decline across serum creatinine 
quartiles: 0.11, -0.08, -0.12, -0.43  P for trend=0.1117) with no significant linear trend.  We 
also observed similar result after adjusting for age, and after further adjusting for baseline total 
hip BMD and percent change in body weight and, in the full model adjusting for age, percent 
change in body weight, baseline total hip BMD, BMI, vitamin D supplement intake, diabetes, 
CVD and smoking. 
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Table 21. Longitudinal Association of Quartiles of Serum Creatinine With Percent Annual BMD Change From 
2004-7 to 2012 in Trochanter, Femoral Neck and Total Hip Bone, Among Tobago Black Males 40 Years and 
Older 
 Annual Percent Bone Mineral Density Change (95% CI) 
Bone Q1 
<0.70mg/dl 
 
Q2 
(0.70- 1.10)mg/dl 
 
Q3 
  (1.11- 1.50)mg/dl 
 
Q4 
>1.50mg/dl 
 
P-Val For 
Trend 
Trochanter Bone  
1  Unadjusted 0.16(-0.84,1.16) -0.16(-0.24,-0.08) -0.24(-0.30,-0.17) -0.64(-0.81,-0.48) 0.1073 
2  Age 0.13(-0.85,1.12) -0.19(-0.27,0.11) -0.24(-0.30,-0.18) -0.49(-0.66,-0.32) 0.2085 
3  Age+%WC+TBMD 0.15(-0.83,1.13) -0.18(-0.26,-0.10) -0.24(-0.30,-0.18) -0.48(-0.65,-0.31) 0.1980 
4  Full Modelt 0.23(-0.74,1.21) -0.18(-0.27,-0.10) -0.24(-0.30,-0.18) -0.47(-0.64,-0.30) 0.1536 
      
Femoral Neck Bone      
1  Unadjusted -0.36(-1.23,0.46) -0.37(-0.44,-0.30) -0.40(-0.45,-0.35) -0.66(-0.45,-0.53) 0.5030 
2  Age -0.40(-1.24,0.44) -0.39(-0.46,-0.32) -0.40(-0.45,-0.35) -0.56(-0.70,-0.41) 0.7073 
3  Age+%WC+FBMD -0.34(-1.18,0.49) -0.39(-0.46,-0.32) -0.40(-0.45,-0.35) -0.55(-0.70,-0.41) 0.6207 
4  Full Modelf -0.31(-1.13,0.52) -0.39(-0.46,-0.32) -0.40(-0.45,-0.35) -0.55(-0.69,-0.40) 0.5632 
      
Total Hip Bone       
1  Unadjusted 0.11(-0.55,0.77) -0.08(-0.14,-0.03) -0.12(-0.16,-0.08) -0.43(-0.53,-0.32) 0.1117 
2  Age 0.09(-0.56,0.73) -0.11(-0.17,-0.06) -0.12(-0.16,-0.08) -0.30(-0.41,-0.19) 0.2411 
3 Age+%WC+HBMD 0.12(-0.52,0.76) -0.12(-0.16,-0.05) -0.13(-0.16,-0.09) -0.30 (-0.41,-0.19) 0.2007 
4  Full Modelh 0.19(-0.56,0.93) -0.11(-0.16,-0.04) -0.15(-0.19,-0.11) -0.31(-0.44,-0.18) 0.1826 
      
Abbreviations: Full modelt,  adjusted for age, percent change in body weight from 
V3(2003/2007 to V5(2012), baseline trochanter BMD, physical activity, vitamin D supplement 
use,  diabetes and CVD; Full modelf,  adjusted for age , percent change in body weight from 
V3(2003/2007 to V5(2012), baseline femoral neck BMD, waist circumference, hypertension, 
diabetes, physical  activity and CVD; Full modelh,  adjusted for age, percent change in body 
weight from V3(2003-2007 to V5(2012), baseline total hip BMD,  BMI, vitamin D supplement 
use, diabetes, CVD and smoking; TBMD, trochanter baseline BMD;  FBMD, femoral neck 
baseline BMD; HBMD, total hip bone baseline BMD; Q1-4, quartiles of serum creatinine. 
. 
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 Figure 8. Multivariable Adjusted Percent Annual BMD Change Across Bone Sites With 
(Serum Creatinine) 
Abbreviations: TB, trochanter bone; FN, femoral-neck bone; TH, total hip bone; BMD, bone 
mineral density; Q1-4, quartiles of serum creatinine; Q1, 0.7mg/dl; Q2, (0.7-1.1)mg/dl; 
Q3,(1.11-1.50)mg/dl; Q4, >1.50mg/dl. 
 
 
Quartile of serum cystatin C with mean annual percent BMD change 
The relationships of trochanter, femoral neck and total hip mean annual percents BMD 
change each with increasing quartiles of serum cystatin C is shown in (Table 23). We observed a 
significant linear trend and greater bone loss, in all the bone sites examined across increasing 
quartiles of serum cystatin C (Figure 9).  
Trochanter Bone 
The unadjusted model show significant linear trend with increasing bone loss across 
increasing quartiles of serum cystatin C (annual percent BMD decline across serum cystatin C 
quartiles: -0.28, -0.34, -0.51, -0.96  P for trend=0.0031). Similar results were observed after 
adjusting for age and further adjusting for baseline trochanter BMD and percent change in body 
weight.  Similar result was also found in the full model adjusting for age, percent change in body 
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weight, baseline trochanter BMD, physical activity, vitamin D supplement intake, diabetes and 
CVD.  
Femoral Neck Bone 
There was greater bone loss across increasing quartiles of serum cystatin C (annual 
percent BMD decline across serum cystatin C quartiles: -0.36, -0.46, -0.54, -0.76 P for 
trend=0.0340). On adjusting for age, increasing serum cystatin was still associated with greater 
bone loss; however, the linear trend did not persist. We also observed similar result on further 
adjusting with baseline femoral neck bone BMD and percent change in body weight, and also in 
the full model adjusting for age,  percent change in body weight, baseline femoral neck BMD, 
waist circumference, hypertension, diabetes, physical  activity and CVD. 
Total Hip Bone 
There was increasing total hip bone loss across increasing quartiles of serum cystatin C (-
0.10, -0.20, -0.31, -0.65 P=0.0001). This bone loss persisted after adjusting for age and after 
further adjusting for baseline total hip BMD and percent change in body weight. We also 
observed that on adjusting for age, percent change in body weight, baseline total hip BMD, BMI, 
vitamin D supplement intake, diabetes, CVD and smoking in the saturated model, the association 
still persisted. 
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Table 22. Longitudinal Association of Quartiles of Serum Cystatin C With Annual Percent BMD Change 
(APBMDC) From 2004-7 to 2012 in Trochanter, Femoral Neck and Total Hip Bone, Among Tobago Black 
Males 40 Years and Older 
 Annual Percent Bone Mineral Density Change (95% CI) 
Q1 
<0.6mg/L 
   
Q2 
(0.6 -0.85)mg/L 
Q3 
(0.86 - 1.11)mg/L 
Q4 
>1.11mg/L 
P-Val 
For 
Trend 
Trochanter Bone      
1  Unadjusted -0.28(-0.53,-0.03) -0.34(-0.44,-0.24) -0.51(-0.72,-0.30) -0.96(-1.37,-0.54) 0.0031 
2  Age -0.30(-0.55,-0.04) -0.34(-0.44,0.23) -0.49(-0.71,-0.26) -0.93(-1.35,-0.51) 0.0095 
3Age+%WC+TBMD -0.31(-0.56,-0.05) -0.33(-0.44,-0.23) -0.48(-0.70,-0.26) -0.92(-1.34,-0.50) 0.0120 
4  Full Modelt -0.23(-0.49,-0.02) -0.33(-0.44,-0.22) -0.51(-0.74,-0.28) -0.93(-1.35,-0.50) 0.0051 
      
Femoral Neck Bone       
1  Unadjusted -0.36(-0.56,-0.16) -0.46(-0.55,-0.38) -0.54(-0.71,-0.38) -0.76(-1.09,-0.43) 0.0340 
2  Age -0.39(-0.59,-0.19) -0.47(-0.55,-0.39) -0.50(-0.68,-0.32) -0.72(-1.05,-0.38) 0.1100 
3 Age+%WC+FBMD -0.46(-0.66,-0.13) -0.46(-0.55,-0.38) -0.51(-0.69,-0.33) -0.71(-1.04,-0.37) 0.1349 
4  Full Modelf -0.41(-0.61,-0.21) -0.46(-0.55,-0.36) -0.54(-0.72,-0.36) -0.69(-1.04,-0.35) 0.0972 
      
Total Hip Bone      
1  Unadjusted -0.10(-0.25,0.05) -0.20(-0.26,-0.13) -0.31(-0.43,-0.18) -0.65(-0.90,-0.40) 0.0001 
2  Age -0.13(-0.29,0.02) -0.20(-0.26,-0.14) -0.26(-0.40,-0.13) -0.61(-0.86,-0.35) 0.0019 
3Age+%WC+HBMD -0.14(-0.29,-0.01) -0.20(-0.26,-0.13) -0.27(-0.40,-0.14) -0.60(-0.85,-0.34) 0.0022 
4  Full Modelh -0.15(-0.32,-0.02) -0.24(-0.31,-0.17) -0.27(-0.41,-0.12) -0.53(-0.81,-0.24) 0.0301 
      
Abbreviations: Full modelt,  adjusted for age, percent change in body weight from 
V3(2003/2007 to V5(2012), baseline trochanter BMD, physical activity, vitamin D supplement 
use,  diabetes and CVD; Full modelf,  adjusted for age , percent change in body weight from 
V3(2003-2007 to V5(2012), baseline femoral neck BMD, waist circumference, hypertension, 
diabetes, physical  activity and CVD; Full modelh,  adjusted for age, percent change in weight 
from V3(2003/2007 to V5(2012), baseline total hip BMD,  BMI, vitamin D supplement use, 
diabetes, CVD and smoking; TBMD, trochanter baseline BMD;  FBMD, femoral neck baseline 
BMD; HBMD, total hip bone baseline BMD; Q1-4, quartiles of serum cystatin C; %WC, 
percent weight change from 2004/2007 to 2012. 
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 Figure 9. Multivariable Adjusted Percent Annual BMD Change Across Bone Sites With 
Serum Cystatin C  
Abbreviations: TB, trochanter bone;   FN, femoral-neck bone; TH, total hip bone; BMD, bone 
mineral density; Q1-4, quartiles of serum cystatin C . Q1, <0.mg/L; Q2, (0.6-0.85) mg/dl; Q3, 
(0.86-1.11) mg/L; Q4,>1.11mg/L. 
 
Tobago Black from Tobago Health Study (THS) vs. Caucasian Men from The 
Osteoporotic Fracture in Men Studies (MrOS)  
Figure 10 shows the comparison of rate of total hip bone loss across increasing quartiles of 
cystatin C in MrOS defined as : Q1, 0.97; Q2, (0.98-1.10)mg/L; Q3, (1.11-1.25)mg/L; 
Q4,>1.26mg/L and THS quartiles defined as: Q1, <0.mg/L; Q2, (0.6-0.85) mg/dl; Q3, (0.86-
1.11)mg/L; Q4,>1.11mg/L. The quartiles cut points are lower in THS compared to MrOS men. 
There was increasing loss of total hip bone across increasing quartiles of cystatin C in THS and 
MrOS men. The highest quartiles were associated with highest bone loss in THS and MrOS men. 
These quartiles represent the worst kidney function. However, because the range of quartiles was 
lower in THS compared to MrOS men, bone loss was much lower in each quartile of cystatin C 
in THS compared to MrOS men.  
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Figure 10. Comparison of Annual Percent BMD Change in Total Hip Bone Among 
THS(Black) and MrOS(White Males Across Increasing Quartiles of Cystatin C 
 2Cystatin C  quartiles was defined in THS men as: Q1, <0.mg/L; Q2, (0.6-0.85) mg/dl; Q3, 
(0.86-1.11)mg/L; Q4,>1.11mg/L and in MrOS men as: Q1, 0.97; Q2, (0.98-1.10)mg/L; Q3, 
(1.11-1.25)mg/L; Q4,>1.26mg/L. MrOS, osteoporotic fracture in men study; THS, Tobago 
health study 
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Table 23.The Univariate Analyses of Correlates of Annual Percent BMD Change In Total Hip Bone Among Tobago 
Black Males 65 Years and Older, Mean Age=70.7(SD: ±4.6), Mean MDRD eGFR=67.7ml/min/1.73m2 (SD: ±15.5)  
2004-2007 
 Total Hip Bone Percent Annual BMD Change 
Exposure  AC p-val 
 
p-val* 
  
Age(yr)S  -0.0611 0.1754 N/A 
BMI(kg/m2) S 0.0832 0.0646 0.1000 
WC (Cm) 0.0677 0.1340 0.1675 
    
 Baseline(V3)BMD (g/cm2)S 0.0781 0.0829 0.1371 
    
Weekly Calcium Intake(mg)S 0.0708 0.1163 0.1261 
Whole Body Lean Mass(Kg)S 0.0270 0.5721 0.6672 
 % Weight Change from V3-V5 0.2958 0.0296 0.0336 
    
Serum creatinine(mg/dl)S -0.1092 0.0192 0.0315 
ACR, (mg/g)S -0.2406 0.0005 0.0004 
Cystatin C,( mg/L)S -0.1415 0.0083 0.0167 
    
Physical Activity ( walk >5 times in past 7 
days) 
0.2073 0.0283 0.0330 
Vitamin D supplement Use  0.1582 0.1977 0.2248 
    
Hypertension -0.1520 0.1109 0.1521 
Diabetes -0.1297 0.1941 0.1606 
CVD -0.1144 0.5259 0.5187 
    
Current Smoker -0.0315 0.8458 0.8510 
Alcohol Drinker (> three drinks per week) 
 
0.0025 0.9879 0.9821 
Abbreviations:  ACR, albumin creatinine ratio; BMI, body mass index; BMD, bone mineral 
density; CVD, cardiovascular disease; AC, percent annual BMD change per standard deviation 
of continuous exposure variables denoted marked s ; p-val*,  age-adjusted p-value; S, variables 
standardized to mean=0 and standard deviation=1;  WC, waist circumference.   
 
 
We performed a sub analysis to compare the rate of total hip bone loss between THS and 
MrOS men [319], across similarly defined increasing categories of cystatin C. This was achieved 
by selecting THS men 65 years and older and categorizing cystatin C according to MrOS study. 
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Univariate analysis was performed to determine important covariates of total hip bone among 
this subgroup of THS men (Table 24). The characteristics of participants in both groups are 
summarized in Table 25. As shown in Table 25, THS and MrOS men have similar 
characteristics. The result of sub-analyses to determine rate of total hip bone loss across 
increasing quartiles of serum cystatin C among THS men is shown in Table 26. After adjusting 
for age, percent change in weight and baseline total hip BMD, we observed significant greater 
increase in total hip bone loss across increasing categories of serum cystatin C (annual percent 
BMD decline across serum cystatin C categories: -0.29, -0.24, -0.50, -0.79 p for trend=0.0285) 
Figure 10. For MrOS study, after similarly adjusting for age, percent change in body weight and 
baseline total hip BMD, the investigators  also reported significant greater increase in total hip 
bone loss across increasing quartiles of serum cystatin C (annual percent BMD decline across 
serum cystatin C quartiles: -0.30,-0.32,-0.40,-0.63 p for trend=0.002) [319] Figure 10.  
 
Table 24. Comparison of MrOS and THS Study Participants 
Characteristics MrOS (N=404) THS (N=219) 
Population White Black 
Mean Age (SD) 72.3 SD±5.0 70.7 SD:± 4.6 
Mean Cystatin C (mg/L) 1.15 SD±0.25 0.85 SD±0.21 
Mean MDRD 
eGFR(ml/min/1.73m2) 
73.8, range 27.0-117.0  
( Mild to Moderate eGFR) 
67.7,  range 27.9-116.7 
(Mild to Moderate eGFR) 
Mean Follow-Up years 4.5 6 
Gender Male Male 
Bone Site Total Hip Bone Total Hip Bone 
Biomarker Cystatin C Cystatin C 
Quartiles(Q1-4) <0.97,(0.98-1.10), (1.11-1.25), 
>1.26 
<0.97,(0.98-1.10), (1.11-1.25), 
>1.26 
Adjusted Age, % weight change, 
baseline total hip BMD 
Age, % weight change,  
baseline total hip BMD 
p for Trend 0.002 0.0285 
Outcome -0.30,-0.32,-0.40,-0.63 -0.29, -0.24, -0.50, -0.79 
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Table 25. Longitudinal Association of Quartiles of Serum Cystatin C With Annual Percent BMD Change From 
2004/7 to 2012 in Total Hip, Among Tobago Black Males 65 Years and Older, Mean Age=70.7, Mean MDRD 
eGFR=67.77ml/min/1.73m2 
 
 
 
 
Total Hip Bone Model 
Annual Percent Bone Mineral Density Change (95% CI) 
Q1 
<0.97mg/L 
 N=178 
 
Q2 
(0.98 -1.10)mg/L 
N=22 
 
Q3 
(1.11 - 1.25)mg/L 
N=7 
Q4 
>1.26mg/L 
N=12 
P-Val 
For 
Trend 
1. Unadjusted -0.28(-0.40,-0.16) -0.27(-0.60,0.06) -0.51(-1.10,0.08) -0.84(-1.29,-0.39) 0.0153 
2. Age -0.28(-0.40,-0.16) -0.25(-0.59,0.08) -0.49(-1.08,0.10) -0.81(1.26,-0.36) 0.0216 
3. Age + %Weight 
Change +  Baseline 
Total Hip BMD 
-0.29(-0.40,-0.17) -0.24(-0.58,0.10) -0.50(-1.10,0.09) -0.79(-1.24,-0.33) 0.0285 
4. Full Model* -0.28(-0.40,-0.16) -0.29(-0.63,0.05) -0.51(-1.11,0.08) -0.78(-1.23,-0.32) 0.0346 
      
      
Abbreviations: * Full model; adjusted for Age ,  %WBLM, baseline total hip BMD, BMI,  
physical activity; %Weight Change, percent weight change from V3(2004/2007) to V5(2012); 
BMI, body mass index; BMD, bone mineral density; MDRD, modification diet in renal disease; 
eGFR, estimated glomerular filtration rate. 
 
 
 
  
Figure 11. Comparison of Annual Percent BMD Change in Total Hip Bone Among  THS(Black ) 
and MrOS (White) Males Across Increasing MrOS Quartiles of Cystatin C 
Comparison of annual bone mineral density changes in total hip bone among THS(black) and MrOs 
(white) males participants across increasing quartiles of cystatin C. 1Cystatin C quartiles was defined in 
THS and MrOS men as: Q1, 0.97mg/L; Q2, (0.98-1.10)mg/L; Q3, (1.11-1.25)mg/L; Q4,>1.26mg/L. 
MrOS, osteoporotic fracture in men study; THS; Tobago health study.  
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13.5 DISCUSSION 
The goal of this study was to examine the longitudinal association of BMD changes 
across quartiles of kidney function biomarkers among Afro-Caribbean males forty years or older 
of West African ancestry. Over approximately six years period of follow-up, we found that 
increasing quartiles of kidney function biomarkers (ACR, serum creatinine and cystatin C) were 
associated with higher bone loss across all the bone sites examined. The highest loss was 
observed in the highest quartile of each biomarker considered which corresponds to quartile of 
the poorest kidney function. The association with bone loss persisted even after controlling for 
important confounders.  The results of our analyses support the inference from prior studies 
showing that worsening kidney function is associated with longitudinal bone loss after 
controlling for important confounders. In a study among white participants aged 50 years and 
older of both gender followed for five years, Jamal S.A et al, found greater bone loss across 
increasing quartiles  of worsening  kidney function at the total hip and femoral neck after 
adjusting for age, weight, and sex [363].  Jassal and colleagues also reported a significant annual 
bone loss at the hip bone among CKD participants [364, 365]. In the cardiovascular health study, 
which examined bone loss among black and white participants , 65 years and older with CKD, 
Fried LF et al reported progressive bone loss across increasing quartiles of serum cystatin C after 
adjusting for potential confounders [366]. Thus, there is overwhelming evidence suggesting that 
poor kidney function regardless of the kidney function biomarker used for examination was 
associated with bone loss. 
The mechanism underlying bone loss with worsening kidney function has been widely 
studied. It is generally believed that bone loss begins from biochemical and hormonal imbalance 
as kidney function declines [154-156, 158, 199, 200, 355]. The body stores about 99% of 
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calcium in the bone matrix. In CKD, as the kidney becomes increasingly unable to excrete 
phosphorous and produce sufficient vitamin D required for intestinal absorption of calcium, the 
elevation of parathyroid hormone (PTH) follows. Calcium bone resorption begins when PTH 
levels exceed 30mg/dl. The long term consequence of bone calcium resorption includes bone 
demineralization and vascular calcification. When demineralization occurs in the cortical bone, it 
in turn leads to cortical thinning and porosity, and eventual cortical trabecularization.  It has been 
shown that CKD patients with  elevated PTH tends to have bone composition made up of greater 
quantity of the softer trabecular bone than of the harder cortical bone [188]. These conditions are 
further worsened as the kidney filtration rate drops below 15mL/min/1.73m2, especially among 
dialysis patients [154-156, 158, 199, 200, 355].  
There are conflicting findings on bone loss among different racial ethnic groups. Tracy 
and associates showed that longitudinal bone loss occurs at a slower rate among older black 
males than whites males in the U.S general population [367]. Sheu et al, reported that the rate of 
bone decline with age was similar among Tobago men of African ancestry and U.S Caucasians 
[368].  In spite of these disparate findings, it is widely known that higher peak bone mass 
formation occurs among blacks compared to whites in the general population [356, 368, 369]. 
However, it is not certain if bone loss occurs at similar rate among blacks and whites with 
compromised kidney function. Our study did not include white participants. Therefore, it was 
impossible to perform direct racial comparison with Caucasians. However, we compared our 
result with previous longitudinal studies with Caucasian participants.  In a study by Ishani et al 
involving 94% Caucasian older men (mean age=72.3 SD±5.0; mean MDRD eGFR=73.8, range 
27.0-117.0, N=404) enrolled in the Osteoporotic Fractures in Men (MrOS) followed for four and 
half years [319], the mean annualized percent change in total hip bone across increasing quartiles 
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of serum cystatin C was (-0.30%, -0.32%, -0.40%, -0.63%  p for trend=0.002) after adjusting for 
age, percent change weight change and baseline total hip BMD. In a sub analyses performed on a 
subsample of Tobago men 65years and older with similar characteristics as MrOS men (mean 
age=70.7 SD:± 4.6, mean MDRD eGFR=67.7, range 27.9-116.7, N=219),  we observed mean 
annual percent loss in total hip bone across similarly defined categories of cystatin C (-0.29,-
0.24,-0.50,-0.79, p for trend=0.0285) after similarly adjusting for age, percent body weight 
change and baseline total hip BMD (Figure 10). Compared to Caucasians, bone loss was 
generally similar in the lower quartiles of serum cystatin C, whereas in the higher quartiles, 
which are characterized by a relatively poorer kidney function, Tobago men had slightly higher 
bone loss compared to Caucasians. Sheu et al, in a prior study had shown that the rate of bone 
decline was similar among Tobago men of African ancestry and U.S Caucasians [368]. We 
further report that in general,  the rate of bone loss was similar in Tobago black and U.S 
Caucasian men with CKD. 
In spite of prior studies showing higher peak bone mass formation and slower rate of 
bone loss among blacks compared to whites in the general population  [356, 368, 369], and in 
spite of higher yearly sunlight exposure by Tobago compared to U.S Caucasian men,  which is 
vital for vitamin D synthesis and protection against BMD loss, our result showing  similar rates 
of bone loss in Tobago black and Caucasian males with CKD suggests that the impact of  CKD 
on bone loss may not be amenable to the effects of higher peak bone mass and vitamin D 
synthesis in the Tobago population.  Future studies should focus on risk factors that are 
associated or contributing to risk of bone loss in Tobago men.  
The following are the strengths of our study. Ours is a prospective, population based 
study. Important confounding factors were controlled and the sample size used in our analyses 
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had sufficient power to detect bone loss from baseline and follow-up visits. In this study, the 
effect of kidney function with bone loss was examined in the context of three biomarkers.  
Although, serum creatinine is the most widely used marker of kidney function, the disadvantages 
are that it is affected by age, muscle density and mass, and protein diet. It is also less sensitive to 
declining kidney function  and therefore has less precision [321].  On the other hand, the 
advantage of Cystatin C lies in its capacity to detect minor kidney function impairment. Several 
studies have found Cystatin C a superior measure of kidney function and a better estimator of 
early stages of CKD than creatinine [40, 48, 49].     
This study has several limitations. Because the Island of Tobago is tropical, the yearly 
sunlight exposure for vitamin D production may have been higher among Tobago men compared 
to U.S men. In this study, we determined only baseline kidney function biomarkers. Changes in 
kidney function, environment, dieting and lifestyle over time may have influenced bone loss 
among Tobago and U.S men differently.  Finally, we did not account for possible cohort or 
period effects which may have altered bone loss or kidney function over time in our study.  
13.5.1 Conclusion 
Poor kidney function as measured by ACR, serum creatinine and cystatin c are associated 
with longitudinal bone loss in the trochanter, femoral neck and total hip bone among Tobago 
black males irrespective of biomarker used. Comparison with U.S Caucasians shows that the rate 
of bone loss in Tobago black and U.S Caucasian men was similar among participants with poor 
kidney function. For prevention, there is a need for proper management of calcium, vitamin D, 
PTH and phosphorus among CKD individuals in order to reduce bone loss and associated 
mortality.  
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14.0  GENERAL DISCUSSION  
14.1 SUMMARY OF FINDINGS 
Chronic kidney disease (CKD) is a major health problem with enormous public health 
consequence. CKD incidence is rising globally and many attribute this rise to increasing elderly 
population, obesity, hypertension, cardiovascular disease (CVD) and diabetes. CKD is 
accompanied with several co-morbid conditions including anemia, depression, infection, anxiety, 
dementia, physical disability and bone loss resulting in untold personal and economic burden on 
sufferers and the community.  
African Americans and other racial minorities present with far greater risk of CKD 
compared to other racial groups, yet fewer studies have been conducted among these groups. In 
this project, we extend studies to include blacks recruited from the island of Tobago in southern 
Caribbean in order to better understand CKD in the black population.   It has been suggested that 
heritability of susceptible genes of kidney disease is partially responsible for the existing racial 
disparities in CKD. Equally relevant in CKD, is the role of modifiable risk factors in ethnic 
disparities and progression to ESRD. The unexpected increase in CKD in recent decade is also 
partially attributed to the characteristics of CKD. In many quarters, CKD has been described as 
the “the silent killer". This is because, CKD does not manifest in signs and symptoms until in the 
later stages when treatment is less effective. In the majority of cases, early kidney function 
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impairment is often missed leaving an individual unaware of impending kidney failure. 
Whenever the filtering capacity of kidney is impaired through glomerular damage, toxins are 
suspended in circulation and further damage may lead to albuminuria. Because of the 
impracticability of the gold standard procedures for detecting early onset of CKD, estimating 
equations such as MDRD, based on serum creatinine and demographic characteristics, have 
found practical use in clinics and research for screenings. However, the limitations of MDRD 
prevent its use alone to identify CKD.   These limitations includes lack of sensitivity to eGFR 
greater than 60[30] and validation on a wide range of population groups. For these reasons and 
others, KDIGO recommendation includes addition of ACR to determine CKD.  It was our 
intention in this project to characterize the prevalence of CKD using MDRD and ACR, and to 
identify modifiable risk factors of CKD among Tobago black men. In this project, we found that 
prevalence of CKD in Tobago men was lower compared to African American men, but, was 
comparable to Caucasian men.  Hypertension and diabetes were significant predictors of CKD 
risk independent of age in Tobago men. We hypothesize that the disparate finding between 
African Americans and Tobago men was due to increased access to health care, and to socio-
cultural and socioeconomic conditions among African Americans which improves coping and 
better survival. In Tobago men, we observed that the most important risk factor for CKD was 
hypertension. The risk of CKD was about two times higher with hypertension than with diabetes. 
Impaired glomerular function was more prevalent than albuminuria.    
Excess body fat is a considerable cause of morbidity and mortality. The locations and 
distribution have also been shown to predict health outcomes including CVD, diabetes and 
hypertension, which are known risk factors for CKD. The most common correlates of body 
composition are BMI and WC. However, BMI and WC measures general-obesity and central 
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adiposity respectively and does not take into account lean mass. The use of DXA/PQCT 
discriminates between various body composition measures and therefore provides a reliable 
estimate of the role body composition play in relation to biomarkers of kidney function.   
However, it is widely known that serum creatinine and cystatin C are confounded by factors 
outside glomerular function. The influence on serum creatinine by age, gender, muscle mass, 
protein consumption and body composition make serum creatinine less sensitive as a biomarker 
of renal function. Also, the influence on cystatin C by adiposity, inflammatory biomarkers, and 
large doses of glucocorticoids use, hyperthyroid state and lean mass makes its use less than ideal. 
No study has been conducted in black population to evaluate the role of DXA/PQCT body 
composition on serum creatinine and cystatin C. To the best of our knowledge, this was the first 
project to evaluate this relationship among black subjects. In this project, we found that muscle 
area and to a lesser degree, muscle density were each associated with serum creatinine. Regional 
and general adiposities were each associated with cystatin C, but not with muscle area. 
Therefore, among Tobago blacks, when interpreting serum creatinine concentrations muscle and 
whole body lean mass should be considered. Also when interpreting cystatin C, body adiposity 
measures should also be considered. However, given high lean mass in Tobago men, cystatin C 
should be considered the biomarker of choice for estimating kidney function.  
Bone and mineral disorder affects a substantial number of people in the U.S population. 
The incidence of bone disorders is on the increase, and it is paralleled by a rising number of 
CKD patients and a rising elderly population who also have a high risk of CKD.  Bone loss is 
largely mediated by imbalances in serum minerals and biochemical compounds responsible for 
maintaining bone health.  Imbalances begin from CKD stage 3 when the eGFR drops below 
60ml/min/1.73/m2 and gradually worsens as eGFR falls below 15ml/min/1.73/m2. Bone disorder 
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is associated with several complications including fracture. The association of impaired kidney 
function on bone loss among black study participants has not been properly elucidated. In 
general, increasing quartiles of ACR, serum creatinine and cystatin C were each consistently 
associated with longitudinal bone loss.  In addition, the rate of bone loss in Tobago black and 
U.S Caucasian men was similar among participants with mild to moderate CKD. Even though 
prior studies have associated higher peak bone mass to black race, it appears that higher peak 
bone mass did not confer protection against bone loss among our study participants. Neither was 
high yearly sunlight exposure, necessary for vitamin D synthesis in bone formation, protective. 
However, it may be that higher peak bone confers protection against fracture in older blacks 
compared to Caucasians.  
14.2 STRENGTHS AND LIMITATIONS 
This project was a population based study in which participants were a representative 
sample of Tobago black males 40 years and older. We benefited from having large sample size 
to test the hypothesis of our specific aims.  The use of comparison groups for CKD prevalence 
estimation, enable us to underscore the relative difference in distribution of CKD among Tobago 
black with African American and Caucasian males. 
PQCT and DXA scanning were used to measure various body compositions including 
general and regional adiposity distributions. PQCT procedures use modern technologies to assess 
three instead of two dimensional measurements of regional adiposities. The advantage of this is 
that volume, rather than area measurements were taken, which improves precision and accuracy 
in measurements of body composition.  
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In this project, important confounding factors were controlled based on extensive 
literature review and univariate analyses of important covariates. Serum creatinine and cystatin 
C, and ACR measures were used alongside each other to tackle limitations inherent in each 
individual biomarker. 
Except for our specific aim 3, this was an observational cross-sectional study. As such, 
cause and effect cannot be established. Direct measurement of glomerular filtration rate was not 
possible. Instead, we relied on estimates of glomerular filtration by using MDRD equation. It is 
widely known that MDRD equation underestimates high eGFR and overestimates low eGFR. 
But we were able to partially overcome this limitation by including ACR measurements. Only 
one measurement of serum creatinine and cystatin C, and ACR were taken in 2004-2007. The 
use of one measurement to determine kidney function and albuminuria may be misleading. All 
self reported responses were not verifiable.  Because all the participants in this study were 
blacks, our findings may not be generalized to other racial/ethnic groups.  
14.3 FUTURE DIRECTION 
Future direction should focus on environmental factors impacting CKD and their 
mechanisms of action and risk factors that are associated or contributing to risk of bone loss in 
Tobago men. 
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14.4 PUBLIC HEALTH SIGNIFICANCE 
CKD is a major public health challenge of the 21st century. Epidemiological reports 
indicate that the incidence of CKD is rising globally and is fast becoming an epidemic, in 
particular among blacks. Hypertension and diabetes were the leading causes of CKD in Tobago 
men. We identified that hypertension in particular was the major cause of CKD and over half of 
the participants sampled had hypertension.  Apart from CKD, hypertension is also a leading 
cause of CVD, which in turn is commonly found among CKD patients. Thus, diabetes, 
hypertension, CKD and CVD are all locked in a vicious cycle and interacting with one another to 
increase the risk of morbidity and mortality among Tobago blacks. 
Bone loss is associated with fracture. Fracture in turn increases the risk of mortality. 
Although, the risk of fracture is high in the aging population, prior studies have also shown that 
the risk of fracture is seven times  higher among patients in stage 5 of kidney disease and the risk 
of dying from fracture is two and half times higher among CKD patients. In addition, bone loss 
has been linked to vascular calcification. Recent reports show that vascular calcification was 
related to bone loss due to ESRD. The consequence is formation of atherosclerotic plaques, 
which in turn is associated with increased risk of CVD and CVD deaths.  
Bone loss in CKD can be minimized by proper management of bone minerals, through 
medications and also by periodical DXA screening. The prevalence of CKD can be minimized 
by eliminating or modifying risk factors leading to hypertension and diabetes through proper 
dieting, lower salt and fat consumption, exercise and physical activities, weight control and early 
CKD screening.  Concerted preventive strategies are needed to address the public health impact 
of CKD. 
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